var title_f1_34_1568="Contents: Family Medicine and General Practice";
var content_f1_34_1568=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Family Medicine and General Practice",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Family Medicine and General Practice",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?35/60/36813\">",
"         Acne and rosacea",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?28/45/29407\">",
"         Adolescent medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?34/63/35839\">",
"         Adult orthopedics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/28/37326\">",
"         Adult procedures",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/55/43902\">",
"         Adult signs and symptoms",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/46/28399\">",
"         Antenatal care",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/17/22814\">",
"         Anxiety disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?11/33/11807\">",
"         Behavior and development",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?13/45/14046\">",
"         Bipolar disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/63/41983\">",
"         Breast cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?39/15/40189\">",
"         Bullous disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/28/462\">",
"         Child and adolescent mental disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?29/8/29837\">",
"         Complementary medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/59/41917\">",
"         Cosmetic dermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/55/18289\">",
"         Critical care obstetrics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/60/38861\">",
"         Cutaneous lymphoma",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/58/4015\">",
"         Depressive disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/56/910\">",
"         Dermatitis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/21/41309\">",
"         Dermatologic diagnosis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?28/41/29341\">",
"         Dermatologic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/42/41645\">",
"         Drug eruptions",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/0/3086\">",
"         Eating disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/58/33709\">",
"         Fetoplacental physiology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/0/22528\">",
"         General medical issues in women",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/63/16370\">",
"         General medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/61/16340\">",
"         General pediatrics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?29/13/29919\">",
"         Genetic diseases in children",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?2/23/2430\">",
"         Genetics basic science",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?25/52/26442\">",
"         What's new in family medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/49/31517\">",
"         Genodermatoses",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?34/5/34897\">",
"         Geriatric medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/29/14800\">",
"         Gynecologic oncology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/57/3998\">",
"         Gynecologic procedures",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/9/26783\">",
"         Gynecologic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/9/37021\">",
"         Hair and scalp disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/16/27917\">",
"         Impulse control disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/19/17726\">",
"         Infections and infestations",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?12/41/12959\">",
"         Labor and delivery",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?7/51/7984\">",
"         Laboratory medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?25/53/26462\">",
"         Lipid disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/50/37679\">",
"         Maternal medical problems",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/48/37646\">",
"         Medical consultation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/0/8206\">",
"         Melanocytic lesions and disorders of pigmentation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/37/5726\">",
"         Mental and medical disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/4/37954\">",
"         Neonatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/45/15070\">",
"         Nonmelanoma skin cancer and related disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?29/43/30397\">",
"         Nutrition and diet",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?7/54/8047\">",
"         Nutritional issues in children",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/13/27869\">",
"         Obstetrics calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/48/3854\">",
"         Obstetrics procedures",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/21/41298\">",
"         Office gynecology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?16/16/16654\">",
"         Other topics in dermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?41/18/42285\">",
"         Papulosquamous disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/1/8209\">",
"         Pediatric allergy",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?39/4/40015\">",
"         Pediatric cardiology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?41/58/42926\">",
"         Pediatric dermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/4/26689\">",
"         Pediatric endocrinology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/49/5904\">",
"         Pediatric gastroenterology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/47/15102\">",
"         Pediatric gynecology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/4/8259\">",
"         Pediatric hematology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/36/27214\">",
"         Pediatric hepatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?20/27/20927\">",
"         Pediatric immunology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/52/15175\">",
"         Pediatric infectious disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/34/558\">",
"         Pediatric medical emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?19/12/19648\">",
"         Pediatric nephrology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/62/33762\">",
"         Pediatric neurology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/45/19167\">",
"         Pediatric oncology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/29/15838\">",
"         Pediatric ophthalmology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/2/37\">",
"         Pediatric oral health",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/33/543\">",
"         Pediatric orthopedics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?24/2/24622\">",
"         Pediatric otolaryngology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/48/1807\">",
"         Pediatric procedures",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?16/38/16992\">",
"         Pediatric pulmonology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?7/18/7470\">",
"         Pediatric resuscitation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/16/10511\">",
"         Pediatric rheumatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/48/11023\">",
"         Pediatric signs and symptoms",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?22/15/22782\">",
"         Pediatric sports medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/18/43309\">",
"         Pediatric surgical emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/17/37150\">",
"         Pediatric toxicology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/8/3200\">",
"         Pediatric trauma",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/9/26782\">",
"         Pediatric urology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/8/21646\">",
"         Pediatrics calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/17/1310\">",
"         Peds environmental emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?6/48/6926\">",
"         Peds psychosocial emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/27/36285\">",
"         Personality disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?43/5/44125\">",
"         Photodermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/37/22110\">",
"         Postpartum issues",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/51/9009\">",
"         Pregnancy complications",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/39/38525\">",
"         Primary care calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/60/31683\">",
"         Primary care cardiology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/54/18273\">",
"         Primary care dermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?24/27/25009\">",
"         Primary care endocrinology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/44/5838\">",
"         Primary care ENT",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/63/18418\">",
"         Primary care gastroenterology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/20/5440\">",
"         Primary care hematology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?11/11/11444\">",
"         Primary care infectious disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/39/31359\">",
"         Primary care nephrology urology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?23/0/23567\">",
"         Primary care neurology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?25/45/26335\">",
"         Primary care oncology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/29/8670\">",
"         Primary care ophthalmology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/12/27855\">",
"         Primary care pulmonary disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/2/5167\">",
"         Primary care rheumatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/13/21726\">",
"         Psychiatric disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?4/33/4638\">",
"         Psychotic disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?12/41/12945\">",
"         Reproductive endocrine female",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?11/16/11535\">",
"         Screening preventive medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/8/35982\">",
"         Skin and systemic disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/55/33661\">",
"         Somatoform disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/23/10622\">",
"         Spinal disease and back pain",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/20/17742\">",
"         Substance use disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?28/23/29054\">",
"         Urogynecology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?2/4/2126\">",
"         Urticaria and angioedema",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?43/8/44173\">",
"         Venous disease",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-55D44ACCBD-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f1_34_1568=[""].join("\n");
var outline_f1_34_1568=null;
var title_f1_34_1569="Hiatal hernia after gastric bypass";
var content_f1_34_1569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hiatal hernia after gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrow shows a hiatal hernia after gastric bypass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1569=[""].join("\n");
var outline_f1_34_1569=null;
var title_f1_34_1570="Vasculitic neuropathy";
var content_f1_34_1570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vasculitic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wasting of muscles of the left leg secondary to mononeuritis multiplex and nerve infarctions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1570=[""].join("\n");
var outline_f1_34_1570=null;
var title_f1_34_1571="Gibbus deformity";
var content_f1_34_1571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75426%7EPEDS%2F81903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75426%7EPEDS%2F81903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gibbus deformity of the spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6APwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC7Y/D+wtViilZmRcAKpAVa3YNA0+DakVrC4HO7HWvQI/DEUmG84H0wKv6X4ZtrbDP87ZyOOlAHLeGbC7S7SS1/dRDhgelekbQUyec8kjvSQxJGAiqFUdsVIQQCF6dqAHxj5RnBpHUMMH/PNR7xH1BPvSNMCQuAGJoAR0XAPHAx0qvcQKcgEdOKlecISNvABzVS4u12ZXk4yMGgDN1OFFiXuwya5O/kKTOYlHPvW3qV4JYiG3DGT96ubuZky4Ukn3oAqByQd2Tk9CMUkPyLk7Wck/KW4p29mTIyM8Yx3qGZRkgAAY6E0ARSapAmtwW0oTcV3DnHfFdRcGOXEiuFZRXkvjS2vEvba7sciSIYyOat6V4m1MQLDNA6ORy2eD/+ugD0afDjqdwHUnjGK5S6EOn3ZeI7PN5PbcagutRu9mTIUXvxXLaxdzTTrGGLPggn0HrQBq+ItZihj8uEZO3r71wU948rAODg9qn1UyyNtRm3dDn1/wD1VXs1tInH2iZic8KB3oA0ILUzWryuoUKOMVnXKZJLLjd2XtVu81MPEyW6FFz+BqKWGSWPgkNt3En0oAybgxqNrKV3cZzVdpwY1GMgfSnXUJMuCzbR0JHWoTiIAdGzwcUAO8xyoOSATng80jzgKF+Yn079fWoRK75JJwO4WmM4AA53Z60AWVdThmOSOMHrURYc5UgH1+tM3GRRuOe2cVG8vmNwOOnSgCXenmABTx/OiNlLnt7etQCTBYNnGfxpVk3jDZHcDFAEm4J0QjFGcksFweoqNp84GDk8mjewJHI46UAT7cOCwzV+2UeX1AyfSsoOVORwfp1q8nmlc9AeR8tAH1zY2GoWrpl2ZTzweldPZO/ypMcSYycd6fGFGcdPUd6sKvAIyBQA4bQQM+lJI3TYe9HAIH0pQeM0AReZg4OM570NIuM9KSUqOvJAzzWdfajDFGVxmT+73oAmmlg3ZYfLyM+prD1KZct823cfTGKivr9HRd7bU6ge9YN7dyMG3ZaT7q5PAFADNRcS7pBIeM47istvkYnduHqaf87YUAqR1GeM1GVfzsFRg96AH+YQikdz0x3qrdq0jphgC3JANOW4KZjIXjpjmmxI07EkEAYx6D60AVxaghjJtbPr261UngRJlk6Y7HofStuSNVbDRgkD5hWTqSLvJOdmduR2oAzdRmWW3AQkYOTn9K5G9uUgEjlkyOmeSfetHXZHVdwDhVfAA6+9cdqSltzMzAn8fwoAgub5nlD8MxPbNVlMshBCquDyQMYPXmmSZGOGHOeRyakhZ5ZIxGrlWPOP60AaunxGV0jADOWGRjiuungijtJmkIxt2KAKxrK2a0QSHHmdCcdKtXV4q2bq3J5GMe1AHJ6iHMhUEBF6kjFUMD+M4PpV2/lZgzgFhms992dxQ9OM0AN35LNxk8cVHuBAAzkHqRSO338KSD29KYvB4yfbFAEqucDcPlX0ppkBACgDk81EXbB+UnPakOBnOCe+OaAHq534YAjpnNLuYj5cYqssj4yqkKO9SB3wTgDHIJoAnD7QeOnAzUe/BGD16ZpqMCcbRkdSD1pFzuywPtigC3FcOgIiIUMCDx2q7FNLsG3p7is+KYgnIDelaEEqeWN2M0Afa9ndgEoRypwTnvV9XGwEnGema4pdW8lRux1x9aup4iXcokA2gdcfpQB1buML6d/as+81OG34lkA5wKwpNeeXMdqvJ7morXT5biVmuMvk5C+maAJ/7Tlu5/kQ7OnBqG7glkYsxxk4+talnpxt8HgD0xmrrxhR8iZHoBQBypsWU5cgoOlVL22W3tppymTGu7GMk12jw5TcyD1xjNUrm2UxYU5HUq3NAHCafIdSTzY02qSQM8c06S2EcjB8nnlTXSmwRUHlgRYbAUCopNMLxsWLL75FAHJ7YEcFIsNuP8qswvCq7ShJHJq5c2awZYYIB7darofvBkwuD2oAr3X7wMfu55+tc7qFqdmZHcIG3cHJOK6C5hLqCpYDpWZPBMCFPI65oA8/129Ch44lO0twS3zVyuofO2wyHA54ruPFWlrcW7yRKFuOce5x0rzSdJxMd42lScgmgDRishIilmYjr16Vo2X2W1MRjG48g81iLHPGgYszZ+6o4/OrtsMKhJDNnKqo6fWgDUmvGXaVbaTxtPrTHYG1ZpP9Yx6HvUa27I6yTOSCM4AqS6uBKgWFAEUfebv7igDE1J1haNCDx82VHGazZvMdgcYB9O1TXflkvt3bl5OT1NV977SFOA3P1oAa7FeVGAMZJpdpLbmzg+9JICCxLc8cEVDEz7i3TAoAkJwdqnqcdaY4YOQAGznnOMU2RlUcHBJx0oKsxB6gHGRQAxiyp1Jb+VSxHEZ3HLYyKh2gylQDheSc96mYyvgbOfUUARpJtODwccVMAxKEkDj9KiQFHcleenNPJbcueT6igCZdvGDgd89quxxZQZ6is8ZOPStK2Wcx8HjNAHsNv4vFy/lCOV5eAVQZ5967LQ7K81JUd08qPOeT0FO8E+D7ewknvJowZ5iM8enoK9HtrOMIFCAKB0HFAGdp+lQ20aYUlweW9a2RAVy3A6cYqQIiqoK9MVKASox/KgCm0TqCc5+hqWNc4OQM8c1I6gHPfHegMpG3byO9AELqQcMOD61EyIDyuc9anYcANkn1pkhQYPQmgCv5YYEAfLnGDVeWBMZOMDtVssGOBxUMiFs/MuDkHBoA5+/tT5pIPytxweBVG9hK8ImFXv2rpbiOP7pAJ/Osu82gEKdy4IwBxQBz0hZeSeD2H+FVbq3LxoEJweprTaUI5G0Egjg/Sq7tFI4VpMHOcCgDmL3TFdir8pnPPY15x4y0NthuLbseR2NezSJb/NlhzWLqOmxSQEKAFPcUAeDQSy5XzgBsHI7itWK5QiNYtm4e2O1aPijRjaSzTworqwOB/WubQhQHTevfntQBpXDNgPNcKg7KO9Vb2eVgnlgCMA/d71mzsz/vGcnJ+Ue1KJ5FG0Oc8/LQBBcISHjk5J5bmmOxyNoXA980kjtn5jg5POaQkxhFjx+JoAUq5dsqpzjmkG4BvlU+wPSjDF/vEgkD0NNyUypwM5wfWgBAr+YdwAUjhfSljDfNsXJJLHnvUIDqzM2MdcZ5p5ZkJI644IoAJj8gH3ScUM6ngE5BxkGkL7gPM4IzjNMwpbcvIH60ATDcxOeCB69aRZMOAw561BuJQEAE5zg07zt2AEH4mgCzG7EDjA9q0Yp5VjA6fQVlwyEMAvTitS2udsQG0Dk0Afa9tAscaqBjb0561dVXxjdx696kSIBz0/GpCM9ACfagBiF40w+SMDkihJXZ9pXA68dqmYZjUt2pjMcAoAaAI/OGTlsDtTHuF3EqDjuemakZQwBZcGqly8casTx1FACy3eXOCDj9KzL7VEjOM7nA78YrF1fVUhZwpJPXOPeuT1HVWdmLy45J/CgDtoNdBlKlgRu4Ap8+vWse8HPqOOK82gvLmQhgpjjzkNjkirYLS4V959CaAOtuPEEYHyKc+uPasK51Sa5YmPK/NgCqqEo0YZdwzxg8dKv2jwunlqAMjjI6HtQBQaeYtltwAIOQKpvI2wct83Qsa17kJEItx3PjDEd8day7maML2X0WgDQ0WBbuSTzfvKOgNGqbYlVexPPtzWHFqD2sjSW2QD1X1qzJJJcsGb5VA5B7GgCjf2sNxHKhOFweoz+VeQ+I9OawuDtLeWTuya9ulCMwYgbMdq4jx5phuNNLxINyYI5oA8rl+8CD0GeBTW35yQGx3J5qRFPl59T0pOjYGPw60ARfMWJJbA6elJKFZVyyuwOQAOtOkLPuVTtx61Eu4sAzYIxkUAKzbWwGAzgkU8rlQQwyeoqObCMW3HOOBSbiGEhAZgOQe1AA2CWAKKo65FJuARzEQzDgYpquS7ufvMcYHpQkkiqWCYHQ0AOKll3SH5x90jp0pgf5AzECT26VHNIcct9MnrUYYFMvg49OaAJN2FGdvTO4GkU7uwGe9RE54HpwKAxHbigC3bt8y7iCf0FakBXygMKce9ZUAJYcY4ya1LeMsnHY47UAfe6RgAFuT7UF1Vvl61GjPjqOOpFKZVTnOcd6AJHIIGenvUUj7Bu7UyeUkYRGPHfiqN7MIYd65Zuuz1oAW7uiqtjluuDxXJapqTYc7io5G3PAqLWddLPKFyMcD+tee+I/EK2sDO5O9s4A6k0AauoaoHlEUB3M33VqXTNFkkxLc/vCRxuHGOOlJ4F0xRB/aWpEPNJ8wU44FdVe3cKsVgAQdCO2aAMq4tVhhDfL8pxwKqO4QhkGcDr1xVueVyDu2lA2cj0rMu72JQygEE/rQA+4LuilQARznNJBNFHErSMF9R0zWFe6hIV+Xd8uDheprNjkvr5z5aFUPygk0AdJqeqQBQFbao9TWCZbm4P7kkKclWPOauW2iqGDzSGRs5IYcGugtdMiQpt5XA6D7tAGFFDti3zctjkdgc1YN26hxsztUk8dq6O506MJiNcj0HX61kXlq6I5RQG7ZoAom+CFPlB4wcVTvo1vrZlVWYMMccjpTp1dQVcpnrgelaWimAWr/dcnsO2BQB4Vr+iXmkXEizgNCzEqy54Oc1jnKt03g8e+a9q8a21rcabOJRj5cjPY4rxMoSq4+YgZBBx0oAZJwQFPXqKY/mBUO8DHyjNSOyl1BkBJHPt6UwHe+Cwx/tDr7igCMswLITk459KDnaSMgE0MyjdjDk8cjimspCZAIB/KgBTkYzx24prblxgfLnkZ61YCBDu3ADaCRVRju5U5ye1AD5WyWzj2qDzG2nBI6dB70smMndjA7g0wYC9OR3oAU7lUck9qcDn5T+OaYU3BeT60hOJCuckDigC9CGLAKc+1aduZBEAGcfgDWTApDKWY7jnFa9q5WLDZznuKAPvJi5HBH4UqDrk/N61Ra+AJCHbnkmoZb7ahJzgDOelAFy8uBEjMBkdyDXHavqolG2E7gOM1Y1PUQ7EK7A1xep3pUuhLYANAEGr3EUUMszsRsOQM9T6V5rdvLrOrRy7PkVhtUdOtaXiTU3nuhArYA7HPNanhHS/NIlVSwc9Ow5oA6zS5WFlGCdo2429quyOCpPI45yO9RvFFHEUaRBjisi71ExMYrcPM5HG31oAtT3aqpWUnbjJz0xiqUKPfuEt4i2SRv9qsaLot1qUytdfVY+mPrXf6bpcViqDCgnrzQByMHh3EKyTLz1yR04pkNskRA2ggHGcY+legXYABVVxxk4HFcnfwiJfMyATwVIoApTQYmR8KMcnA61ZiZEAYKMHj0rPa9+Xkrgdsc1SF4MMQxz/P6UAdRLfKFUCMBsc46jmsDV73Y2TjaSeKo3mrpJvWMvJKpxtz1rOuWluA/mAopzjnnOOaAGam7TSEA/LjPFRxTeTkxlWc/eA9/wD69UDaySri3aZskLu3cVrw6W/yDGDuB9PwoA57XoJry0dH3JGUPbk+9eTzW5ikkhl+8pwRmvpKTSFaBWlyQOMV5F8StDSxvEu7cBY3O1uKAOBZAkZAUA8HOaiIUr8j7t38LHoasSqASRnHXNRzIhROQGHcUANQYYbm+Ug5+tM3EfKWGzPJPagHKBXAHqc9KRNpTay9M9DnPvQAjEhMMAGxjGO1RoAu4AEehNLMoEgCltm0ZJ7GgbVGS5YehoAiUcbWA6jNI7gRgckjjpSkkhRkBT93NMZQqNnGSQBigBEbBG7jPGaeBkls/pTMYPy5BNSDLMeQDjk0AWbcOXBU559a1YJGCZyME5GTWTBu3DJFaccJK59T60AfbU80cSYKkDpnrk+9Yep3uwg5+XBGB0NQXN+8rM27AB5ya5u7uD5m8ykLk5HUUAPuryYkY6EZ3A1yPirWksodiOWncYwOoqfXtbhtLNyrL0wNprzWe6fUb5mkBZnPy47UAamh2txrGoiO2+Zupcnkete9+G9IWy0yOIJvlxjdjpXJfDnRRBHFtVQ7ck4r1u1g+UYGAPQUActeeG4n3sOCxJbJqCy0JI5GbYpI/Ouvkj3Bs4GO1ULp9rZC4Pt1oArW6/Z51IQZPBOPap5bzDEABmB78Vm315ww+6wJ6cYrEur6UFgW7+lAG5e6qrZG8gj0rltS1EttGflB71mX2r75RbWySz3Bz9wZC49SOlJb6FqF06/aWMW4/cA7elAFGSaWVjj7vsas2FtdykDyNw5HArqLPSILS23NGd4HYc4qxZBhIxRTt6jFAGZpvh6WTJmIRiKnuNEhgO/buPQc10tjOSxZl+XkGq+oCN8sHC459qAOSljW3VUVArgcimSykAO2VIO4jrxU2sXaF2SPIVOCayvtbEHylLEkdsnFAHQf2zbzWK4wd3ORxXAeOFTVLFogu0gEkdhW4iXDx5IKg+1UtQtB9n3HPy9QDQB4bLC0TSROSCDz74pgRQSQoPtntXQ+MdM8ucXUYILH94M9K575Q+GJI5+WgBkyqct3APTpVLBdTk4C9CBirkyDDGPcp/u5quihecE5B4oAjuSfLVdxOcE5PemhMMNxyM808xr9488dDTAA6BeQ2c/hQBFINrgKQyjpg9KkAyBnp60+cDqfmx2App+6Bllz6DrQBEPvYT7x6ZNPjJ3NkZ45oRNr8nk9PpUsChpCFyfWgB1vxLjBOSK1I0VVIOAc85qsbVoDGzOp3DsehqyrnHzMufcUAe+3WpTEOGkAzxkcYz3rmtc16CyBZpd3UbQfyrBvfEazK32diNwxk9jXL3Je4n3Md57k/wBKAJL3UJ9UnCs7bCTgY6Cuq8E6QZ7mPkgIOrDArK8PaNLdXCoo2A/eOe1ey+FdEWKAptXaCSpP4UAdZ4bt4ra3XOFIHBNdRbzjy+q/X3rm3j8uINt3Ad0PWr1kssihl5XnIY85xQBqTDzMNyMcZFZ1xEzs2fu9MVcjDqM5yQMD61CGk2ZOFIPcdRQBgauBBGZCM7ugzjFYKaPe6zIMhobZmH1IrrfsLXl2HkO2ENwD3q+iiNwVwFUdcYFAFPRfDdlpkS+VFg8kkjk1Yuokjl8xCC4798U2XUkRQGIJA9eaz77WogSAVLY7HFAFC4vBCzDGQe5qDT7llEsjnaF5ye1Yura7HG7EqCM449axP7WuLstHEHVW79e1AHSSay8crEsNuSM4xiqlzqM94FWAksQRlxxx0/nVOyt0jYPd/OucAHovNTyX3mjZYKpU9WA49KAIksWkctPJyx+YVprax20aeUgYE/jVazsZri4Ilf5s5AA5HFdRa6dKiqz52D170AYU0ThQWjVhyAd2CKwb2BtsinuckV2WpwbJABwuMg+1c7fRSGNWUYGcfUetAHn/AIk01Z7JtwC5ByvfNeYXFu9vcvHKchckY7j1r27V7NpEZ22gg9SK8/8AFGjvMvmxBTKmSQO/rQBxMyqW3E4br1/KoflIIY4O3GRUjuTJwy8HkEdKbOAR+7jBboc0AREBGODvG3ucUwFSc52/1okCt8oPsTu4pZlJRQfLJHcUAMC9snJpHG4FckbRwaUAq2XGQOvPSlkYbskDBFAAF4JBznipIwISdvU9eetQ8gAEkL1GKUADLA5x+lAFsvlxuAAJGD61pxoHjUtisZMsgBYlQMDPatOEsE+UjH1oA0rYM4RBj/arotH0tnuAI1B6ZDVYh0OR7pTAAvqo/rXeaBogtsvGu1j/ABGgC14f0uK3CsY1DcHrXdWVpcXG0IFRBwDjg1nabaRMyAt8+3PFdXplq8S435XkEUAItisJRcA8cgdM1PHH5eNxwGORipLmUIpZV4AG7PGK5i/1qYnEPfIJI6UAdI0wRiOTx1FV5blFifziM9AK5u2uZ3cEljnqB0rTFjNPgtuA4I56igCRNQ2wkAHrx6VmSXtwqMYvmGMnJrU8iNICHPy+pFc3ql2luzrGxAIwCeh7UAZ9/qLkFsrnvz0rm9S1XzJSEYlgucg9Kl1XRNV1KSNNPZwhPJIwBVzTPhxOVZtRuJMHqq9KAMCJ0lklWQfvCc+uRirekwagUaOCDcE+7kEcHrmu5s/C9jYRgnGOmTya07aOCybEceV5JI7UActZ+G7nUoi9+xUIeE7GtWLTorCQRIoQKBx2rfjuAQQCoUH7o4rntWvlE7Ln94OnfNAGiZYLSVJSNrKASfWk1HW1kVFhBz7H2rl2uZ7i5VY97MT0AyK2NM02R5RNOrI2BtQdvc0AOknmnijaUfeGBmoJIJJI2yvHQCtxrHgPtxtHI9aiaJdr+XvXdwRjigDj72yzGSw+Xr1rldVtdzAc7SMZ7GvQb21by23ZzzyO9c1qduI0cAtuxwAcfpQB4z4l0lbS5NzGo8tj8wXjBNYhAbjaRhDzXqurWazRzJLETuHKg9eOteaalZm0uZFcNtOSpPT6UAY7Km8YGTnJzUpCtGxAww7jtTCoLA5PuakyrcDqT+dACSIVzuGXbgAVHhUBDqwK9qmn+VztYfzqGQoqgnLMx5YnrQAwfdGRz6UgOSc4z6Umc7wDjnqKamMtls/WgC2FViCoAxjgHitO2VfL+YDOfSswYWP74+nX8q0IXTyxnH4igD6b03SVks4p4Ihux8yjPFalrYTO4GwoCM7s8e9aGhp9gufJ2/u2OQOprolh4JXqe+KAKVjp8UQRiiq2Oo5zUt0zREgs2zPY4xUxeQPtcADryaoX6tOvlQMQxYmgDP1m/RSyJIAxXBFZNlYTXLFnfCHueK0rXRIxcebMSWbnPrXQSJBGB9wDADAdPyoAztN0vyHO8jDdwf5VoySOi4woXHBHbFZV7qkFtLtgGTxhQetUp9TkkRdhyx7AYzQBJqN2Xix1weR0A9xUGkaaJ5UluFDDJwvQVAyF4w8ygnIDAHgU46kkZCx9RgZJ/lQB1SQxw7SiIO2ahv5vKeT5hj271y83iQlFUIAiZB9axr/W2IdfMGT3JoA0dT1JYpcyEZBx161RbWBIRiTjr9PauR1u9kuCwtySzY5/CjS7WfySZZAe2wmgDorjXC8bpACWBwMHqais7C7up1kmuCwz9wgYH41ZsbUswCR7nHByP8/nXTaVYMjkyAKV7dqAE0rTPLwF+UkD5j16VtCxYCPZISBwxPWpNPTYGXaM9ielWpNxjGzAY9utAFKS3Ypjkk8D25qq8TRDYrK2BjJ+ta6KyxrncAKoXTgDO0ZIPIHvQBjXkLspKup479ua5XUoDuzIcgHaVArrZ13SCNgOhOfUVmXVipDO3QEkZPv1oA4O/tszMqDKeuO3vXJ67psVzA0cjYCcqwHQ16FexYZjj5T8vBxnisG8s9kWPLVieW9x6UAeLXVu1tcPG5yc8cdRVRQFwARkHivQPEmiNd2okgjUTx9COMj0rz6ZSWK7QjglSD2oAa5YqTkelR7xkKTnHOaVwWHz8Y7imLtVhjpjrQA9TnkEA0ImSRIMDOcUwyMw/h4Haj5vvNxnigC5Gik4V9qg8ZNX4GiVMP8AMfWsmJeQM5J9s1qwBRGAVDe9AH2fKAoVxJvzwc8H8qivdSmhUqCSOmelPNxCWZWG8g/KSMcVm3d0rFoDJyDz24oAsjxAhXdImGBwM81HNrLGTdAFXPHzCsaa0jdA+5m56Z6VDGy4BU4JPP1oA1Z724VS0svBxtC8YrKfV7oyyJkkNnJ5PFWHVTbupkJJ56ZrLlQoAY85LY6UASRs2fMd8KDk+vNWzqEYj2/dJ4z6msa5cL99tsYAA9zVZ7lIlZTlXUAk4zn2oA17+aUYUltuc8nGaxtR1VYwVY5IGeKy5deku2EbbsK2AfWsW8vkeUqrl3J4AHQ0AW7vV5GkXytwVuMipYYZp5AWKknpz1pug6ZLdsJGVhk4JxxXpel+G1gRDLtxj5QOxoA5K00UuyYXk8Z/nXV6d4eSPDGMZ7gd66G20xYf7oGetacUIibarAr1OOpoApW9nBBFgIM+mMEVZlgTqFIHGccVNIuIZDwf4jk9TVSWRp4yqEB+hwc4NAE8QDHajAKuMr6VIQqnAHy1WgYJuyScAHd70RXe6MrtLH8qAJRKwUFm4xgL6VUmdWj3BQCrHgVOXZl3MmeRz0qNjmN93AyTg8UAZ1xGqspH33HOOw9KrXSERKrc4zwO/NXQSzjOBjPWqwR2lfcQQhbmgDlNWXdiONAPmOcj9awrm3KNjqcZwa7G9hALhtpIJxtzXNXVq4ZmY/L7UAczdQyTSJGAQu4nI9M1574x0N4d95bR4I++oNel3jyC4KrtXbkDjmsrUYnmtslyynh+PWgDxqTJjUbWC9j2pqqowdvH9a2vEOmvYXZEWTDJ0B7H0+tY7YXnH/1zQBGzkliF2noKTkkknNKXJc8Hj3o3MfkIUY/WgCUDDZGcAdRWjDIqoON3uaoqNx5yCBjFXoVQJhlyfXNAH2NKsSoZeQ2OG6VlXUiPOAgJyOWFMu9SQxBCeSOvcVlXesJErAOi9iTQBosVSBdz8Yxg1UmmjjQDKluMAHgViX2sRqBkjBHHvWHd66iO5STDKOM9DQB1kl1LJIASBnsKge/WMrHI4JLEg+tcPceJ3jbIZVA/DNYuq+KGdCscjblOQEHT8aAO41LU1RnMjLjdnGcY/GuU1rxASd0j7Tghdpwf8iuTutXuZkZjJsyeh5qk8j+dkOXLY5+vNAG6urzyOMA4HpxXT+GNLfU2Dz5CnlWH1rn/AA7o811MhdWJDbuvH0r1/wAM6ULaKPKgdhmgDo/D+jLZ2qDIY993pXUrGiFWGF+nQVm2MqJDgjJzjFXvPB2KvyjPI9aAHLghuMNnII6VY37S2Op79Ki2BSxjccKflxxUTu5UdAe+RxQBLPuVThyQeMYqBYShJ3KrHrg4JH1prMSpG5s+9Qkl85OCAQG70ATLt8rIkOScepohV0PGCWGQaSHCx4JBcY4x1qQRkgbsAD0oAcqfKFZhwc1VuBiVmdgyngCrIiCKS2dvsc1TniQ7mdsgHjHagBjR7Fywxjpmq7yyMCqqpyTnFXJSrERt0Azk8ntiqkoCngk8ngGgChdx7QzHO7pgjvisK/R3dyFG3Hf+ldFcqzsC8hIBOfyrG1QhkbbxgHigDj76JQ7RrgnHJIpkVoDAQeFYYx1xVy5UCdS3zHOP0poBMTzAMV52r69qAPPvGGnb7SdmySnzKwOeK82kDFV44wCea9v12BXtJFVirMhBBHT2rxa7yjsmOVJBOKAK6sEBJ60kbE5OO3XpT0Ygnvn1oDgr98CgCVH3MMir0LMVOMjn0qgpG4DtwavxSAIMgN70Aer3niyFkD/LnB5LZya5q58WSq7BMKT3B4NcdHcMu0nGey57VHMM7sNlvY0Ab13rt1MQrtkAcDdWfNqF0+Q0pweMDrWYqsx3LjIA5qwqodvyOxB+9nFAEqvK8wLbn6dT0qxAk0oKQBjuOSvrWjpGizXcmQhI45zzXqHg/wAFDCtKuSeQcAYoA810/wAM3tyAxRyvHbp+ddroPgGUhGeMj5eh6k17DpPh62hCARqSoGa310+KIr5K7f60AeeaL4d+wqqtHyOvGc/WuohtmcAYwuOMit37PhhhiD34pJIYgcFzkfhQBgi3eFivAycnnkVq7kCRMPmGMkntTbi3yWdsew70xIBDt3k4ZTjJoAmWYmF3QHb6Z5pBIFU+WdwHBFVZpVj3E5IPBCjiiGWOQfL0J6/hQBZ81SvyZLfnSLjBHYkcHvTUnVVy+AQcdMfjSqFyC5br1AoAlBzxhVwO1SpGigEtuzxhqgC7uVbIB6nvSsCEwWyOnH1oAlddgH7wjJzweKp3SkQ7vMI5PAqzMh2+YfmRcnAqjPMvAcnoTj+lAD0LFfnY8jrUUiKIwWwwByajd2kAwcLzxioVK4+Vzn+6OaAG3HzMSvIznj1xWVqChbeQsAeMc1pl8AhcAnsPpWRfgMGDEEcZHtQBz0qeZKWbgEipiVWPCdFHQVXvpiMrHkD3FRq4SE7/AMM0AZ2qAfMrDAIJzn0rxTW4wurXKj+9mvadYY/ZHcq2cHGa8d8RDbrErdCygEfgKAMlxuAz6U0AEHdgZyM06QPgkenA9aYq7s4GPrQBYTbuGD+Vado2Iuduc9wKygD95R8x9K1IM+WMqM/WgCrGN0UYwM9sD26GldgZB8qhc9hzSQl2SMgnpx+VS+Ww3/u8nOc5zzQAyFMyADaT2BFdRoOky3O5sKzDpgdBWdoVo9zcKAo4Oea9k8H6MqyAN1J+bigCz4T8OfZ086VgeMniu/s4RBtVRkEA8CprHT/Lh8tVUen0rTihMFusacuo60ANtigkXcjcjqKsvOpkBVjj0xUccj/ekAVsdDUckwV8OihscnNAFoMsgO30JNRjY0xL42gVEjo0q7WwvUAHjJp4VI3IYkgdD1H40AIWVy275gM8mqV1HJOyCRyQpIHbHFW5gC7EEAkZGO9U9cnews5b5o5pmhhJ8mIbi49h60AV44sSEb8kHpnvUiRbZGK429/WmWzPLbRyvE8JdVdoyOVyM4NWJiCAyA465Jx9aAICY9244IPUHtUkZDgFWAA9e9RR7CmC2FJyT3oEsayKVKlGyOTgn8KAJVZwu/AB7DNBL/L84HrUaNHIWPBXpimyudnBAUDjjk+3tQBekk5wxJQDAbpVOdPNC5xnJ5J6CmoTtZADnnGaV1Ei85JB5BoApeW+xvNOFBOMU6JF8vHygg/e71bkhXYAzAY4GR3qp5Z2gPjg9qAK8zhUyuMgc81jXW53lZDgZ4z7VsXEGA20KRjp71jTiR/MUJtx/k0Ac5qjMHEa43t/ER0qlBMBKBKSSWzx0AzWjqMLB96gjHDbu/0/lWdFEI5DIN2CcDPJxQBV16UsAgYYHTGenrXkniFw+qTrgHpkj6V6neSKIm/uctx0J45zXkeosJbmaTozMQPpQBTbKgBcAexpCSrMOpx60uCCu7POfxpS21+R0oAfBvJAC9+laUQIQAZHrmqCyAMp6Veidwnyhz+AoAitxuiTAyUHP0q1HG0isVHX9arwhmjj54x19qsxcIoP3ATyfXtxQB3PgPTVlKFh0OTjrkn+Ve4eGbSOGBc4LMecdvpXlfgSDfBGC3LrliBjv/8AWr2fQkiRIyTjb6UAbEURVAygNwM5q3jCkBQcdarxHKEAKFHQinpKJMk4HPT1oAOjZKZxz+FN2xyEsq59RjqKeJN+eScelQwyiJHDKc8jJHSgCvJLEOiqG3YGc8jPaldBIBhirYYgU/O7/VxqABkNUe9m6EAnPAFAD0t5CucgMuev8qWRn3BQCRjjFQBiqOC3U/nUfnujlolLkDjHagAmnkLMu3B4P14qN/nVBjp69KLnUI4ZEYoN744qP7ZHIyuoKll+7jg0ABgBJ+UjPcVFLZKoUgkBR97HSrIdXBZQU3AcGoZkc4+bjHOB70AVYkUSYySvPqMVMBlFYx5yMYznmntAjj5VwRzmnLEu2MKfkB5oAiDgEEKXxnGacJj5zFomVfTNWCF3kcYPSmtKC3I+UcDIoAimlUjaytt4OCP1qKcB4vlYj1Gf6VYTYyNwN30qsIkHzDoe4oAozNuYZOPpxWfcIAnG7tzWhdW5ZycnHGAelZ13E6RHy2BbAOCaAMXUVBI3Zxnjn3rGuSzMFiYsq/ePtWpeiTnI46njpWPcOFDomck857j0oAwNccwafN5TE7VLZYY4715U7h+Wzu9frXoPiuYnTbjCgDaeme/SvOyQFXOSB1FACBi3IU8H8KZgq3GAcd6PMypA+6TwcU4ArnjOeeRQBIOWAPG2tG3kRIgGAzWaGbeB2q7CTs6ZH0oAms4ykMRlIxt6A5zViMkN5ZCsxBKgCsuDJRGwOMcdOKvxpks24KR0K9RQB7F4ADf2da4U5Ycn3z0r0/TWEaR7unQj1ryj4a3MraPbRkjO5gzfqK9W09xNbI+AynkMKANZrtmkCIMDOCo7inhzGFDEgBsjAqpHMAmY15Ixu96spjyAJJMuOR7mgC5DMZGONwA6tjg0TkEFHJLdMg9ahtGjVZGBw3seKhLA3ALDJJA46daALUYUja+AAeGpjvGFwr9B9KTYBvOeoI571TuDu25CkfT2oAlZpWOAwKkkg4pqB41dXbaD/ETzUQf7wBbcTx+lOnlPyjZ8pwDmgCpdQhmGSJHHcjG2ooLfaVDPn2xxVqYrMwAjGFxknrSGZMooOSBnB6igCVYmRNqup+o5p6HcuOAMZFMaSPy1H3nJGPXrT3dDG6pjHNADxyreUF469+KYOuOFz1odNqnDHIGdtRshJjJBAbPWgCVwmTtYFuox3qB2U5BkCc9DzUxjTcCVw4qndInmxhcepoAcrscgLjpjHShdpIBwM1Ck6/Mu1lwR24qVHYndtyO2O1AETAF2XP5VmyFFOX6dPYc1pTskZBC5J9O5rOkVShZwVxn3zQBzet5LsEKjrlVGawLp444cOArsQPmrb1UlJWaFcjOBmuYvw5X7oMgB4OckUAcf4uYCxlUkbiAM1wzKOOeDzXXeLZCbJ9kYVQwCnPUVyMgZ9wXBI9KAGn5AcjOe47U15CrnJ3Beh9qNpGMnHbrTUYYxkAA8UATxSAt61dilKpx9azeGY89MdK0ISUTHH40ANiwY1ILAhQBsOeatRAA/KzcnnPaqtuRt3LkjHfp2qSJlldlyqn1I60AeqfC252C4gbiRHBXnOQQK9f06YxxnzPlUHgH6189/DXUPsPiMrK2I5k6n17V77YXXmRAxqSOCOaANeB40jYxocn1571MyoRuz8zDt2NVVl2z5kCtnk8cg1bRw5RyoJzz7UAIispYBlyT1xnFAdo3Zm3AHoccA1b+zoWJLYjByeOtLclGBAYbT6igAhCrv3Hk9zREu+Nwe1RW6gN5cillYdetPV+ZIwQCvQUAVsAt8y7vcUsuVjVNvX5s5pVbLYzz1wRSLI4Uh1AB6f0oAy7l3jjXzWO4tjIPalg8pk3BvmQYOatmJCQ2Pm9+1VzbAO0i5DDgE/WgB2xJVznn9cVKysoOxxt9OmaYcKSAcHHJFSs6cZYBm4FADlkZUY85Oc8UryMFz2HTjjpTPPwsil+ccYHWpTIFVWYqe3NADN25Q4zkkDFREpx8wGe9OadjgCJWU8EsMULGCnKgA0ARStGqIM4YAE47io1OCNvTqSDmiXygDtPI/UZqS3CyRDPTrwP0oAZNtwGzjHPWqFyrSEZOMgnPaluI3+8q/Lk457U26kkWI4Ib5SduOKAMLUomRGYgbgTjpXHXzybpWYqpUcHHGfQ12V8rPyyqoGevOa5bVUCqQPmUk7sDJoA8y8VGQWbIeFEnB/CuVdiegA57Cuy8WBpbSc7TsRsj1rjpjhyRzkbsfWgCOUMeTjioyo3DLAE+9LNufAHGKYiE5DheOvFAE8fHRgCeatIeP3nXtxniqcca8OmD25FXNjBVBJBx6UAIsiGIBfl7Fs8mkLhnHlgso4B7ioiwwGGOucY6miIh5Fy4QZzn0oA1dOuGtLyGeJT5iEHk8Y719NeGrlZ9Jt5YSpRkDZBr5bhVdxILHPf1r3T4N6qbjQxbF1DwEoRjPGSR/OgD1KGIGUM7bWbkZHFWjhEDLyDx0OKppO0sagKSR3xyasJI4DI7KzDLBcY4oAtiYkruUBPQd6c8g5yB19OlVXmOT8meKqpOxkYpk5JyB60AXTO28kLkAdR16UitiMscZ9Kptcso4jbeSRnt0prSsxU8A98c9qALaZwCxwRycmop7nKIVZWYdVIqHzgwTcTzxwO1VbidS6iIkKBjp09KALIvt6AkcHt0NNkuhtyse0Ds56msmVpJR8oIPQjtSQpMrfviCmeM896ANkS5jAG3JJP4U5eX3P17c1m20p34Y7Rn8KVpwrld2Ofrge1AF8ELJIxUAjmlEysyqQVb36VmtcbRgtvDAn61ItwuFAIGDg+tAGj56um3aQyMOlRtOWGNpAGCPrUUEqqpG8Nhug4Jpyh15ZeGxjJ6igCP5cHzCM4yCKVXbygyg8elSxx7VVlQkY5A69alEQWNcZXnJB4z9aAK4DScMSw9P7tRyQhQ24Mxx+VXHwvC/eFNWBcfIuMfjQBg6hbmaEbwQgyfwrkdWgWNQI2O4dh1rudUYyTbBGQu3GBXMauUDgsm3vnFAHmGv2/meYpH3lII9K86u4XtbhklyAB37ivZL2zeTzGYF8kkevNcb4k0Xz7YMq7bhOVA5OPSgDh5GLfdByOhqL5t53EnP6VJLlHKkbWHBBpAXK9cZFADotyY3E4B6etXmDHGw8YqkhYAEjgd6uZcAbRkUAQJDgRtkAHrkd6GdWycfN0yT1oVd20feGM4NQqBGc9MZoAuqxaMMCVA4yBmva/hHo72Ogf2u0zu10CREBjCA9a8QgJcFBjb154r6S8Fa9p+oeHrfy2SMIghaPptI/pQB1FtqIZAQwI6kirbXyuxwQX9QK4iK9Echgt13AMcmtKwmYtFuY85OQP50AdELt3uOVI565xTo3PnNk555wKzpbtgQpz35706Od9/zMQSMdc0AX5bxWQBeSuTVL7VwQD36/WolbygcDIwQOevrUAlLIykYIOcAUAW5Lk7Mf7PI9arC7Vn3gjgdD3qoxdo2YdyRnd25qKPbCuSy54yKALT3vlRMw69+ajl1IuE+U8HORzVC7ukTLYOAOcioGul3LsGUPJxxxigDXa6dsbW2rnqajgkdJCpLSH3rN892C4GUJ/OrFvcA5cnkcUAaoRgx6DvnPerkIVMFkV2JBGay7WCeZNyttDHjnFbljaCEBi4Y5yPagCW0CMTtC8nAwKtwoqsqnO3PQ9aIUVG5OB/dx1qcxBASp3YA5yD3oADG4bkApgYx2NJLgnD9Rnknk1Os5QYwD257USNubOFPH5c0AVXZUDbvfIxyfpSKMRls5bnmp5Y1DsSwJOevGPaqy7tucjbyOBQBWnSOQfMoDY+9WDqdurA8AAHAzW1dN02D58Hk5rJvm3jdJheTnHbigDkr9OfLKBhjGwHmufvdP2gHfhmBAJ7fWutu1VVcgF3xgEfzrMmgJc72VN3Qde3NAHk/jHSBb3S3KIRG338dj6/jXLuCRwAAOuTXrXiOGO4R4MIqDqfT/JryyeGSK4kgcKGj689aAGRKzkBefWrXkkgbeR9arQlge4ByKvKH2KRjkZ5oAqMhOw9BjnHb8aJFiX5d7GMHgEd6lt5QEjaQEjH3e2aidxvZsn5s0AEao+RuVf7p9a0bXULmx8yOKVkDckKeM1lABcHPB61Z3lQpXhj3oA6TR9eu7W4jlNxJIuQWXOc/WvWdC1eK+t45Ed8OAVIHvXg8MjbihYnPUYxiuk8L66dNuUhdz5DNkZ7UAe7wyh3yMKDzkVLIpaQZYZ9RXNWOpmSGLy5FcSDcSTyBjIFW1u5W+VWwDxnFAGypA3ndnHXB6H2ppnVCQeu3I+vvWal0sf38uw4yvTFO+1RyS7kXYSOc9xQA/wCZgrhfmwQ3PBHNM8qPc7Zw3YHnjNCtKvlgEBCTntSpIpAIIwxw3pmgCjNypG0tgEBagSXjoM4wFNW7qXaQ4AYH09aozMwnBiHysfmz2oAtNKSVUBQTnGPpVvS4vmLS43hsAEcUunxGUpKArKOSe5q00rmMGNACDxgUAWUdg+3aQM4z71qWVtKswZmG3A5PasqwW4lYM4AGT7Ee1dFYrwocZU9KALcYJIDMGx6USYi2A9T6fWp4m4+6BjpSOFfBJGMHJ70ANPzIwI27hnOajVdwIYE8YzTd583hcgD7vvVuOVARxn2PagDPuS8blXbgnBGKVi5BCjjHQcVLdg7mOOvOMVEzbg24kHBzigChcI5UcKM8hu9ZlzFIqM8xGDycDjNbkpCY3jPXisfUpyEYugUA9AaAMe4KpA/GeOAvrWFdZacmXKIBgAjnp1rYvpkUc5IPBx3rOuZfNLBOg7sO9AGBerC+xvLIcthtx6V5v4xsRb3qzD+MAED1FeqXsSswKE7gMjI6/SuD8awh7PKnDRsCfxoA4uJAzgjB4JrSg4iAXdxnp9azIJB5n7v5TyKuxyHYArkY46DmgCiGUEKDjA5z3qRsEJINocn7tVUKqy7jyQMY+lSSMcjaQ2eDigCR2QYRMhvpwKkm4wQu1MZAzVZ5BtXbyQOlDPujweCOaALfmoyr0GKj8xfN5yecD60zcscKEdR14pjk7ecEH0FAHY6B4ke1CW1wxMf8DenNd0mpmSKBy3ysC6EN94d68YEihUAHTkmtbStbe1eJSXeIHoeQPpQB7BBO3lvI46nA55q5BOjCIEDeB1Pf1rhbXXYLlDg7iOflNbFvfF4FIYB8Z47egoA6l7lmJ6AYzg/WohcbUUYVgM4xxmsIX0jjapAwM59qg+1SFm3lSDjbg9DQB0k1xAiruO5uwHfNVmnjuL6KOMbgw5Xpj3rnpr6S2hd5icrkqr9RXSeF7SSa0W6uFEbtySRzj0oA2YN0FsIogGwfvMaPP2SJGgxgcADmlaZpmaK327xj5j0xVy0tdpUgZfoW9aALNoJC8e8ZJycV0FscRrtPIxjNUbaH94S6/KOTgcj6Vf24KBfukD6igCfc5PDDkA8CnSnhRGee9QkuOAdp68+lPOVK4OAOuBQBKkflMG/iIzkjmoppIwzMgz2JI71JI74DL9wc9eT61A7HB69+tACSFnd+RxyRVaScgHZ0I/u1JJujkYKRnk4/Cq32hGJEJVhg/MOQaAKt1MoTEpaM5yA3WsPVJfMDHc2V6cVdvX/eSq5O5Mds5zWFNeb3ljReGPBzjNAETvGsb72BCjp3zVGaV2lUglM5AXHrUsiBNzTbMZzu9aguQZFj8t8DJx+VAFO+mMbbBgMByc8CuP8AE7GexuELLk4y2M8DvXQX7CSPEZAz3PU//WrmNaIawuSAqhUwcd+P/rUAcQqoJT8/AJAYVZCkKME1WiYYChePTNWSGOMNgY70AUrbYqjJDHHcUpl5yVwM9BxSW6DarPhmK5H5Uu+MFeSSeRx1oAAUyWDdOqsKapIUbkIPcnpTJXG7HQ9hilL4Xacn60ATYXaRuG3t6n6UyRyyZPXsabHhh8uWCZyfSmzkEBRhSPzoAkEhPykEjHT0pQVxt255z1qJmUIgClZTzuJ60wN93a3IHzGgC7BdPby742ZWFdHYa+C4W5ykmBgr0NciuTg7uMHnPNTQYRsNknsetAHpcGoqy/KAQF6g81It3GJVYncijgE9a89ivZInBR5FOMnb9a0U1WYMCwyV4H1oA7mwjOvaoITxaxYeVic9+n4138kixxRpBgZA29hXHfD4w3OmNJAAJQ2JsjGTmu30y28243Ph1QcZ7+tAGhpNklnExIyzfMxPqa0raH97kKPmGcdqlggCRAZJGO46e1XbWPapG3ocAZ6cUAPSHYuc8nHU9farABIB7EcCmwRb9x+XIGetPAXcCoIcDHtQBG5Ifc3CgYNOmkYkDcDx0FEx+UBwVyetQyW7SoWI5HA+metAErnYp6g4yBUSylmII4wfwpvlMzKCCAAcEUgXCYQ72wQSD0oAJ2BkL4YY64rIvpV/1cYKg/3RwK0HXZuU/MuC2O4rJuZFO/Z8x9KAM/UJAVAOD9ePWsO6nOCqfeHB4q7chnfdKwG3lSe3Wse6kVh8nynJ3Nj8qAGykFXlkbCAZYdhVaWVpEUkBVxkY+lQ3EOEIYsy5zsJzn/Ckml2ws6quzHyqTypFAGXeMgGDlV25J6n8q5bxBOi6W4VmycKxI25/Cuiv3i84DcWzjB6YNcd40ummeGBmVj95iKAMGIoCB1PGTVxSgUc1nxjLqBWgGGOo/GgDPtTuhicE7duD7ECkJHmE/xZzx2rOt2IfaCduc47USE7+p70AaJdg7FFChhg00o7x5VcsPSs8sdp5PWk3Nu6n86AL0gkGASAfSkZiRknnPWqMjMSMsfzpqkhupoA0fvMCxpxIyAGz+FZwZueT371LA7COfDMPkPegDR8tsZ4PbFOAZcDgGqAdgDhj19advb5/mPT1oA0ED7gVIJxjmr1tG00yQoQXkcIqjnmsGN3wPmb866/4afvPGNgH+YZ780Aet6HpJ0bTY4wQdqjdk9T6mus0WJmRWxtXO4YpbhR9nHA5P8AWtDS+EOPU/yoA2oojICwJwPQ5BqTZhSFBRl/i9ah0liWwSSMjvWpMB9oYdsCgCiCVOM5wBxnk1Kih9rO2E7+4qeP/j6I7YH86g/iUdtp/nQAk6thmjwAOgPU1CFJ3ZJOQSSc9fQVYf771UYnzwM8ZPFADHaVcgEgY6UodFUnDbwOg4qaUZU55qtOBuJ/2T/SgCGVX8xnjJBycZ5rPvpFSN1VvmYADjFa8pPk9fWuduyS+SecmgDHvMu8g2r8ox2/OsW7lC7kD7iuCD6+1a11x0461m/8vrfQ0AZ9/G9wpY4C9CMZ/KqM8yxwODGvB4IH61JcyPmT524du/tWNeM2H+Y9fX2oAh1KRQHbcWOASD2+lee3kpuLyaXnrhQT0rodakcWUxDt1I6/SuJjZtrfMe/f6UAaSKRjBAxjFW8gKvAyRk81jwuxblm6+tW4nbafmPX1oA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McKusick, VA. Heritable Disorders of Connective Tissue, 4th ed, Mosby, St Louis 1972. Copyright &copy; 1972 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kyphoscoliosis in mucopolysaccharidosis type I (MPS I, Hurler syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 150px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kyphoscoliosis in four-year-old male following bone marrow transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1571=[""].join("\n");
var outline_f1_34_1571=null;
var title_f1_34_1572="Chondro low radiographs";
var content_f1_34_1572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Radiological presentation of a conventional lowgrade chondrosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 516px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIEAeUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKbI6xozucKoJJ9AKdVfUv+Qddf9cn/AJGgDgP+F3/Dj/oabX/v1L/8TR/wu/4cf9DTaf8AfqX/AOJrxjw74P8AA2mfs42XjDVvDNtqOstbsIxJLKPPnaZo4wQrDvtyBjgGrKeCvBOtfAnxF4gHhO00vxHpsF3BcxRTysLa5hyMDLnttPOetAHr3/C7/hx/0NNp/wB+pf8A4mj/AIXf8OP+hptP+/Uv/wATX55UUAfob/wu/wCHH/Q02n/fqX/4mj/hd/w4/wChptP+/Uv/AMTX55UUAfob/wALv+HP/Q02n/fqX/4mj/hd/wAOP+hptP8Av1L/APE1+eVFAH6G/wDC7/hx/wBDTaf9+pf/AImj/hd/w5/6Gm0/79S//E1+eVLQB+hn/C7/AIcf9DTaf9+pf/iaP+F3/Dj/AKGm0/79S/8AxNfnlRQB+hv/AAu/4cf9DTaf9+pf/iaP+F3/AA4/6Gm0/wC/Uv8A8TX55UUAfob/AMLv+HH/AENNp/36l/8AiaP+F3/Dj/oabT/v1L/8TX55UuDjoaAP0M/4Xf8ADj/oabT/AL9S/wDxNH/C7/hx/wBDTaf9+pf/AImvzyooA/Q3/hd/w5/6Gm0/79S//E0f8Lv+HH/Q02n/AH6l/wDia/PKigD9Df8Ahd/w4/6Gm0/79S//ABNH/C7/AIcf9DTaf9+pf/ia/PKigD9Df+F3/Dn/AKGm0/79S/8AxNH/AAu/4cf9DTaf9+pf/ia/PKigD9Df+F3/AA4/6Gm0/wC/Uv8A8TR/wu/4cf8AQ02n/fqX/wCJr88qKAP0N/4Xf8OP+hptP+/Uv/xNH/C7/hx/0NNp/wB+pf8A4mvzyooA/U2wu4NQsba8s5BLbXEazRSAHDIwBB59QRU9c58Nf+SdeFf+wVa/+iVro6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq+pf8g66/wCuT/yNWKr6l/yDrr/rk/8AI0AfNHgW7+H3iL4N+CdF8X+KbG0XTJWup9Pa7WMyuHk2rJ/EBhieCOtXtfuvhv4Z+H3xCtfCXivT5F1q0ZotNW8WQJKIyv7vJ3Et1OSeQMV8eUUAFFFFABRRRQAUUUUAFFFPhjMsyRjqxAoA3NOiCWkYI5ILnj1/+tir6ouBwPyqJMbjj7o4A9qnXG2gBNqkfdH5U1kHoPyqSk60AQjchynH4VtaL4v13RHDaffPGAfukAg/UGsogVE2OfagDvLv4jWuuxiPxp4Y0rVjgJ9pSPyJwvoHTBFYl34d8D6yS+iaze6JOxJ+z6jH50Q9AJFwwHuQa5tgKiZR6UAWNW8Ca5YIZYYodSthz5+nyCZcfQfMPxArl2UqxVgVYcEHgiuigubi0bfbTyRN2KsRWhJqdzqIA1W3hvF6eZIn7zHsw5oA4uiuul0HTLzm0nlspD/BMN6fmOR+tZl74Z1O1UusAuYR/wAtLc7x+XUflQBiUUrAqSCCCOoNJQAUUUUAFFFFAH6Y/DT/AJJz4V/7BNp/6JWujrnPhp/yTnwr/wBgm0/9ErXR0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV9S/5B11/1yf+RqxVfUv+Qddf9cn/AJGgD8s6KKKAHMMHqD9KbRRQAUUUUAFFFFABV/R491y0hHEak/ieBVCtnSU2Wm7GDI2fwH/180AaEecGph0FRxmn5zQA4GkJpjHnmm7ixwoJPtQA4nNMZuOtTpbSP947RVmKxUckbj70AZo3PwikmpUspX5YgCtiO3AHAwKtWlhPdyCO0glnk/uxqWoAxorFE5xuPvVuO19RgV1kfg6/XH2t7a14yRJKMj6gZq5H4Y0tSouddYnHKwWxb/x4kfyoA5BLfHX+VW7aNo2DROyn1U4rvLTw3oC9DeXTA4/eNtB/Kui03w14dlcI1nGMnnDkkUAeXXVlBqKEajaQXHH3yu1x/wACHNc/e+B7S4y2nXT27f8APOYbl/Mc/wA69u8Y/D06dbLfaIXntMZkhByy+49R7VyNpaBtp7daAPHdT8Jazp4LyWjTRD/lpB84/TkfiKwgvz7WO05wc9q+lbK1ZJFZOuOMVzP7RsVlYaZ4VsktLZdVuI5by5nWMCQxkhIwW7jKyH8qAPDqKKKAP0w+Gn/JOfCv/YJtP/RK10lc38NP+SceFf8AsE2n/ola6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqvqX/IOuv+uT/wAjViq+pf8AIOuv+uT/AMjQB+WdFFFADmYsck5PSm09ypI2AjgZyc896ZQAUUUUAFFFFAC10UaeWqRj+BQp+vesbTYxJeRg/dX5j+HNbSnJJJ5NAEwPy0DcxCpyfanQQtMTjIX1rWt7ZVUACgCjDZM/+sP4Cr8VqqYCqBVyKAngA/Wr1tYPJ3AA7npQBnJDyMCrttYFxubOK0xppVFMboxPUDjFOjWSDGVJQ+nagCGKKGE8wRuf9vn9KvS6rdSQrDE4trcdYoQEB/Kq0xXIbcMH0pFniQAbdxFAE8EmDvRXLdQc5rqdMnuhte7sLaYddroAx9+Olcot/Kg/dIsRPcdfzqSNJpfna4kLHuW5NAHquj3ejain2eW0+wydmU8fgTW/B4OeBN8Ukc6P0kX72O1ePWgmI2ebIQOnNdX4e1HVNLdXhnd4u8bk4oA9Html09WSVSysMENWRqHhTRdQmadJWs5XGW8scZ+nStOy1G31aBSC0c/8UZPI+gq0LFuGUE++KAOcsvBNt9vgEepSSLvA2iMZNfOn7SOrrf8Axc1OC1m322lpFp0RHGPLUbx/38MlfXWlNHpoutTv22WtjFJcysBwFRSxP5CvgDVNQl1XWL3Ub8l7i7nkuJSOMu7FifzNAFKiiigD9MPhp/yTjwr/ANgm0/8ARK10lc38NP8AknHhX/sE2n/ola6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqvqX/IOuv+uT/yNWKral/yDrr/AK5P/I0AflpRRRQA5lKnBx0zwabRRQAUUUUAFFFFAGnpKYimk7nCD+Z/pWpbRGaTH8I61UtU8u1hQD5iN5+p/wDrYrdsYNiKMc96ALdrCOAowK04IPlGRTLSPtjitOKPAAAJY9hQAkce3HGTWzp0A+yrkZY8ipLXQpniElzItuD91SMn8RW1aaPHFborS+c2OcDaAKAMmRU4A6j0phVHIxz6ityWytA2GgBPTAPSoJdLtzkRSPEfY5FAHM3tq6zsUQspPG2mwWM8h4jZeercCuojtJbE75VEitnEg6Dt+FXI0ilb99GPrQBiWnh8PsaeUnnGE7VuweF7YhSsswx2ABFbui6PDcW0sqBwVxgZ689RWrHYowzHKR7UAc/ZeHIUfLTkZxjeP8K0xaG3O2QDnlcchhWh9ikBOHUnPercVo7W5RgGB5X/AGfegDMQRIoYnDY4xVmN58AJcTKMdAxqG2tJC7K6sGzgnFbdrbx74wAcnjPvQBzvxU1mfQPgd4jmkuWFxqBTT4d38XmN84/79iSvjFVLMAMZPrX0z+1/qYstI8K+GopMFjJqNxHj/gEZ/wDRtfMlABRRRQB+mHwz/wCSceFP+wTaf+iUrpK5v4Z/8k48Kf8AYJtP/RKV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVfUv+Qddf9cn/kasVX1L/kHXX/XJ/wCRoA/LOiiigBzHcckD04GKbTmxn5SSMU2gAooooAKkgjMsyRj+IgVHV7SV/fSSn/lmhI+p4oA2rVRJcswHyqcAfyrdtE71ladGVjUnqeTW9Ypnb+dAGjbIFx9M10OlBbaGObbmd+c9do9qxIULlEHVyFroolxMqoeE4/KgCbz3klHmZJHOfSr2l3WyZg+07hkk+gqEQoNj5BwME56ipobcyKiooYnpxgEUAWzC5VXyDnrzUkcRZxtPXse9OgDl5AwwUABxzVgK6nBX/wCtQBJaqBH5Uinaxxzz9fwqB7IW99DE+DbzkAMvOBkZq7BGzEArx9a1Y7WHYryOuYju4Oen0+tAFhGaCUKkYAX7vp6Vq27+YwDW6keqjmonez+zxzGORsjB28VYsbq1mbZCzowGdrUAEttGWIXd0z9Kfb2kiJhVb2NaKWmZQ4GV9Md60be3CqWYBQKAMOOKRHbjBzyR3roNItAxiO0Fgw7dKjWKEnJc9OcCtK2vLLTLK7vrpylvaQvcStj7qIpYn8hQB8W/tQa6Nb+MWrJFIJLfTUj0+IjtsGXH4SNJXlCnawIxx61b1jUJ9W1a91G8bdc3k73EreruxYn8yaqLjI3HAoASiiigD9MPhn/yTjwp/wBgm0/9EpXSVzfwz/5Jx4U/7BNp/wCiUrpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq+pf8AIOuv+uT/AMjViq+pf8g66/65P/I0AflnRRRQArAqcEYPWkpaSgAooooAK2NOjItEA+9M+fwHH+NZAGSAOprpbKHE6oBxEoX8e9AGpaJ8uK3bNDtzWXap0BHWtu2XCj1xQBoWBEd7bE4wJFP611C222aSR1JXec/h7VyLfKm4diDXbhftd2sSIQzyBBtOCR1zQBHHDG5RwGWNOCD69aus0hgD7fLdnwFIwMVpamkJZAjq284+736ZOOpH9a0bHRcsVuP3/Qndxt/zxQBnWKxxRqocLKSWcsucjNPlg3XTt5m9WwAWHT8Ku39pHbf6sKVU4YZznNWDHGLeNdqoWcsvOelAGYltiQgk5BzWvYwhIpCcY2EdKrxgSO52jnkVfXKWY4wZWwB7UAWrZN2j8/3xjNMMKq+VGPp1FXY18uxhTHVi3Pp2p8MWW+YfMaANnRZ9kCmQlnB2k1YDSTBkXnnqKzLYP5nlLgFmGAO1b3mLa2uFAz0X1NAFecx2MG+Q7pD91T0z71wnxk146N8FfElz5u26vwunx5/i81vnUf8AbMPWlrN3JcT5csNzBR7V5L+1nq32bQvCvh6OTmRpdSnjx9I4j/6NoA+aqVQWICjJNJS0AJRRRQB+mHwz/wCSceFP+wTaf+iUrpK5v4Z/8k48Kf8AYJtP/RKV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVfUv+Qddf9cn/kasVX1L/kHXX/XJ/wCRoA/LOiiigB7sGIwoXAA47+9MpzAA4ByMDmm0AFFFFAFrTI994mRlU+c/hzXUabGdm5vvMdxrD0SHcsjf3iE/Dqf6V1FqmAKAL1omWUCtiBcY+lZ9kvJI9K1oB8y+1ADpF/cN9M13thEDJbMZDH50CMGBxztHWuN8v92w74rvVst1jpxZCc26MQPpQBcito2mhWIJ1ydvSupgmtrZWgmwMdz95uKxNItlS3llRnREAAZh1YnHHtita20z7QJJHfLkYOOcD2oAb9jSeEjO4M4dQR2A71DrMKvLCItpAXt3HvWlpC/ZpJba4DMdoxnqBUd40cCySuCY0OIlI+8xoAx0jaJA7fKpzgt2q7ZqbqaHj5I1P/1zWZO8k5MsjbmJxj0rb0d41txGWCseGJHUUAX1IkOSuQOBj0qeKPDHIH4mmwxZI5GAcYqyUzz744oAn0lfMmaQHcduB/n86brM+1iSxAQ/KPWprE/ZvMkAwAPwrntYmlmWaRWJcgnHoKAMm3nN9rlpCFO3zOmehr58/ab1oav8XtUhilEltpkcWnxEdti5cfhI0lfSHgZba3vbjU719tpYRvcSMRwqopZj+lfE2s6hPq+r32pXZ3XN5O9xKfV3Ysf1NAFOnIwVgSob2NNpyAFgCcD1oAbRRRQB+mHwz/5Jx4U/7BNp/wCiUrpK5v4Z/wDJOPCn/YJtP/RK10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVfUv+Qddf8AXJ/5GrFVtT/5Bt1/1yf+RoA/LSiiigBSMdaSlJJOSc0lABRRU1nCbm6ihXq7BaAOk0m38uzgBHLDcfxrbtx8ufeqsagzkJ91flH0FX4V6UAaNih2ZrZs4u7daz7OLOFA4retIS8iIgOSaAJYIC6scYGK9QSGO3jtFkIwkCrhv92uNhtFASFf4nC8dTzXfagqLcPEwXOFXce2BQBNpMcclg0EZALtuwTzitWHy7ayBtwN5OOe/vWbCD5IYArJIAFx2qWaQmFYuSQQMntQARSPPdSbgvUndjpWPql0t1dfKw8qM4X/ABrT1CQ2OkEqR5s/yAj07muZ2tsB7elAFyJd+NuPStO3jChBgZ9aoafCVXJPX1rXt1yefzoAtwAxqMZI6nPeraMMjGR9arxjOQvIzzViGMmYHJ2DrQBYvGMdltx8z8n6Vy2oSHaUVcnrk9Me9bV/dbpHLNtiXgE1j6i5lmigjTaSwBPrQBkfEm8j8LfAvxHPFKFutQVbCMkff81gHUf9sw5/CvjKvpj9rjVvsug+EvDcTgFvM1G4jx3/ANXG3/o2vmegApQMnA5NJSgkHIODQAlFFFAH6YfDT/knHhT/ALBNp/6JWukrm/hp/wAk48Kf9gm0/wDRK10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVbU/8AkG3f/XJ/5GrNVtT/AOQbd/8AXJ/5GgD8tKKKKAHMQT8owKbTmGDjIP0ptABW14Xh3XU1wekEeR/vHgf1rFrq9Ch8nR1Yj57iQt/wEcD+tAGpbLjFaNsu6RRjvmqluvFamnpumBI6UAbVjHtXJFdVoNntiMzjDydAewrC0+Dzpkj7Dk128MOxFxgYAAoAn0iDztYs4+CTMCfoOa6qZVlv90gG0Nu56fjWR4VhDaw0uOIYmP4nitK5DPIoUZJPIoA1o2cTMzAbV/L6Co1VJJSsYKr7+tWQhRFUqpKrvJpLLh5J24UAyE4/SgDE8QSq98sKkeVAuD9e9UI0yMkA57U7ImeR25aUluferdtEPlHcUASRwsqHGCPWrUbMgGR1wMCnopxggcVP5eWzjp3oAmgwwAGSa0EiCQsWbb71FpltvTzJBiMd/WqesX4SMtn5R0AoAy9Wny4WOMbVBAz0zXO+H7mW88WWtquJR5gJbrimaxqL3UMsSlgp++478dvatP4Xw2ttLc6zdyBbXT43uJHPZEUsT+lAHz/+09rY1j4warFFIJLbTI49PiI7bFy4/CRpK8oq7rOoz6vrF9qV4265vJ5LiU+ruxY/qTVKgApykBgWGR3FNpyjcwGQM9zQA2iiigD9MPhp/wAk48K/9gm0/wDRK10lc38NP+Sc+Ff+wTaf+iVrpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq2p/8g27/wCuT/yNWaran/yDbv8A65P/ACNAH5aUUUUAFFPkkaQgsc4AUfQUygByKXYKoyxOAK7tohFJFbr92BAnHsOf1rl/DMAn1iEsMpFmVv8AgPI/XFdVBmSVnPJYk0AW4V4H0ra0uPbg9yayoxxitm0G2PPfoKAOs8OW+8GVhwxwPwrq1UBM5rL0WDyLSNSACBzWs/ERPFAG54STZZajcEcswQH/AD9a0LdGa6TghiSRRoMHleHICRgzOZD+dSNkMOSGXoQaAL92SIo48gnAzjrTL7/R9FkXPzSNtFOy0zoSAWxg1H4gyrQQDHyDJ+tAGDbxc46dRirttCeGP4UlvGSe4yPSrsKndigCSNcA9z3qzDGTtUdWOKYigHjp6Vb09N11FnoGz+VAFvWP9HsFjh4IOOvavPNYuXmlCQk7AdrN2PrXceJ5CIwi91yT/SuAvgzE+XneecHsKAMHVpAsflxBt2MYB4P/ANarniu8/wCEW+AHiS5EgjutS26dFkfe8wgOo/7Zh6hnt1F9bxmQM8hCscdeegrB/az1FdP8O+EvDMDhd5k1GeLHI4EcZ/WWgD5pooooAKKKfFI0Th0OGFADKKKKAP0w+Gn/ACTnwr/2CbT/ANErXSVznw0/5Jz4V/7BNp/6JWujoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKran/yDbv/AK4v/I1Zqtqf/INu/wDri/8A6CaAPy0ooooAc2M/LnGO9NpzKVOD9abQB0vhaLy7K7uD1ciJfw5P9K6C1X5RVGyg+z6ZYwdGZfMYe55/wrXggcBfl46igCxbrkjitjTY/MubePs0g49s1mRKVAra0Fc6jB/sgmgD0G0wQBxirE/zKFX7znGPrxVax+6MdfetbRYPtmtWcR+6r+YfovNAHazItvaW9sOkcYFVSuWz+VWL1i9yxHPOB9KWCLcQec9eaALljDumBI6dayNUJnvpm6gHA/CuhhxFA7k4wvWuexufPqc0ALEhAwAPoKnQbSCozxmkRfmG3OCOTirBXnatAAgyc/jV6xQC4Xn1x+VV406YGSOtXrdQrhvSgCh4gO+ZQFy2MfpXHapmNiiKHaTj0zXSa3cBJGY4JIzkGuR1m48uISudoHJOefwoAZ4a06S78V2wucIkbYC9814b+1BrY1n4w6pFFIJLbTI49PiI7bFy4/CRnFe/fCzb9pvNe1OUizskkuHc87VVdxJ/AV8ba1qM+sazf6neHdc3lxJcSn1d2LH9SaAKVFFFABTlxuG7OPam0qqWYBepoASiiigD9MPhp/yTnwr/ANgm0/8ARK10lc58Nf8AknPhX/sFWn/ola6OgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqtqf8AyDbv/ri//oJqzVbU/wDkG3f/AFxf/wBBNAH5aUUUUALU+n25ur6CAfxuAfp3/SoWbcc4A4xxWz4Wj/0yScjiNcD6n/6wNAHTSHzr5tvAU4HsK35WHkptHbIrDsEyNx6tya2YPmTH5UASRn5l71ueH0DXjN6J/WsRBhwDWvob7bph6gUAd5aD5ODn/Cuq8Dw77y7vNvyxoEU+55rmNKRpTsTqevtXpHhuxFnoYAADSkuf6UACR4TPc1dt4uhOM4pI4znGBxV23jy6YoAi1H93YlBgFuKyIoSoHTr6VraoctGvuTVMLgEnIoAYi7SeoHWnoMsCQcVLtxgYJ96IwdoBoAfGCTx1PSprt1trZssdxFSW6bU8w8A9M+lYmr3TFz2QcsT2FAGNqk24GR2Axjg9BXD+I55LiTb2PCL7Hv8AWugv7kyyHaC652bT396zzYGXVoE3ZBZQRQBZ8YTnwd+zz4hl3rHdagq2MQP8QlIV1Hv5e8/hXxzX0/8Atf6qLPw/4S8NQyD5jJfzx45GBsjP47pfyr5goAKKKKACiinI21gcA47EZFADaKKKAP0x+Gv/ACTnwr/2CrX/ANErXR1znw1/5Jz4V/7BVp/6JWujoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKran/yDbv/AK4v/wCgmrNVtT/5Bt3/ANcX/wDQTQB+WlFFFADmAB4ORiun0KHyrOLPWXdJ+HQfyP51zSQyPLHGFO9yAoPfPSu0gRReiKP7kYEY+gGKANO0XbGPUitOADCjtis+LuPTgVoLx06YoAmHLpmr2kB5dXtIYgS8rbcCs9d0k0UcSlpXOFReSxr0nwP4b+w38E91te5ALY7KfSgDstJ0oW1ssfV2PJx1P+Fd40QjgjiHRVxWLpcIlvYgegO4/hXQ3AyenUdqAKyKcDgdau264BI9KgRTx7VaUbYT9KAMm8JNy3QjoPao8Y6jpUxGTk4OeaagP/1qAEHYZzz1qRFDZOeaOPanxLmdB6kfzoAkv8x2ihV529BXDa5d8GEDdjOTnqa7zVeLAt0YMVGO3vXDzWgM25/vDoD0FAHPlH2Ey43AAkDt7VoeCrP+1fEMEpyI42xgnrTNceCxtvMkdtoGwAdTx0Fa3wleIW19rV+fJtbJGkc/wqijcT+lAHzj+1Jrg1n4xanDHIr2+mRRWERXttXc4+od3H4V5JV7XNSn1nW9Q1S7INze3ElzKR/edix/U1RoAKKKKAClUAsAxwPWkpyKzttRSxPYDNADaKKKAP0x+G3/ACTrwt/2CrX/ANErXR1zvw3/AOSd+Fv+wVa/+iVroqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq2p/8g27/wCuT/yNWaran/yDbv8A65P/ACNAH5aUUUUAa/hyMvqPnvyttGZefUcL+pFbukn5956k9a53TdVewguoY4YmS4Chiw5AXJ4Puf5Ctax1yxCqs8MsZH8SncKAOnQ4J+tXLVJrqdYLVDJK3AHpVDTJbHVLlIrXUreMt189vLx+fH61634W8KT2Vqs1vGs6MMmaJg4P4jigCTwb4ci04edJiW9YYMmPujuF/wAa7PToBHco3cAjpUOnQmHClDmtqzgHJ6UAbnh+HEsjHkqAK1nBJ4Aqtokfl2hcDksT+FXFwelACIvPAHrReHZbN6nipYkOenU1W1PO5UUdOTQBQHJ4HWnxqepHQ0iHAIA7c1NGMD680AJs4PFSRrtljJ6gilVeh9aljTcwwOM5NADb4D7GysM/OT/SuSvkIRmPCnr6j6V1Oot5gba2FBzXDa1K1w/lRlliXkkcE5oA47xMZ7u5jD8puCKoP3eefxroviFfjwn+zzrkibYZ7+MWMSt/F5pCuB7+XvP4VnJbyXOsWUEY4Lj69a579sbVhZ6H4T8MwyKdxe/nQdRgbIz9Dul/KgD5booooAKKKKAClUlTlSQfakpVIBBIyPSgBKKKKAP0y+G//JO/C3/YKtf/AEStdFXO/Dj/AJJ54X/7BVr/AOiVroqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq2p/wDIOuv+uT/yNWar6j/yD7r/AK5N/I0AflnRRRQA5htOAQeM5FNoooAK0dL1vVNJmWXTNQurWRejRSlcVnUUAepaD8cfGOmFFuri21SJeq3sIdm+r/e/WvRdB/aN0qVY4/EHht4HJ+eaxmyB9EbJ/WvmiigD7q8NfF3wDrNvFDa68tlM52rDfRmI/iwyo/Ou909oNRhMumXdrfQA48y2mWRfzUmvzYq5p+p3+nTJLYXlxbSIdytFIVwfXigD9JkQx5DAgjnmsy6O+V+/pXxj4e+O3j/RQE/tp76HOWS+QTEj03NyB9DXoui/tOBwR4g8MQsxP+ssZjHge4bdn9KAPoEqA2KmUdsV5vonxq8AaxkHVZ9MlwAFvoCAT7Muf1xXoml3thq0e/R9SsNQ+UMRazrIQPcA5FAFy3iaVgsQJPUn0q41nKkRCbSew6VajjNrZp8uGI5z6mszUNSmtWBVt+TyjdMd6AOd1p5Wla35RUOWPTPtWRNbq64CZwcgA5rr/E8ETxQ3ADYyBgdWBGRXFahM0qyxIWXjDMP4f9ke9AEPhO0k1HxHGtv/AKuNv3kgPv8AdH+NfPH7U2uDWvjFqcUbq9vpkUVhEV7bRucH3Du4/CvrXwJb2uj6Nc6jcYhtbeN5pGP8KqCWY/ka/PzXdSn1nW9Q1S7INze3ElzKR/edix/U0AUaKKKACiiigApyKGcAsFB7npTaUDPSgBKKKKAP0y+HH/JPPC//AGC7X/0StdFXNfDEk/DbwmWOSdJtMk/9cUrpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq+o/8g+6/65N/I1YqtqWf7OusKWPlPgAZJ4PSgD8tKK6D/hCvFX/Qta3/AOAEv/xNH/CFeKv+ha1v/wAAJf8A4mgDAYljknJ6UldB/wAIV4q/6FrW/wDwAl/+Jo/4QrxV/wBC1rf/AIAS/wDxNAHP0V0H/CFeKv8AoWtb/wDACX/4mj/hCvFX/Qta3/4AS/8AxNAHP0V0H/CFeKv+ha1v/wAAJf8A4mj/AIQrxV/0LWt/+AEv/wATQBz9FdB/whXir/oWtb/8AJf/AImj/hCvFX/Qta3/AOAEv/xNAHP0V0H/AAhXir/oWtb/APACX/4mj/hCvFX/AELWt/8AgBL/APE0Ac/U1vcz2zbreaSJuuUYr/Ktr/hCvFX/AELWt/8AgBL/APE0f8IV4p/6FrW//ACX/wCJoA6Tw58ZvHmgAJaeILmaIAKIrvE6gegDZx+FehaR+0teOwHiTw9aXa4wXtZGhc/XOR+leMf8IX4p/wChb1v/AMAJf/iaX/hC/FP/AELWt/8AgBL/APE0AfVK/H3wV4gt7eCSW70ibqxuYd0aHGBhlJJ/LvW/pVxpmu+Sujazpt+ZGzthnXe3/ADhv0r42/4QvxT/ANC1rf8A4AS//E1JF4P8WxMGi8O68jDutjMD/wCg0AfaXxy1P/hFfgZr+0rFcXcYsI1b+LzSFcfXYXP4V8FV3Wo2nxH1PRYdI1Cw8UXWmQyCWO2ltZ2RHAIBAI4OGP51i/8ACFeKv+ha1v8A8AJf/iaAOforoP8AhCvFX/Qta3/4AS//ABNH/CFeKv8AoWtb/wDACX/4mgDn6K6D/hCvFX/Qta3/AOAEv/xNH/CFeKv+ha1v/wAAJf8A4mgDn6crFWypwa3v+EK8Vf8AQta3/wCAEv8A8TR/whXir/oWtb/8AJf/AImgDn6K6D/hCvFP/Qta3/4AS/8AxNNbwb4nUEt4c1oAdSbGX/4mgD9EPhh/yTXwn/2CLT/0SldNXOfDWN4vh14WjmjeKRNKtVZHUqykQrkEHoR6V0dABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcz8SvFieB/BOpeIpbRrxLIRkwK+wvukVOuDj72enavDo/2p0kQPH4H1B0PRlusg/+Q69G/ae/5IZ4n/3bf/0pirzO71TVdP8Agd8JodGutRge9vIreVLC6W2lmQrJ8gkY7VyQOW4oAmk/anSNC8ngfUEQdWa6wB/5Dqv/AMNa2P8A0KNz/wCBy/8AxFTx63qWo/Av4o6drl9fXN9pk8kYivZUnkt4W2lEaZPlkPDEkdDx6V8h0AfWn/DWtn/0KVx/4HL/APEUf8Na2f8A0KVx/wCBy/8AxFfJdFAH1p/w1rZ/9Clcf+By/wDxFH/DWtn/ANClcf8Agcv/AMRXyXRQB9af8Na2f/QpXH/gcv8A8RR/w1rZ/wDQpXH/AIHL/wDEV8l0UAfWn/DWtn/0KVx/4HL/APEUf8Na2X/Qo3H/AIHL/wDEV8l09UzQB9Y/8Na2X/Qo3P8A4HL/APEUv/DWll/0KNz/AOBy/wDxFfKUcRZlCqzkngKMkmuisPB2tXflMLCVFdsZYY2jGckdQORzQB9Gf8NZ2f8A0KF1/wCBy/8AxFB/azs+/hC54/6fl/8AiK8XtfhdqMjbZLmNZipZVwce2T/npWReeB9UggkmSMTogO7y2DEEEAgDvye1AHvx/a0sh18I3P8A4HL/APEUf8Na2X/Qo3P/AIHL/wDEV8u3NnNCXFxFIjodrq6kFT75qBoCBkqccdaAPqn/AIa1sf8AoUbn/wADl/8AiKP+GtbH/oUbn/wOX/4ivlLyh6/hTWhKjOaAPq//AIa1sf8AoUbn/wADl/8AiKP+GtbH/oUbn/wOX/4ivkxlxTaAPrX/AIa1sf8AoUbn/wADl/8AiKP+GtbH/oUbn/wOX/4ivkqigD61/wCGtbH/AKFG5/8AA5f/AIij/hrWx/6FG5/8Dl/+Ir5KooA+tf8AhrWx/wChRuf/AAOX/wCIo/4a1sf+hRuf/A5f/iK+SqKAPrX/AIa1sf8AoUbn/wADl/8AiKRv2tbLBx4RuM+98v8A8RXyXRQB+hnxo+JyfDKx0q5k0iTU1vpnhCxzCMqQAR2Oc5rzL/hqP/qRdR/8Cf8A7XXRftNj/iY/DY/9TDD/ADWtPV3vPFnxm1bw3qGv6ro2maZpsNzaW+m3ZtXumfO+VnHLBfu46frQBws/7VcNuB5/gu9iB6b7sLn846i/4a1sf+hRuf8AwOX/AOIrN/a/iSHwb4Cii1KTVI0M6reySCRpwFj+csOCT6ivlygD61/4a1sf+hRuf/A5f/iKP+GtbH/oUbn/AMDl/wDiK+SqKAPrX/hrWx/6FG5/8Dl/+Io/4a1sf+hRuf8AwOX/AOIr5KooA+tf+GtbH/oUbn/wOX/4ij/hrWx/6FG5/wDA5f8A4ivkqigD61/4a1sf+hRuf/A5f/iKP+GtbH/oUbn/AMDl/wDiK+SqKAPrX/hrWx/6FG5/8Dl/+IpD+1pYkc+ELj/wOX/4ivkuigD60/4a1sh08I3H/gcv/wARR/w1rZ/9Clcf+By//EV8l0UAfWf/AA1rZ/8AQpXH/gcP/iKP+GtbP/oUrj/wOH/xFfJlFAH1n/w1raf9ClP/AOBo/wDiKP8AhrW0/wChSn/8DR/8RXyZRQB9Zf8ADWtr/wBClP8A+Bo/+Io/4a1tf+hSn/8AA0f/ABFfJtFAH1l/w1ra/wDQpT/+Bo/+Io/4a1tf+hSn/wDA0f8AxFfJtFAH1l/w1ra/9ClP/wCBo/8AiKP+GtbX/oUp/wDwNH/xFfJtFAH1l/w1ra/9ClP/AOBo/wDiKP8AhrW1/wChSn/8DR/8RXybRQB9Zf8ADWtr/wBClP8A+Bo/+IrW8JftOW3iHxTpGjL4YmgbULuK0EpvAwTe4XdjZzjNfG9dd8If+SreDv8AsMWn/o5aAP0mooooA8u/ae/5IZ4n/wB23/8ASmKvC/C3xr8CQ/DrQPDXizwpd6udMiA/eRRSR7xn5lDN6HFe6ftPf8kM8T/7tv8A+lMVfn5QB9JeLPjh4Iuvhtrfhfwt4Wu9IW/hKKI4YY4w5I+ZgrZPTrzXzbRRQAUUUUAFFFFABS0lPiRpZFjjBLsQAB60AC5B4GT6V3fgf4e6h4iENxKPs9o7AKz8Fxnkj8jzXY+Afh3aaRotzrvje38uInZBDN8nIPJI71f1D4hL5n2Hw3EqW33fMaMfT5ABmgDsNK8I6doJit9Hgj+2x7WecQ7yoxk/O3AJ6Y96o+MdesPDsiWtwJNa1icYNnG+xI19XA6fjzXHPrusaA0y6tqn2WWQbmtj98g87to6E+nFefXF3IbqS5guJGklO55W4ZyfXvQB3GpX3ie/uJbr7fBaFf3gs4MkKMbeSeTx61U0XxlrPh/VFGqmO4tHO2VJF425/Q+49a5eLVruMeWj7mfjLHpXf+GvA76tBDdaq7JIwLwoRuBx0DDjv6mgDobW8svFN48trBC6KG2m6df3nIIX5vcnjrV6z8CaVcPIbvTYUeQERFSWjTHIPJ4Iz9MVY1Pwba+JLDdp0yxXCQeQ32dQEd1/iwMYYY24+lefaB4l1fwxrH9m6qZj5L7cN+WR68d6ANrXPhlpxKrBN9nblZPMXIVgeuB2PT8RXB+IfAd5p21lRpI2UlGRSd2Dg/T1r6B0nWILi3jexeK9ikBR43GCj4J49sYq/dCE6fBHOV8uOMqIxwrHAGSccDgnNAHx1PbtG20qRngZqq8XpX0J488IWWoWlzc2CoskBzIq5G7nA2/TIOe+a8N1PT5LKfypFw3OeaAMcjFJViRRyOAar0AFFFFABRRRQAUUUUAfav7W2oR6Ra+BtSnR3is9aS4dUxuZUAYgZ78Vyvij4+fDLxWYG8R+CL7UXgyI3nihLID1AbfnHt0rY/bd/wCRO8O/9f7/APos18eUAeyfHj4oaB490bw7p3hrSLnS7bSjIFikSNECMECqgQnAG2vG6KKACiiigAooooAKKKKACiiigAooooAKKKXFACUU7bx1FGB2NADaKXFFACUUuKMUAJRTjjnFJQAlFOVSxp4jByRkigCMDNOC+vFTLGF4zg9akVF4Xqc9aAIPK6Z78YrrfhFHj4q+Dzjpq9p/6NWucQbn9MnJNdZ8Io/+Lp+Em9NWtev/AF1WgD9GKKKKAPLv2nv+SGeJ/wDdt/8A0pir8/K/QP8Aae/5IZ4n/wB23/8ASmKvz8oAKKKKACiiigAooooAWvbPhJ4V0/w14cb4ieMo1azRjFpdk4+a5m7Pg9QOT+Ge1cn8EvAv/CeeNoLG4k8rTbZTc3khOMRqRwPckgV0/wAZPFSeJ/FzWum4TQNHzZ6fCvCYXClwBxzjj2AoAwvGvivVPGOrPeanMywKf3Vtu+SBOw9z0+tZK3D2hJsJGTI2+aVw5+npVSXzJCI4Y5ZIlPzFBkFu5Jrt/AXh7SLu8lk8U3NvHlAYLZpuAvd3IOMcgYoA4M3Ekczs0gkkY/MXwxNSQNBcSEeakUg7N0NfSqeGdOs0WKytLZY8ZQxRjaffd3rndf8ADWl30RFxaQykjJwuGHvmgDxO3up9PuRJCYt68jaNwrsPh54paz1MwXatJDc8EM2QrZ649ic/lWJ4k8NyaRcyGDzZbNBn5h8yD1HqKoaZahp1mWXEafNuXqaAPpZWWy0u2tNKSWV7qMiOUnGCSS5bvyea8C8QadPrHiW8i1CSdb2N9gDdQc969J8K/FDQoYltr6eSGdfk82SMvuGOPp7/AErmfiPq2nXPibTNctrq2uobi18i/ayBxHKp6hTyAR3+vNAHOaJcX/hW+M8DM4RsPFMpKsMe9e6WuoxX9qk9oS4nRHWKTkEdce3NeA+Iteh1W9kj01SkbkZlmTGBjoB616P8LtctbuF9BlGTAuIWJ+bIHJ9wT+VAHc38iXpthFb/ADoTJ5LjaBwcg+2T+leZ+PvCcNyklxCY1miiDSDePmbPb1rvtTsri9gWBr+W2uYzmOdDgbgep9fp71JeWsgjjEmxJHIztG4DHU/T/GgD5TvITE7KwI571SfhjXcfFLTl0zxBNEM4Pz5xjrzXDtQA2iiigAooooAKKKKAPsT9tz/kTPDv/YQb/wBFmvjuvsX9tz/kS/D3/YQb/wBFtXx1QAUUUUAFFFFABRRRQAUUUUAFKB9cUlLk0AHHrSU7kmlCE5wCaAG0VNFA0sgjjDO5/hQbifwFakXhnW5kDR6PqboehFq/P6UAYvPWlHt1rptN8FeIL9GeDSbpIlbaZLgCBQfTL4zWkPhxrLK22fSC6jlBfLn/AAoA4fqKO3XpW7qvhXWtMObrT5gh6SRkOh+hGRWJsbJBHI6g8GgBCOevJHajoBg0pQ+hoK4/u/nQA314pQMH0IrV0jw9q+s/8grTL++HQm2t2kA+pAwK9E0v4IeJVtDqHiRYdB06MBne4YSSkYzlY16/iRQB5fDCXKjI5PAz1ro7bwxftCs0ttLEjglGdcBscHBr0vT7Dwv4etZIba1XVGdwRcX0Y+YYx8oHKnOKNX8QSTaW9kbeOOFGBiC5+STuQT2I6j8aAPLrvSPLI5ySOfb/ADiqq2qqfmAJHY+9dBdkM7P98tySeOcVUbaCMhcjnn+v5UAZj2qoFBTDgc88Cuu+FdusXxL8KbyDnVbUpsH/AE1Xk/hXPxbI5VVgW/xNdT8LAT8S/Cj/ADFTqludwPrIuM0AfflFFFAHl37T3/JDPE/+7b/+lMVfn5X6B/tPf8kM8T/7tv8A+lMVfn5QAUUUUAFFFFABRS0UAfT37PMEPhn4TeIvE0kf+kzJPJGzjjESEJz/ALxP5V4Zbhika5y7Dlj6n/69fQ/huGMfs1XMMUiyrHpMrsg52SMxY598Y/OvAbAK13b+YcJuUMfQE4z+GaAPQdd0K1sPhj4bWNxbTTSk3FwFOH3FsZP4Vw00lvBeELEJIseWM5Gcev1r1fxUIZ/ghEsyCSfT7kQk55Dh2GffrmvJY4zMp2YREwAp5Az7/hQB6J8OvFD6VOmm6nfb9JkVgisMrDITw2euPUV6TcGJwJYbi3niYkK8Z34Hvjp+NfNjuGXYo3YbggYBq/4Y1OfTNetbi2eSNDKFaPcdrqcDBoA9i16wBtpZyi7VjLKxQknOeMH2zXi/lLa6rJZElYLjiPPRc5x+te6nUEuYykpQMN+dxyM9M/zrxL4jEw3lvKo2S5bkDHcEYoAwWUq7RyAEqdrA+1IOGA6Y6EVauibq/YsQJHxuJ6ZxTJbZklMb/LKvb8P5UAQqfmHP51Y0vUJ9K1KG9tHKSRNkEdx3FbOm+DdZvbGW9W3RbGJN7TGRSAPcA5rnpVxIUHzYOMgUAfTMN3Fr+mWGp2wzBL87sg+4cYII9s1aeyjWGG5g3Moz5g3E/J1OK81+BPiBba5u9AumO6T97b5PGcfMv5fyr2C2jjiuWSMZSfkr2Xj/AB/nQB4d+0Jocianpt3CjeTPbD5j/eB5/mK8SbIJB7V9qeKdKOt+ANZtjGJLm0t2eLK5bK88e+BXxheRPDcyJICGyc0AQUUUUAFFFFABRRRQB9jftuf8iV4e/wCwg3/otq+Oa+xv23P+RJ8Pf9hBv/RbV8c0AFFFFABRRRQAUUUUAFLQAT0qREzx36/hQAzb68U9IyxC45PA9Sa7Lw14FvNStFv9SmXStLbBWedSzyg/884xy2fU4HvXdaUNM8OOD4cstky8Ne3aiW5fqPlP3Yx/u8+9AHC6R4A1e5jS41EQ6RZnnzb47XI/2Yh85/LHvXTweGPDOlxoXju9Yuefnuc28Ix6Rqdx/E1dZpLiZ5pWeadzlnclmP1NTpYTyKH2YzydxxQAyPV7m1j8vTUh0+MHhbKFYsn6jk/nVNr67klDPdXRIbIzMxP4c1tR6XbhR50j72BPH4dKs22mWptZg8ghmiOUDQk+aD23dj9aAOXubie5IE00knoZXLU2N9spcbBgZ29jmuifTbUgYRB1IAHT2qGXRraWNj/qyAGAHfnB/wD1UAZ1tfy2j7Y1JjfloyfkPPTFam7w5q6btd0y0lcKQrKpjYc8fMpBI+tZ0+lzRB3RllUcsM4IHrj/AAqkrKVZXQ7gcD0BoA24tM8BwxCYeFHlKHa+7UZWXJ5B28HtW7p+v6JpfktpnhTw9ayLkLMtmZHI+rEmuPhJMLpGS2WBIBx070/c/lOm0/eDAHqDnBFAHoviH4i6rqOniCzddPgBwosf3Idcc7u5+nSuFnuppYFxMywqSZE3k8ccnPrVaWV/skYPByTk9/8APSq8zIlltYkyl97AngDGB+tAFeSdFl5BOepHP5VBezebIG+6gA+X6DGfrxTSxxucqigYx7e1Vp5GKHIHBAODyf8A61AFGXJHJ6tgn19v5VUd8bgxyG4Kg/e9jUtw+NxDBgSML3qs7qjZfOS2eB09qAFVwdjnCndtbI7eldT8KnL/ABJ8K8rxqtsBgdcSr+lcgJBGyAsTuGT749PyrpPhXdf8XO8IRqhUDVbZR2yDKv8AjQB+hVFFFAHl37T3/JDPE/8Au2//AKUxV+flfoH+09/yQzxP/u2//pTFX5+UAFFFFABRRRQAUtCjNB6mgD7U8N6cB8E7e2VFWOfQ8soH32KE5PucgV8sQf8AHvj+8pX8a+uvCMXl/DnTiz5K6PHtPTA8oGvkYDaCB03H+dAHVa74iurzw/Fo5MK2l1LHeh3yCrgFWP55rC06JneObcERWZGLEFSPU/yqK+KSaJbbhl7acj/gD4/kR+tIhtltbhZVkUsVAkQ9Fzk8UAMu2DAQ2akbWDOG7HFOg3G3S8ALeV97aP4s5GahSxy24vIYwCQ3970Jx0pXjl0yGNh+8iu1G4qflXn17mgD1DSpovLS4VDAxt1k2vngnrn8cmvPvFN1/wAJP4qjijZUgjwHlH3QO5q74z8SyXrRRWU7Nb/ZUikbGC7Ac/4VjWMrWllHFGmJJ/ndu5HYUAQ30apdyLE4kjU4V15yKfJcm4s0im+aSHOx++30z3FRzSOSN+AR90gYNQg/N6H3oA7Lwz4wltfDmpaNeDfHcR4jk7qR2NcbuYSNg8+tOZMA881HnnjigC3YX9zYX8F7ZyeXdQsHVwO9fT/hnWk1/RLfWbAAuV/exj/lm46j/PrXyvjC+wr0L4LeLBoOv/2XeZ+xai6orZ4jk6A/Q9KAPpTTJg11DcRjNvPHtcE9c9P618v/ALRfhGPw54wae0j2Wd6vnx46ZJ+Yfgf519KWjeRasjDclvIyuuO2cj9K4P8Aaa0hdV8B2urRDL2cmOBn5HH8sgUAfJlJSkcZpKACiiigAooooA+xv23P+RJ8Pf8AYQb/ANFtXxzX2N+25/yJPh7/ALCDf+i2r45oAKKKKACiiigApSMUAZqSNTk8Zx60AKq7U54PX6V6n4R8JRaLa2+q6/apPqEu1rWwnX5IQQSss47kgErGfqeODU+Hfh8RWo169t0mcuY9Nt5F3I8i/encHjYnYHhm9gRXa69LbyPaRW0s058sTXE8p+aa4f77H14wo9h70AVbma9vbhw1zLK9zIshZzku3QZ7DGSAOgqbT9Ikuc5+VQMlS4U8DnknmorJoUlkaRlLBd2D/Dz39K1VSI7X8wAOMIQMjnvQBY017Kxtr1XsBcSvARb/ALwp5bk/fI/i47UalZSWt15b3EUwKRyo6A4YMucfUc1fNjDHbfaLx1ityikOx+98uTj16U7wpBe+LtT0+10KEQWqAh725jJQbSSF56nnGB60AZphuxZBfJ/cvJ5qkr/FjGQepGO3So2iklQxqoQxrvd2OBjpjn+Vdvf+ENQe/uxqOqalbyRiScyrAHjKY4CKOnI6EdK5DW47/TIn1K4aLWtFXAubq0T/AI9yRnc4HTjn2oAoqJT8/lYXhzj34GalVisaSuqujZEZkX5XI4OPpWrr2jw6CFS61G1KXUKSxuZ1Cyg8jbzk9ay5V3KsAVnwuUGeOfQfjQBNDc2a2xH2FftBG0ywzsPzU5HTNZmo6Zb3IJUpHI2WWTpn2Iq7dwTWWDLbyIpAwwXAzjoKZatELqI3S5t5ZArjH3VPGf65oA44efaXYVgY50PH1/r/APXrUv5Yr6wt7+FPIuIsQ3EYJ2ydSGHoR0IrR8YaRPp95cWVzCGuoMhCrffBPGD6dDz3qjpsANo5O+Jn4lil4VyCf8KAMMyK+NqScE9eR+FNVJjhRESpOeQTxnpXUxLsU7HjCHopXPHp+tBSMBQUJJJGF55B6fhQBygspmXcIGdsHB/xrK1DbGGEsiBgvQdq9A1JVfShLFGkYZyox6YzyOua8u12RVlIXODz0xQBTvLoq5WNhjoKoGZiwZmOR0OaiPP3j1OcmkXBwTwTzgmgB4ywOeODx6V1nwmJPxQ8IY5H9rWhx/21WuRI+YFjyK674TLj4oeEAAR/xN7Xj0/epQB+i9FFFAHl37T3/JDPE/8Au2//AKUxV+flfoH+09/yQzxP/u2//pTFX5+UAFFFFABRRS0AKpIpPWlHekHQ0Afd3gVV/wCEV8OwSSbwdMjRdwALbkH8ulfIUylJZFbO5XII9wcV9eeBrmMeC/DTlV3tZQ7QOSSFAzXyr4vtTZ+MvEFrgARX84AHYbyR/OgDLcF7eWM/dIwf6Va8KSW818i6ij/YpVaKRgM7CRwfzFNuAvmF8YDKrYB79/5V0fwy8ML4m1LUrCQSQxW6PiZTkZfG0EfiTQBymtfZYdRlttIu3+yBtrXDn7574HYV0mi+Hhq+jJHdXxit7OViy7cjYRnI/I1k2fg97y9s7e1+0qLqaSJECZyUOCeeteja/p1xoHh3xDHetC11ArK3kcRr8nyso7ZB6etAHksFvPrN6kOlWskrMTsjRc8Zq/rNo1m8QeRSNihShyOld5r+jx+BvhN4W1aws4YtV1BklnuZQZGV8FkCjoPlNcR4pvzqFxau7KbhYlE2xNqA+gH0xQBjcg896CfalDFc9CO4PINWrOKxuJAlzdPY7ukhTzEB9+4H50AV4thP7zOB+tTXVskaLJDL5kZ9sFT6EVvp4C124thc6THBqtmTgXFlKHUH0YHBU/UVteFvh/qN3NPbalC1uNuNzjGDjg+9AHAbspsHHvTG3BgyEq6nKkdQRXS6p4I8Q2FxIjaZJPEjHE0RBU1kvoesblU6VfKXOAfJJA/HtQB9LfDPxOPE/hcXUhAvARHcD1fAyfx6/jXRa1pa+IfCV/obuI2uIiqn3HIP5iuP8J6Jp/hvw3ZQ6cxmhkjEl1KThmcjr+HT6V1sc8sMKT58yIH51A5A9RQB8W+JdJm0bVbiyuEKSxOUdT2IrIr3P9pbQli1WDWoAWhu0AZsdGA/wrw00AJRRRQAUUUUAfY37bn/ACJPh7/sIN/6Lavjmvsb9tz/AJEnw9/2EG/9FtXxzQAUUUUAFFFFAD0rf8F6A/iTxFZ6WkghSVi00zdIYlG53P0UE1gdD9K9m+GOmLpXgm41GcFbzXvMt4GxyLeLlx9HfAPshHegDbvrmNyTbQNb25VYLaHPEVso/dj8clj7nPeodJt4bm+jN1P5FsrfvJChfAzyVA6mqpcuzYX5m+Xn8OK2Lq2aNYokOxo8cjuM5Ax0oAt3MC2089pHHvhDFQWH317Egdc/1rqfhx8P1bT7vU5fNMCszQRHJAI52gHt7e1cRpuovNrcVncwSoFcZnzlNuentmvorxrfSeF/A8UmnRxgKI1RegGVJOPyoA8ehWPU08uZYWsbWeTETNuaVlADMRx8vIGPX6V6YNa0bSdYij1nULP92gmt1RDhQVIYgDgc8e+K4jwcL2XwV4dFvJbhL2a7kuLudFZk+dsxqhHJztOc8VzHiS5s7jU11Ge0lvI0ZIhJMgUAAvw23649iKAPYbpv7T1VL66uNUit5IvLt8rtVlcriTj7p5PB7dcVSnsdN8OeF5NN1+4heymY20kcMfzX0jghE9zt45xjFZkt9J440LTdKitbq0iaUkGK4+dogQeG78jr6VzXiia41T4m6MlhIxitbeTfayXSkRXALL17ycEkEUAcDNZaPFd2Vt8StCu4Vt4FtrG5ilfb5SSkrvUHoAdvHI/Kut0abTPEct5pxm+wqBthhRjue3GFVBjkcAHOc10F94c0610y2jkvBfzWV1Il9skMyxLNjcmCT0PP1zXFXng680Hxj4Xl0m5Wf7bIYImjUgKxUhcnv7+negDA1rwZq+hQiSw1y/EDzKBFKu4RRtnkgnJxxUWl6s9lq8VvrkfnJHMrNPAmFlQ8Hg8A+xrq/EyXN9pj/a5Ghv0Xbcwq+Sjo20gexYH8K5rynkimLsWlTGQB1B/+uaAN/wAYazZ+Idfe7svMMJhRGRxzkArzWdd20kdlaycENlVGeRj1HUA5NczegWssKwRLAQJGZtx3Md3Rh0AHOMetQrfSRIFSaSQejZ6/WgDok8zfs2Bj22gn3/z9K0dEla/doxHLLcQqZNiAAsc4BHfIzn8K5OCYXSBpftG5TuIibd07g9a2NA1+/wBIk87S9SmtpQux/wB2A7D3JFAFfW7jZE1vbsJNpzvx0z2/TH515zrO+SQ7IuOMnFdhqZWCOSSabzH5baOx98fXNcVqN/IzYWNVTGCepJFAGbJbskm1xhjlsk9RTUGAGBBbA5PUUkjySNukbcRzyelIM7TzwfQ8kUASoAobpkHHPfnvXZfCOP8A4uX4WYZIXVrMZb+H94vH69a46OJZXKrl2POP8fSu3+EiGP4meFxnJOqWuc9v3q0AfoPRRRQB5d+09/yQzxP/ALtv/wClMVfn5X6B/tPf8kM8T/7tv/6UxV+flABRRRQAUUUUAFLSUoGSPc4oA+3fhsYl8CeH1DhpUs1Dn0IJ4/WvB/jFbC0+KOsbVws6xXAA6Hcgz+ua+jdGjitvDmioFAYWUIwo6nyxXhfx8szD470u6dWRLy0C591YqR+ooA81jAKsNxwFyM+vpXb/AAgvksvFmpxTuY0uLFZgCcZZRiuMssoLkFclF+ZT6ZxRDNaw67ZvqImNi9oySeUcNtBPT8qAO68Tw3Vzb6bawXEdszTSGNtpyhOPmYjsM1Z8XqU+FeoKbhbmeErHNchstK28DJ9R6VBqV5Yta2OqRvI9nHEZolcHD/whHx3OOab40jc/CqO4gWGJJ4I2ZIR8py+T+RoAl8ca1q1pBaWAmdbQWUBjRhleI1wcdyOxrzGQE5LMWZiSxz1Ne8/ErQDqnhnw1qFv5MYfTISzu2OPLXoO9eF3MCwtjzVc56jigCr0yOw6UYGaceM5obrzQBf0LWtS0C4efR72a0eQbXEZ+Vx/tL0NerfDzx1Hd6UllrE95HdQMS14uHUqTwHXGQBzyK8Y4KnFb3gXVo9F8U2d7OT5IbEgzwyngg0AfSoigkCsWaRZVyriTKP7jHWqF3p8F5OI0jKbRu2tny2PuM81U0PVtHfzLewmUW8r7o4i3CE/3fT6VsmRWlCKSQM7iO3FACww7dOkglVQUXaAnQDGBj0pdFMosipYluhB6fhUVw7RmOVQXULwB1NMsZiwkjI2oxLbs9D6UAcv8abdb/4bTtuVhayqy4P4f1r5YNfV3jJVf4a65HIgygyMjnORXyifTBoAbRRRQAUUUUAfY37bn/IleHv+wg3/AKLavjmvsb9tz/kSvD3/AGEG/wDRbV8c0AFFFFABSikooAmgieeaKGIbpJGCKB3JOBX0HrMX2XUU0e1z5Oj2qWMWBjBVS0h+pctXk/wj07+1PiJokJKqsU32hi3QCMF+f++a9R1+SK41TUrmB2eGaVnRznLZbJP5k/mKAINLiE1y7IwVkUOoHTcSAf610c1s06g26mQEHcy/LsOfU+1YOgnMs2GUBhsbPXHOOe3OKk1G8mgQFIZbny/4P7qjrx3oA2LPS71JIJpBbxQAgtcPMuw9M49SPpXtHxMnjufBSQoPNjZkZWxtP3fvAHt14r5vuPEWmrPYweZI73LBEBQ/ui+MZ7CvedYcXHhTwtly4vgbPzC3yiQAlM/iCB9aAOK+FEekX00vhjxHeS2d2szNpu1tolEuSyqexyAcVmfERJPBOlT6RaaZFJo1xdi5e6lud8jKWwQU4OAVP51neL7AS6beyGGVdd08l7eWIlTC4JOePx/KpvCWoWfxAhsLXVb25j1P7IbRnnZZYlIcMWCnv1A+tAE2gXV7oiQEvJJOXaG18rKtEucgDOM5zj6Vl6No2j3mt6rqmoLLdSpYz3k0Pm7DA2/BfI67cngVsj4S3Gq6ENX8Ma5cSR2ySx7boNuLKT8y46AjGPSsaC7sPBljqNvfXbXN9f2DW81vEhaMFjnO89uAfoaAJfh/4o/s7xnBoUc5v4NQdSs8TAb0Dbg2D/EAO/oas/Eq7n/4Sm30WHWlulspWnnllkCrGDj5Qw6kjjA6Yqp4b0zwX4Ti0/xB51zqN1NarLb2ajaI5SDvbzOm0Akbetee3U0+sanNd3EbxwvlY1jHRR91F/DgE0AeoSanpd94sh06winlt7pNks084eSSQ/xZOOOwGfemalod3oWvr9utJJdPYFRNENx2MCASB6da8rt5mbYceSM4BLc/nXb6Xrl2NNk097hvLmyMP821u2D7igDI8QafPFrJsbcCZogdrqMrJk9VPcYwfxrNKyK8aPG6SKMgYxyPT0rcsbJH8QwWF9M0EdwwXzg+0ZPQ5PAGa7+/uYtA1V7GzMCrlDDOsaMXHfLnI69xxQBxfgDwtB4g8SW9lq8r2ttIpZZD8oJHYHj1r1D4hfB9LHQnuvDty7zwIXlhlO/zUx1UnuMHiuM1K/i1F9i60b6QLtaJkwCcjp+XWsu91zXtGt5IodWuzaSKQIzIWXk+h6UAcHqrSSwKEjXc3BZVOB/hXKXttP5mFTcOgPX6muyvpbq2tdhAmgdwW28hjjuex5rlbq4dfm4UjOKAKMVpMXACnHfPSrK2UKE+e+4E7cDjHuafHMWc7shQuRhuuP8ACrBIK5bG5RtJ988UALERHEVhYc53ZPUH3/Cum+FxB+JPhEsOmq2oxt/6aL/iK5cgNI5ygU4BDdjn278g10fwyMa/E7wiqAsBqtqM44z5q85/SgD9B6KKKAPLv2nv+SGeJ/8Adt//AEpir8/K/QP9p7/khnif/dt//SmKvz8oAKKKKAFowaBT+MUAR05eCD6GkNHagD700WRJPDPh+ZQzBrC3YN2zsHH1ry79pK0abRNC1FUx9muXh3em9cj9Urv/AIeyyXfwx8KsjDa1ggOeuVJHX8KyfjHZ/b/hxrS4zLbhLhcdijDP6E0AfN0Cn7VKM5LxbiR/FnBqsl35Op6HJIoZIZWQ7ujKSDg/ma0fD0P2qS5GcbbWR1OOcqM/0rC1cbbGKcZwlzjH1UH+lAHu3i7SJb/wbDbaKLbzgVZ0d9iMvbaMdfauT8cyT2vw7gspbabakX2cCMgrGV+Zix9yOK63w1cRXMcDXEZltSEZCeQGA/xqD4kSRv4H1ONLcxybHJUdG5+9QBZ1qeWb4TeEZ2nWO3awjiyFy24Lj8emK8P1Dy1mfYWY7uWNepvqEj/BDwssZDbYpU57bZWFeSzEszFjnNAEeef1BpM5PPNIw55Bz0xRk+vXqKAFbnpSHGMDpS9PekwxU45FAEttdz2zhopGGD617H8LvF39ouNNvZMTY/dux54HSvFiSR6Y9auaPey2GpwXMB2ujA5oA+l9TiuBcRXllJtljGJIn+44HXPpViHZHdttBbeA3HY4qhpl+b/SYrxGP71BvyOhxzVvzUtYBnl9meKAOb8cXyx+AtakZSryNsGRwea+XT0/rX0f8XLiSy+G6xMQGnkyQTtP0x3r5vbOMUANooooAKKKKAPsb9tz/kSvD3/YQb/0W1fHNfY37bn/ACJXh7/sIN/6LavjmgAooooAKUDJpKeqkjjrQB6n+zfbfaPiRGCMgWdwSB1/1Z6VvqS2l253ncUBH4k5H54rlvgNevY+N2khbZcNaSrE3o5XjNdzfJBuLWrMtuPlj3DBAyQAR7YP6UAWtISM6ZmMGSRicEDngVpwaOby71lIblLUWti98qyc7yoX5PqdxH41naLsXTYcKrTGRgqj+Ee9Uri51aO3uhYwRYlIWSZ36+zf7P8AOgCcW0TyQ+XboZt4aPzFACsO/wD9evVbKxk1v4Oz6Ucpe20hmsp+m2eM7htP4EfQ14p4eivoI7qXV5pJrh5f3agjYijoRj+XtXsXw+vbuXw9Pp0ccgWI/bIGZfvIpIbH4lqAMnULiHxf4ei1uGPbqMSGDUYQMfOBjfj3614ZqNq2jawZ7beQcEEHbn6fjXos+ozaF4iubu3DC3mkxLF2Zfp60viDRrbW7E3GnZcH5zGBkigDIi+I/iGaxtbVNZmihhBAiTjJxgBiOtaWq+PtKvLC1tb7w9Y3JtgI1a4lYARsSX/4Ef71efX9g1pPLl9rE4x3xVZ44lE2ZUyBnLDI47UAaPiLW4tReKOysk0/TYFHlW0JOPdmJ6kjvWb/AGu0EC2cAK23mb2x344zVUlZY12qxB4Rc9hUthbbiskygxMe/UH/AAoAvRx+fbBwm35ujd62dHiE1jeo2UngAkjx0LAjj8aS0htxCXEchRchsnA6frW/pVitlc6jCY8sEG4gjG0nqPfpQBX32txOF1BSA2GRieFOP1Fa9hbafbWrtLbS3NqoCiOKQbhkZI56dKoXdhJIBCiqJkXaCOMc579Kzb67urVojIAskikl87gwXoTj9aANcnw2yumnWt3a3bDaC7KRnGRyP51h6pIxkaLYIlwTgvnn6/XNZd1OwmaWV9sshJUxrjPHP8xT5dW89o/MLtH5Y4YAlcDoP8aAKEt0kEMsUbGOCQ7dp5PTnH+NchfDDvg47gkcn6V1ni97UujWQcqyBirDbtzzXIyQhmDyIwGRxjJGKAHWa75VYnC9WK8n/PNTksGBPQH7uOh//VTY4yMhRhmBKnpkfX8KhtWkknGACVIGB35wfr2/OgC0WIWSTKlh0BGFyf5mt/4VMT8TvCaHYAurWpP1My1zl2yxIbc8sODu/hJ9K3fhQoHxT8JYcHGr2vT/AK6rQB+ilFFFAHl37T3/ACQzxP8A7tv/AOlMVfn5X6B/tPf8kM8T/wC7b/8ApTFX5+UAFFLSjjNACHpSgmhqSgAPWjtSU/nb7UAfaXwTRbr4N+GWOSqrKu31Ilf/AOtWr4lt0uPD2swn/VS20kQHbJU1ifAVDD8E9A807zJNcOiY5x5p4/Q1ofEe5ksvBesXUZwY7WR9o7cYGfzoA+ZPDbtYXGmzlg8F2r2zgdVJBXn8xVHxDYmDSrkHgx3YGPYhhXWeHNPjvvgrLqEePtFpqh80dzhVIx/30ax/FNyL3TpjsCmZ0m+X+7jtQB1/wo1RmsLWIsrlDnY3T6V2fxRjeHwlrUj7PLO5dq4+UsoIFeM/DrUUtB5b4OHyB9OtejfELX1vdBl8t1JntyrYGQ2BwPqPX3oA4/RL6Kf4TaVazOxaG/lRUHOQcNjH1JrPm8L6pefvtO065khY4B2/eI7Y6034dy28Xhu4vbsOyaZfQXOEOCFJ2kg+uSOPaui0PUtemtrdbGZ/sr3w3uJNrMwDHj2xz6ZoA88mjkhnaC4jeGeM7XjdcMp9xUZXgete/eL9AsfG1lY6iItt/cRbzNHxyBhs/iP1rjtI+GFq7wyarfSTW7Dd5UIwSc8KT/hQB5lGN77IlaSQ8CNFLN+Qq7d6Rq1nALi70rULeD/nrJbsqj8cV9H6Vo9jocRGm2tvapjpFEAScfxP94/nVzdJI8kcojmgZQpVs/16igD5UDbgCSM0+NDI4CgZzX0Nqnw80PVJmle1FoxGf3PAz9K5if4Z29tcFYbovHyfmGMD60AavgJpf+EcHmFhGGwxbjH0raedZbpryRttui7Y896r6LZzCKCzmCrbDkKvVvrVy9gEmo21tGoMfBKr0AzQB5x8eJorbTNOtoWZnnxIxZy3069K8SdicdOlelfHbV01DxYYIHjaK2UINnt615mTk0AJRRRQAUUUUAfY37bn/IleHv8AsIN/6Lavjmvsb9tz/kSfD3/YQb/0W1fHNABRRRQAU9OtMpQaAOq+Ht+NO8W6fOeVLbT78f4ivYtSszG00Ecm6NG6Hjd9PbOa+fLSZobiKRM7423DHtX0Z4euxrWjR3rDeyIiy4OMkcDn/vkc9STQBU0tcWV9GisJUK7SvdTnKn64Bq/LZSpbSGSRTESI40JB3k5yV9cHqarWTFb26Us4doQVVDwce/0/lSXl80VoxKAtbRsqgHIAzkD8+aAF07U5DpH2aaCBMP5EzoMvPtfKlj2xg9O1eh+ANZttOvJLzV5tlhb2jwRQZJO/IJCL9OufWvJvDyyW1hEJGAlnmeYsOQcnPf0x+tbUN8djRNumUGRg7cHkcZ9uBQBf8YWcLam0tkjNbXo86AHvxyB7jGKwdNmudPm8y2YlTkAA4APofatSxumv4v7PnKeamZrc4J+YDlR9R+oFNuLZW26hAI1sppNrAD7kgHK89jmgCYWWmeI7iNr2Q2Xm5BmChhn1I9M/jXnHxA8PXfh+3ZZoAn3Lj5fmWSNh8rg+h5NdvG0NtODbRicA5KP1x9PT3rTu4dJ8T20kUsaaZquzygjkmGZQOB/sHrQB5B4fjUzec+WVFG5iM4J9K6nRjp9uy3N3bC5ZJgywucRuBnhsc9ccZ71j3ulXXhi5kiljZocgg5zgZ6EfToahtryCaWPynUIZArAHJGGHUfjQB1+q/YNW0zzLS2NlLHHJOqRPlGG7fjHUbeR+WaqeE7+XULiaZicj9w3uSCQPpxgfhS6JmHVYY0iaRUlPyjhyMHIH1FZvhaWGw8bXugO8Vnb6p/x7zXHSCUZaPJ7ZPy/jQB1v2tPPa4ljMURJ+TaOGHb8vWsm+gW5lmDBQZCXRVPAyCePQVLbx3DxlFUxttbOcc45PXv706P9ygZ/LZUC+4Izzj6c0AZcXh+/uomlsoHuBHGzsycsijqQO4xzWNuYiYooy4yGB7j1H5mvRYJ7GC9J1KVxbbV2wWzbQT2YY/rXJeK/JaK0ubaB4JpUdJUP3CcnBHpwRmgDmb9EVvmVcBQOue2M1lOPMbAO5gMgA521cuHJdVcF3C/xNwecdPSqk5RkYghSozheMjtQBBHLtR3UjcevqR7fnmmPPDGuwKgOMjDc5pt82xUy2XZA4/2T6VTzub5jwwz65+n5UALdOXlO7DZAzz3rqPhQf+LpeEFVhtGr234/vVrlXyQvljBA47103wnIHxQ8H85B1e1/A+atAH6MUUUUAeXftPf8kM8T/wC7b/8ApTFX5+V+gf7T3/JDPE/+7b/+lMVfn5QAtP8A4aYOtSE9gKAIznNJTj1FB/SgBKdj5R6+lIv3hW/4H0z+2fGeg6Y3S7vYYmz6FwD+lAH254D0FvDvw58NaTMhFzBaK8uRyjuS7D8N2KxviRZ/bvBfii1TqbByPwGcfnXo+sXRmnYQIcd3f5QO3Tqa528s0urO/gOCrxNH9Rjk/rQB8neFdZbQPh1caa6nzbq9eYqy9FEYUfzP5VgxSNdQQRkABMx59R1FT+JrhJdVligJ+zxMVT0xmq+jNm4dQM5XePqOv6UAZNmxsb+VRwqNmuvvLoXWjKwQsAGDEduK5PWgsWoGReVcZ4/OrVvdu1pNHn90wzx3oA0Phtc2scWuadqSNJZ3dq6lEPJdfnTH/AlFegeD7myTR4rbymja3u47lQxyGTBVx9RxXj+gXMlrfSXMLFJY3DoR2INerahLb+dqWqWUawre2C3vlBuBK5xIVHoCv60AdB4PvZbZrrSUkXyN+6Bj0CPk8fX+YrvbLSYdPtQbYfvXGWZuWBPTH414x4A1L7Xe2LXGAq4hb6Hofzr3iSVhtbblgvQUAeV+OL/xPoWsQhb5TYTNlU2jIAPrXbabPDfWyFrhPtLKNyKcEGsH4x3+mRaPam/cJNG25Bjlh3wak+HetweIdJX7MoY24CsSuC3pkf1oA6dYJ4xtW7cbhgBwCaZOqrbMr/vZDnPOW/KpivzcIuFHcn9KguXRisdsmZScjK4I9aAM+3jZSJQrlhgYx90VQvrk22m6rqRITyUYIx7egrWuLgCRbW2w8vR8dFPua4P4w6omkeFv7Lt2IM+GkOcE0AeAalcNc3s0ztuZ2JJPNVKczFjzTaACiiigAooooA+xv23P+RJ8Pf8AYQb/ANFtXxzX2N+25/yJPh7/ALCDf+i2r45oAKKKKACiiigCaIgZJ969U+EOqsHFhLNtgYgEMcD7wwfw5ryhDj0wa3vCl09tq8RzjcQDnoBnNAH0dqGnCOVZ4AC8TDIIxxkg8egwfzFY1xPLpd1Df2WVCyCaEOgfZj1BGDjFdHotyNT09pHXeDEGyWADY3YH14z6+vSsvUEW5Bt5N3yxgH247e/WgDJtdSjk1SLU9TtFvYZJWmngQ+SDknJGOg7/AIVE9xGkVxHbxsIbj5Ru5ZF9AfQ0+C4m0SdDp7MGUYO9N+QeoYEYIxVaeaW5kdUihVw5YIgwp7nHt7UAdX4QsdDv9A1uK8P2bVrK0a7gmEp5IyQNv5fnXO2N80t1JGZBHHcfOVf7pPbPoc1BbXH2WaR1Ybnhlicr15UjFY877Xh81guVwxxjnqDigDUmEqyiQYRw2Mjgg+mDSieG5ZPMIt7lifn/AICff+7Ti4nhmmlnY3UQGWIGHGOv14NZTMvlu4zucfNx29KAL95LOkP2e7GeMKcZ3L659Kr3Oi6Dq8qSarbvbMRzdacBHKe3Kn5Wwceh96jhuJQpWIF41P8Aqi3Qe3/1qnhdHcNKD8owVJ744ANAHLx3ms+D9cFxc+ffWFrLmG+RCG2gEKxz04PQ/nWT4pi/tLT4tVtJPPaI7mdTk7Tzk98g4r17wv4hi0C7YX2npqmmSrslt3ALAexNL49+FemJo7+JPhrO00My77rRZHBKRsDlxzlcY78elAHG6RqMl7pMFzw0rAFsd8Ywa0LlyB5jKqzzEsyk9B6/j1rlfA8rHRbpGiwYJFU88qCSAK7nRRELG7u7ja8cMixAkHjIbAP496AME3FwblDNKvlspGQRjb/Sq+rvA1lPG2VnVd+8tnjj+mea1b90uIplWCKONlByowGOK5DVZkNtJKFYiNPLGGxyOBxQBncPBvlyzZxvHUdgKgby0jXblyV559T/ADqtpMgeaRJNxzgr/snp/Km6hiMEgGMj5cdenrQBn3D+ZKwbPHHB/lQsTH5TuHGc+n1pkILkkD8T9akc7Ay5+f77cfligBrysy7jkYGPcYrqPhQB/wALU8IsSM/2vaY4/wCmqVyxGCN3I79+tdT8JsH4oeEPbV7Xn/tqtAH6MUUUUAeXftPf8kM8T/7tv/6UxV+flfoH+09/yQzxP/u2/wD6UxV+flAC09j3596jpxOeaAEFK3SkFO6j3FACR/e5rvfgd5X/AAtnwzJcKxhiufNbaMkbVLZ/SuBX7wxXpH7P5/4vH4cwT80si9P+mTZGKAPsTUtQcXMaoMLIxHzD8eP1rE8Rap9j8Ga9dRycxW8wUnqDjH880/V5XF2juykKM4X8s/8A1q4nx7dyp8NPEClwGYbc565kB9fQigD5s37ld2I3E5/OpLNzDcoy5+XJHv2qJDvUKBg9/wDGmhiwJHBHagCPVCWk+Yfc4x7YqhFK6qfm4xyK0L0q0CliSxzz+WKzZf8AUqQBuU4I9RQBJYHE0pGMsua9Z8PKmofD7U5bkK0NlAYufvRMzAqVPvlhj2ryTTwRcYx/DxXZeHL94tF16yaXbHNbLLtPRijgj8RuNAFz4ZS+T4lSzmAKtuGxuh46V9B27LJaRR7mPy8HPOMdPwr5dt717PUbO+hbDq2S2MYPvX0J4QupNT0q2nA4K889fUj8aAJvHOjW/iHw5c20sYFzEpZCy9CO1eM/Ca81PT/Ec2m2CK0DHEjyHChR7177bI7CWKQh9/U+o6V4zpDHwn8UJbNhm2uHKgHuCeDxQB6/MYAyBJmQLgiUPwfWq00xkj8mzRvNc48xhgEc81YZZXB2LCc8hXTAPvmmyPNxDDEnnHnGcADoT0oAbZWY+wqI0/eZJY55JHrXz98cNY+3eLJrWJtyWwEXHqOte+ahdW+k6Bf6pdsfIsoi4HYv6e+TivkXUbyW+vZ7uc5lndnY/U5oAqmkpaSgAooooAKKKKAPsb9tz/kSfD//AGET/wCi2r45r7G/bc/5Enw//wBhE/8Aotq+OaACiiigAoopaAAdatW0hWRXXOVORzVSnqwGARxQB9D/AAo1mO8svIKeZKqtKq55YjH/ANfj3JrqtetbiFTdCExRqFjG9uTkHGR2OBXzx4H8RS6JqsUqsyrnG5TgrnjI/wA96+gI7pb+1d/MMkZhkm8xnznBBPHc5I/WgDFvcyIzxEBinz88jIBNZ1qVkubcXbAIpHz8DaexJqa+b7PeOQwZUPK/3l96zbi9SaX94iqSc4x6UATXT7t27aHJy3GNwJ6VBI0UzAuSEJAYkA8eo9/apXupAqgFfUMRk8fWum8HNpNwNQXVY7WS/SIyWxmjIjXaDktt/DFAGPoklnDq6xXzB9OkVoZBtIKqw+V/wODWbqFo1sWWGQPHG5QsDkdeD+NRhXdc42rgkgdhnNJBMY97YEiEDfGRwwH8jQBAhDsd+EJyRjuRn8s+lSLKdpJGEzuO4ZwOO9SaharFI1zZhjZsqujn+Ak/dJ9c1QhkIxySMFW96ALqq2wMjKVYYdS3OMdQK6TwbYXPiBrrQ/t72VtMqtIqSbXmAIBVfXjt7VzMAAbzI8hhkeXt4atHT8w3MGoWE5juIn8yNi3zRsDn9T0P50Aeg/Enw3p2hWWrS6dZWtvp+oWsFrAYV2yfaInMmWHQ/KMAj3rg9KQXXhvXrbev2pWguEIHXDFWOPo1dn8R9Zk8ceGFuQkkN3ZLHK0Kcq5QkOwHYjeeK4Lw+6Jq/wC+nMSzo8bE5AB25X8SwX8zQBUVka1A3FWTGFPPQdvfmuL1qU7Zoe4Ycjv6/nxXaasYFknMMJjiUb1UjhR6e+MmvPNblK3TBSSMk57mgDNspcXm1twD/Idp45NJqJAuCqn5V4HOc81UJ3SggkE4PFTTsZJAxCDdhhj60ANjIRvlBORwc9T2qRlYgFSMnI9Oe9QDaj5B6HIP41K3MeRhW9qAGD5SQR3/ACrq/hQxPxU8IDBx/a1p14/5arXJg8EYO09TXWfCVt3xR8Ik4b/ib2uP+/q0AfoxRRRQB5d+09/yQzxP/u2//pTFX5+V+gf7T3/JDPE/+7b/APpTFX5+UAFFFFABThkCm0oOKAFT7wxXe/BKVYvix4WaTobvbjOOWUgfqa4JPvCuq+Gspg+IXhuXcVA1CEZxk/eAoA+wtUYR3AUFsNwBjnP9cV5x8S5ZE+HWpgkr5lzs3Y5f95n8K9B1WZl1S3eMgBSVLt6+3rXmnxWlWPwBeorBf+JggXv2B6igDwyMhSMYwQCR2Pt7UMPmIJwvoRkimP3VVIA64HvmpXwBuBIJJ4I60AVrzBtkK8NjBNZr5DMN3GOlacx3xE4BYn9KzjzwRhs/pQBJaIfPj/75rUgkMbS7RnzI3jx9RWdEP3YI6hgR+dadvIYLuFxglTx+o/rQAkpMmnpgfKpxnH+fWvXPghq5ubK402VsPFynqQa8hgJMDRZ4HPvW/wDDbV/7G8W20mcRzHymJ7ZoA+lJoFmjWRcoQMhl4OK8l+NOmyafdad4gtFOUIEhI7//AKq9ftsmUjYSrDcoHcNj+uaxPifop1nwHqcduMzW6mUAf7PX9M0AGi3g1fQrC+QlCyBiUOQDjofrWlZ2i+ZPdOdiiNjLJI2AqgjueBXH/A7W7N/BUEd9cxwLFIykyEAf5615/wDGn4rPrMk+g+G2aDSFJSaUcNcEHp7L/OgDL+M3j2LXLgaPobuNJgOZH6ec+Tz9B2rysnNGeKSgAooooAKKKKACiiigD7G/bc/5Ejw//wBhE/8Aopq+Oa+xv23P+RI8P/8AYRP/AKKavjmgAooooAKKKKACiiigCVCAOep717N8HNaEiRWd3JuhikBwwyQD8pH02uce+K8WHTnNb/hfWX0bUFnU9cA4/nQB7NrlrLYzG0uV8q6hOySM9R6E/Ucj2NcvfNtctkB/8iu38TXi+KLqXxFYDzPthQyxIciMqgUY/BelcZqG6SQ7htOcfTHFAEdrqLkiOXG08gnsfeuk0TU4tPujJLbJcwyRlCGGMeprh5vlbP5GtDTNRZVRGHI6ZoA3g0a3Ekot0kjJ3LGznHXpn0qO+lDMpiTyUJ3NGBwD7Hrj61EkkfyN1U9QOCKeskahSzHysgkYGcZ5GaANzwdqUFkmq2ur27SaPqdq1u0gXmGXqjr9DXHpEycseTwcdCa7V9IhudCh1CwxPbNJ5UiySmMwtjOMn5WOP6Vi6WLe4vFtJjBFBPuV2lBwh2nGCOQcgCgDOZ+QCRuGAOasreEHnAkHfGAT3NVdgWKNnGMjhj9akQfMASGOCOf60AWJpriIDypvLL7jkHjOMdPxqGWaa9jmuHSO3lVws0adFfjGPTIpS6SK4EYyOwOQD/k1WRxaXXnMCEZdk4XkOh7/AFB5/SgB2rSh9KhkWbfNA5idPUHlT9MgivONWYPMxU5wTyRjNdvrs8luGBKPHIoKSL92ROoIrgb+RpLiQ5ODzigCmrckce3vTjhkU88HofemEqhIxwe9ByGGD1Hf+dADgQCBliOucVJxjnpnkjg1ECTg8nHoelPZiW+XOM8D0oAEOCOpzn8q6v4TYHxR8IY4P9r2pPv++WuVYdy2dxxnpj8K6n4Rrj4o+D+ozq1qf/Iy0AfozRRRQB5d+09/yQzxP/u2/wD6UxV+flfoH+09/wAkM8T/AO7b/wDpTFX5+UAFFFFABRRRQAo4Nb3hGQR+LNEdiFUX0JLHt84rBq3aytbTQTpgPE6uCfY5FAH2RaTzXunWkt2riUPJuLL93a7L29QM1xHxfQQeBbmAAH/TomGDx90nGK9Ee8W4htrqNP8AXJ5yDfhcHBOcfUD8a86+Mb48CSAFGI1GHI6DPlccUAeFh1AcNv39cg8HpT5shQWYDtnt9aZKFEa49TsDDGTkZz7Vb2+ZbYUAuHyzKR82cADB75zQBTKEB/myvK5Xn61RKKAeMn07j0rWBYsy7lO05KjtwOf5VVaNiQQygN93noP84oAjEX7qUICGC7qmVsGPII6H6U0lsP5YwGIGA2SM54p8TNhFcMHBww9KAHw4Es4IO5lKj86rh2hdJlzujYN+INSSyFpmc+6g+p+tJOmImUMC20ZA7ZFAH2L4OQ6joenXWC2+2ViT1Ixn+tdfpuiLcs8M6745YyrEr1BFcX+z9cQ6j8MNLkleFZoC0bkvg8EdfwxXskElopUQyw5xhdrjkUAfmlr0l3pGr6jpQd4xaXc0ZXOOQxH9Kwyc9a9B+PKWifGDxUtgmyFbtsjIPzkAuf8AvotXnx60AJRRRQAUUUUAFFFFABRRRQB9j/tt/wDIj+H/APsIn/0U1fHFfY/7bf8AyI/h/wD7CJ/9FNXxxQAUUUUAFFFFABRRRQAufWpFOMYyKipQSOlAHX+CPFVz4e1CNkkY228M0ZPHp+ozXq+vWFnqenWuraG67p8RzwjlVb1B6DNfPYfArqPCPii/0WcJDJvtnIzG3IoA6y9gEN3LA2N0cjRsw6cHtWexaNi47Dj0HNdlrUMOqWY1Wyg8nzD+8QHdsb/P8xXMSxAxkDopy3vmgCG2vZY5h5jlkOCfpWtbajFKuZCN+fSsIoFly+dvOfaogEO77w6kGgDtItQcaTc2IuJDbTyLKUB+USDocfSqzNksSTkfex3965u1neGQbWaTjleh/CtBdRUHZIGBOMEjqaANeExi3KSMATyme3GSKQkRuRL8g4PHY/SqaXcctp5ICAK5cMAN/IHGfwq/cSW/yCGSWVSo++gVkOOee4oAJIWC74gCSu5gvQrmoJ4RIrMm1WjG7DfxD0p6YAOW4HKspwB7U2bd5biUFWHU49KAOY1OQxQGJmbyAWKDH+qJ64/2T6Vx90ArAFzjnpXV69ICpUnIrkZsbyAOP1oAjOSuONvr60d8nA6UnZSGBz3pwC7iAenGD3oAcDk+np70/JMny8NkdaYoI44P0pc7XViWPpQBOh3K8Ljkn5WHZq6f4UIU+KfhBSTkata49MeavSuXQ7yAq8nLcetdV8LGDfFPwhjIH9r2vBP/AE2WgD9FKKKKAPLv2nv+SGeJ/wDdt/8A0pir8/K/QP8Aae/5IZ4n/wB23/8ASmKvz8oAKlRMj2HpUdSxtwfXqKAEKdc8EU0Lz0qxI4YA/jUBbBz1oARhirAyUBIzkYqqTmpoGIBwaAPqLw5qBvPA+h3BVmcQpCCmMDoM/QD+Vcj8Sr6SfwtMSgXzbuBiinHVW6jt2NV/Ad858I2cdvtzGjByGwRhu351X8dSg6BdkNje0ZwOp2knOfTDUAebpnYPnyqHnd79Tirav/ow8tzvB2Bmwqrg5z9SaqgldjgKRkEcZyPx6cZoSQGIbUj3MGGCpIHvj+tAGvaqbiQNFGskjKCGb7/ygElvwDYqvGguizIjkMQWJIPAAwM+nIzVa3mdVkAARlKnAHDDuCc/TmpGn2zrE4jDhhKWUYx6jHpxQAN5YuhtR0UOGOcjy1Dcqc+nrVi+txbPOkWTH5geMFt29Xwy5P0P6Gqt1KJSWGZOd67xknHZvUc024nV5pnllKkgLiNMbsdTjoOuB7UARJPh2Ma7WyDvPIGe/v8A/Xpt3c7pEAZXVVGSB1/z0qOWTY7MiFlUbhk1C2BKgx94HOTyc880Aen/AA78UX+neFZ7G1fKGV8ttxjcB+NdTo95rlzdJm5YAYXdnntxn8a4n4WRfabS7j7rJvIIzkD/ACK9q8MWIQDeoXa2T747YoA8E+PHhu68O+Pppbkl01OMXsbEdd3Df+PA15uwwea9/wD2uVc+I/DkucxCw2DHb5ia8BcfmOtADKKKKACiiigAooooAKKKKAPsf9tv/kR/D/8A2ET/AOimr44r7H/bb/5Efw//ANhE/wDopq+OKACiiigAooooAKKKKACiiigAqaKTbjnBFQ0tAHp/w+8Uxk/2XqbkwyHAycDPr/I10fibR5NPsrWddslvOZJFdD2LAAH6AH868QSRkYMjEEdD6V2fh3x3d6fClpegXNqpOA3bNAGw0W44Uk9dwqvLE3qFA6D2rdsvEHhq8Fw8jfZ5ZozGq9AuSCf0yKpvdeH7Z99xqUZ2kDYgLE8e3vQBmSQ7WKqQCOjDqaYY2GM/MR0JHatrTLzwzeTJGbuUOTgbYuoJ+vpWnf8AhtFaQaZeRXCY+UbgGOOelAHIJtbJztc1PHNcRt+7nJXoc81uLo9nPaTh5prS6tbfznMyBkkIIG0Ecr17+lZNxYNDgkbkblZFOVI+ooAHvZ4nBO1jjAKHAx7irttqkc8flSn5tuBuPSsuaViU342jsBUD4KhgoDewoApa43zkAjH9a5yTJGQPx71v3i+eoQtz2NYNzG8ch3DBB60AMGCQDxntjg0pI3EDkDgD+tMHIyAfUEdqchAI+XI/U0APOCc8fMOeOlCkE4wcAdaRuvHqSDnpQoIPqOxzQBKpYFHBKEdD2NdX8JSH+KXhEtg/8Te1PA/6arXKROUIG45znr0rsPhREp+JnhGQYUrq9qGGep81aAP0QooooA8u/ae/5IZ4n/3bf/0pir8/K/RX49aFqPiX4Ta9pOiWxutQuRD5UIYKW2zxseSQOik/hXxx/wAKI+JH/Qszf9/4v/iqAPMaepr0v/hRHxI/6Fmb/v8Axf8AxVKPgR8SP+ham/7/AMX/AMVQB5mTnHtTTXpw+BPxI/6FmbP/AF3i/wDiqP8AhRPxI7+GZv8Av/F/8VQB5jT4+WxXpn/CiPiP/wBCzN/3/i/+Ko/4UR8R88eGph/23i/+KoAs/DebOnxREsFHmIrjH7t/vD/H8KveL5pW8FxlnEpV92VPysinaTjvgnk9uK1vCHwj+IFhbyQ3Xhx1Qvu+eeM/XGG61r6p8KfGtxpF5bp4e+9wiiWMEkHOc7ueMj8qAPDFJVBM3zMc5IPv3pUEiLvi3L82CAMED3+teiR/BP4hCOYDw3IoJGFM8Zz+O6np8EvH65/4p+4JJHImjHGf970oA83SVkKlMk4z8p78gn+VIxlYOxkDDGCe+D1r0dPgr8Qgu0eHZgCOcyxc/X5qSX4JfEHJA8OzYI4ImiOOf96gDzdjsLKi4VxgipZ5+CNy78fOQvIPp6dh+td7/wAKQ+IYHHhyY5J48+Pgdv4qVvgj8QtgC+G58Z6efFk/+PUAedeby20KV28jb0FJgs6E4z/WvSD8EfiHuyPDswyoB/fRcfT5qQfBL4hlkJ8OTDA/57Rf/FUAP+DURka8PmKhwcenHNexaZMVSJ8bmlBzzjmuM+Gnwr8caNPcjUNDkiikzjMsZOccdGr0G18GeJ4YolXTJVKEY+dMe/egDmfjlZxeIPhrJcNC0t/p0g2vj5kTuCfyr5VfkA+1fcNx4P1y/wBM1PT7nTZhBexFSS6fK2OO/rXzjc/Af4hLLIIvDszIGIU+dFyP++qAPJ6K9O/4UR8SP+hZm/7/AMX/AMVR/wAKI+JH/Qszf9/4v/iqAPMaK9O/4UR8SP8AoWZv+/8AF/8AFUf8KI+JH/Qszf8Af+L/AOKoA8xor07/AIUR8SP+hZm/7/xf/FUf8KI+JH/Qszf9/wCL/wCKoA8xor07/hRHxI/6Fmb/AL/xf/FUf8KI+JH/AELM3/f+L/4qgD3n9tv/AJEfw/8A9hE/+imr44r7n/ap8G694z8KaPaeGtPe+uIL0yyIrqu1fLYZ+YjuRXzN/wAKI+JH/Qszf9/4v/iqAPMaK9O/4UR8SP8AoWZv+/8AF/8AFUf8KI+JH/Qszf8Af+L/AOKoA8xor07/AIUR8SP+hZm/7/xf/FUf8KI+JH/Qszf9/wCL/wCKoA8xor07/hRHxI/6Fmb/AL/xf/FUf8KI+JH/AELM3/f+L/4qgDzGivTv+FEfEj/oWZv+/wDF/wDFUf8ACiPiR/0LM3/f+L/4qgDzGivTv+FEfEj/AKFmb/v/ABf/ABVH/CiPiR/0LM3/AH/i/wDiqAPMqUH35r0z/hRHxI/6Fmb/AL/xf/FUf8KI+JH/AELM3/f+L/4qgDzUPz6Ub+CK9K/4UR8SP+hZm/7/AMX/AMVR/wAKI+JH/Qszf9/4v/iqAPNlkZTlGKk+hq/aa1qFqqi3u5Ex3B5ruv8AhRHxI/6Fmb/v/F/8VS/8KI+JP/QtTf8Af+L/AOKoA5O68Xa3caTcafNqEr2twwaVePnweAT1x7Vt6B40s4dHi0vVdO3xRH5J4Gw4Ge4PB6Vof8KI+JH/AELM3/f+L/4qlHwJ+JH/AELM3/f+L/4qgCSL+ytSX/iValHJIRnypx5b544GeD19e1Ur+1mtCVnR42HZlxmrg+BfxIAGPDUwP/XeL/4qteD4U/FVLcW8vh+eeAdElnibA9juyKAOFmHBC8Me2KryjzEMcq5HQZHWvRYvg98Q2Yb/AAzOBn/nvESP/Hqmk+C3j0of+JBKw/umWLP1+9QB5LPaAEm3YsOu09R2qq6OpZGyvHU9q9fX4KfEBAAvh+U5PJ86POPT71Mm+CXjuYDd4bnBx186Lg/99UAeRnDEjkY60rcjoa9Rf4FePyx2+H5wfUzxY/8AQqj/AOFGfETKr/wjs20df38X/wAVQB5pGpDKFGMjg4ya7P4TBR8TfCQD4B1e22gH/pqvFbI+B3xC3jd4bmxntNF+H8VdL4A+EXjzTvH/AIb1C/8AD8kVpa6lbzzSebHhEWVSzYDegoA+0qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Conventional low-grade chondrosarcoma in the proximal humerus with chondroid mineralization on conventional radiograph. B) Discrete endosteal scalloping of the anterior cortex is seen on the T1-weighted magnetic resonance image. C) Axial T1-weighted magnetic resonance image with fat suppression after IV contrast injection demonstrates the typical peripheral ring-and-arc pattern of enhancement. No soft tissue extension is noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320. Copyright &copy;2008 AlphaMed Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.TheOncologist.com\">",
"      file://www.TheOncologist.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1572=[""].join("\n");
var outline_f1_34_1572=null;
var title_f1_34_1573="Psyllium: Pediatric drug information";
var content_f1_34_1573=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Psyllium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"    see \"Psyllium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/23/21876?source=see_link\">",
"    see \"Psyllium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bulk-K [OTC];",
"     </li>",
"     <li>",
"      Fiberall&reg; [OTC];",
"     </li>",
"     <li>",
"      Fibro-Lax [OTC];",
"     </li>",
"     <li>",
"      Fibro-XL [OTC];",
"     </li>",
"     <li>",
"      Hydrocil&reg; Instant [OTC];",
"     </li>",
"     <li>",
"      Konsyl-D&trade; [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Easy Mix&trade; [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Orange [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Original [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; Plus Calcium [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; Smooth Texture [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; [OTC];",
"     </li>",
"     <li>",
"      Natural Fiber Therapy Smooth Texture [OTC];",
"     </li>",
"     <li>",
"      Natural Fiber Therapy [OTC];",
"     </li>",
"     <li>",
"      Reguloid [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metamucil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Bulk-Producing",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"      see \"Psyllium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (3.4 g psyllium hydrophilic mucilloid/7 g powder is equivalent to a rounded teaspoonful or 1 packet or 1 wafer):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adequate intake for total fiber:",
"     <b>",
"      Note:",
"     </b>",
"     The definition of &ldquo;fiber&rdquo; varies; however, the soluble fiber in psyllium is only one type of fiber which makes up the daily recommended intake of total fiber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-3 years: 19 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-8 years: 25 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 9-13 years: Male: 31 g/day; Female: 26 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 14-18 years: Male: 38 g/day; Female: 26 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults 19-50 years: Male: 38 g/day; Female: 25 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnancy: 28 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactation: 29 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Constipation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years: 1.25-15 g per day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 2.5-30 g per day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reduce risk of CHD: Children &ge;12 years and Adults: Soluble fiber &ge;7 g (psyllium seed husk &ge;10.2 g) per day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fibro-XL: 0.675 g [sugar free; provides dietary fiber 3.8 g and soluble fiber 3 g per 7 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg;: 0.52 g [sugar free; contains calcium 8 mg/capsule, potassium &lt;11 mg/capsule, sodium 1 mg/capsule; provides dietary fiber 3 g and soluble fiber 2 g per 5 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;: 0.52 g [contains potassium 5 mg/capsule; provides dietary fiber 3 g and soluble fiber 2.1 g per 6 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Plus Calcium: 0.52 g [contains calcium 60 mg/capsule, potassium 6 mg/capsule; provides dietary fiber 3 g and soluble fiber 2.1 g per 5 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid: 0.52 g [provides dietary fiber 3 g and soluble fiber 2 g per 6 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:  (454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bulk-K:  (392 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fiberall&reg;:  (454 g) [sugar free; contains phenylalanine; orange flavor; psyllium is in combination with other fiber sources;  also contains vitamins and minerals]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fibro-Lax:  (140 g, 392 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocil&reg; Instant:  (300 g) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocil&reg; Instant: 3.5 g/packet (30s, 500s) [sugar free; provides dietary fiber 3 g and soluble fiber 2.4 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl-D&trade;:  (325 g, 397 g, 500 g) [contains calcium, dextrose, potassium, sodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl-D&trade;: 3.4 g/packet (100s, 500s) [contains calcium 6 mg/packet, dextrose 3.1 g/packet, potassium 31 mg/packet, sodium 3 mg/packet; provides dietary fiber 3 g and soluble fiber 2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Easy Mix&trade;:  (250 g) [sugar free; contains calcium, potassium, sodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Easy Mix&trade;: 6 g/packet (500s) [sugar free; contains calcium 10 mg/packet, potassium 55 mg/packet, sodium 5 mg/packet; provides dietary fiber 5 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Orange:  (538 g) [contains calcium, potassium, sodium, sucrose; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Orange: 3.4 g/packet (30s) [contains calcium 6 mg/packet, potassium 31 mg/packet, sodium 3 mg/packet, sucrose 8 g/packet; orange flavor; provides dietary fiber 3 g and soluble fiber 2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Orange:  (425 g) [sugar free; contains calcium, phenylalanine, potassium, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Original:  (300 g, 450 g) [sugar free; contains calcium, potassium, sodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Original: 6 g/packet (30s, 100s, 500s) [sugar free; contains calcium 10 mg/packet, potassium 55 mg/packet, sodium 5 mg/packet; provides dietary fiber 5 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;:  (390 g, 570 g, 870 g) [contains potassium, sodium; unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;:  (570 g, 870 g, 1254 g) [contains potassium, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (609 g, 912 g, 1368 g) [contains potassium, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture: 3.4 g/packet (30s) [contains potassium 30 mg/packet, sodium 5 mg/packet; orange flavor; provides dietary fiber 3 g and soluble fiber ~2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (283 g, 425 g, 660 g) [sugar free; contains phenylalanine, potassium, sodium; berry burst flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (173 g, 300 g, 450 g, 660 g, 1020 g) [sugar free; contains phenylalanine, potassium, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (288 g, 432 g, 684 g) [sugar free; contains phenylalanine, potassium, sodium; pink lemonade flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (300 g, 450 g, 690 g) [sugar free; contains potassium, sodium; unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture: 3.4 g/packet (30s) [sugar free; contains phenylalanine 16 mg/packet, potassium 30 mg/packet, sodium 5 mg/packet; berry burst flavor; provides dietary fiber 3 g and soluble fiber ~2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture: 3.4 g/packet (30s) [sugar free; contains phenylalanine 25 mg/packet, potassium 30 mg/packet, sodium 5 mg/packet; orange flavor; provides dietary fiber 3 g and soluble fiber ~2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natural Fiber Therapy:  (390 g, 539 g) [natural flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natural Fiber Therapy:  (390 g, 539 g) [contains sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natural Fiber Therapy Smooth Texture:  (300 g) [sugar free; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid:  (369 g, 540 g) [contains sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid:  (369 g, 540 g) [contains sodium; regular flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid:  (284 g, 426 g) [sugar free; contains phenylalanine, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid:  (284 g, 426 g) [sugar free; contains phenylalanine, sodium; regular flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wafer, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;: 3.4 g/2 wafers (24s) [contains potassium 60 mg/2 wafers, sodium 20 mg/2 wafers, soya lecithin; apple flavor; provides dietary fiber 6 g and soluble fiber 3 g per 2 wafers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;: 3.4 g/2 wafers (24s) [contains potassium 60 mg/2 wafers, sodium 20 mg/2 wafers, soya lecithin; cinnamon-spice flavor; provides dietary fiber 6 g and soluble fiber 3 g per 2 wafers]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes wafers",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Granules and powder must be mixed in an 8 ounce glass of water or juice; drink an 8 ounce glass of liquid with each dose of wafers or capsules; capsules should be swallowed one at a time.  When more than one dose is required, divide throughout the day.  Separate dose by at least 2 hours from other drug therapies.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary fiber supplement; treatment of chronic and occasional constipation; management of irritable bowel syndrome; adjunctive treatment with low cholesterol and saturated fat diet to reduce risk of coronary artery disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fiberall&reg; may be confused with Feverall&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F215665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, constipation, diarrhea, esophageal or bowel obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis upon inhalation in susceptible individuals, rhinoconjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to psyllium or any component; fecal impaction, GI obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with esophageal strictures, ulcers, stenosis, or intestinal adhesions. Products may contain aspartame which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation of psyllium powder may produce allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14191258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Psyllium is not absorbed systemically. When administered with adequate fluids, use is considered safe for the treatment of occasional constipation during pregnancy (Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stool output and frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Psyllium is a soluble fiber which adsorbs water in the intestine to form a viscous liquid which promotes peristalsis and reduces transit time. Paradoxically, psyllium may also be beneficial in diarrhea as it delays gastric emptying, probably by increasing meal viscosity, and reduces the acceleration of colon transit, possibly by delaying the production of gaseous fermentation products.  Postprandial serum glucose and insulin concentrations are reduced with psyllium. Psyllium lowers serum cholesterol. The mechanism for this is considered to be binding bile acids in the intestinal lumen and also by stimulating bile acid synthesis and diverting hepatic cholesterol for bile acid production.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: May take 2-3 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Oral: Generally not absorbed; small amounts of grain extract present in the preparation have been reportedly absorbed following colonic hydrolysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/23/21876?source=see_link\">",
"      see \"Psyllium: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each dose must be taken with an 8 ounce glass of water; inadequate fluid intake may result in throat swelling and choking",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Dietary Reference Intakes for  Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids,&rdquo; Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, National Academy of Sciences, Washington, DC: National Academy Press, 2005. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James SL, Muir JG, Curtis SL, et al, &ldquo;Dietary Fibre: A Roughage Guide,&rdquo;",
"      <i>",
"       Intern Med J",
"      </i>",
"      , 2003, 33(7):291-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/34/1573/abstract-text/12823674/pubmed\" id=\"12823674\" target=\"_blank\">",
"        12823674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh B, &ldquo;Psyllium as Therapeutic and Drug Delivery Agent,&rdquo;",
"      <i>",
"       Int J Pharm",
"      </i>",
"      , 2007, 334(1-2):1-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/34/1573/abstract-text/17329047/pubmed\" id=\"17329047\" target=\"_blank\">",
"        17329047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12749 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1573=[""].join("\n");
var outline_f1_34_1573=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215645\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215646\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061662\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061655\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215631\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215618\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061665\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061664\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215667\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215665\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061669\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061654\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061653\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299962\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215627\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14191258\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061661\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061652\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061667\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061668\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061659\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=related_link\">",
"      Psyllium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/23/21876?source=related_link\">",
"      Psyllium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_34_1574="Fungal Etest";
var content_f1_34_1574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Etest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Etest method is based upon the establishment of a stable concentration gradient of an antimicrobial agent following diffusion from a plastic strip into an agar medium. When an Etest strip is placed upon an agar plate that has been inoculated with a test organism and incubated for 24 to 48 hours, an ellipse of growth inhibition occurs, and the intersection of the ellipse with the numeric scale on the strip provides an indication of the minimum inhibitory concentration (MIC).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Pfaller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1574=[""].join("\n");
var outline_f1_34_1574=null;
var title_f1_34_1575="Treatment of delusional parasitosis";
var content_f1_34_1575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of delusional parasitosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1575/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1575/contributors\">",
"     Kathryn N Suh, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1575/contributors\">",
"     Jay S Keystone, MD, MSc (CTM), FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1575/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1575/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1575/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1575/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/34/1575/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H521793394\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delusional parasitosis is a rare disorder in which affected individuals have the fixed, false belief (delusion) that they are infected by \"bugs\": parasites, worms, bacteria, mites, or other living organisms. As with all delusions, this belief cannot be corrected by reasoning, persuasion, or logical argument. Many affected individuals are quite functional; for the minority, delusions of parasitic infection may interfere with usual activities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delusional parasitosis is a delusional disorder of the somatic type [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/2\">",
"     2",
"    </a>",
"    ], a subgroup of delusional disorders in which nonexistent disease or alteration of the body forms the basis of the disorder. Delusions of parasitosis are the most common form of monosymptomatic hypochondriacal psychosis; others include delusions of dysmorphism and delusions of body odor or halitosis.",
"   </p>",
"   <p>",
"    This topic addresses the treatment of delusional parasitosis. The epidemiology, clinical presentation, and diagnosis of delusional parasitosis are discussed separately. Other psychotic disorders are discussed separately. First and second-generation antipsychotic drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=see_link\">",
"     \"Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=see_link\">",
"     \"Postpartum psychosis: Epidemiology, clinical manifestations, and assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521793401\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"     &nbsp;&mdash;&nbsp;Two forms of delusional parasitosis are widely recognized [",
"     <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/3,4\">",
"      3,4",
"     </a>",
"     ]:",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521793416\">",
"    <span class=\"h2\">",
"     Primary delusional parasitosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary delusional parasitosis is a psychiatric disorder with the delusion of parasitic infection as its only manifestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521793423\">",
"    <span class=\"h2\">",
"     Secondary delusional parasitosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary delusional parasitosis is a symptom rather than a disorder. The delusion of parasitosis occurs secondary to another psychiatric disorder or to a medical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625559\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key to the management of patients with delusional parasitosis is the development of a strong, therapeutic relationship. Many patients express dissatisfaction with previous clinicians whom they believe are incompetent and uncaring. As a result, patients often fail to attend follow-up appointments and receive inadequate or no therapy. A non-judgmental approach, acknowledgment that the patient's symptoms are real, and empathetic exploration into the effects their symptoms have had on their daily lives can instill a sense of trust [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been debated whether or not the clinician should overtly agree or disagree with the patient's beliefs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/6\">",
"     6",
"    </a>",
"    ]. Many authors suggest that a non-confrontational approach be employed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ], using phrases such as \"I cannot see any parasites today\" rather than \"there are no parasites\" [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/9\">",
"     9",
"    </a>",
"    ], and acknowledging that a problem may have resulted from a previous infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/10\">",
"     10",
"    </a>",
"    ]. In our experience, it is important to neither dismiss patients' complaints as trivial nor to overtly support unfounded beliefs and feed into their delusional system. Reassurance that the patient can be helped can be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625566\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625574\">",
"    <span class=\"h2\">",
"     Secondary delusional parasitosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of a secondary delusional parasitosis should focus on the primary medical illness or psychiatric disorder. Antipsychotic drugs are sometimes used symptomatically for limited periods, but play a minor role in treatment unless indicated for treatment of the primary illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=see_link&amp;anchor=H15122200#H15122200\">",
"     \"Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis\", section on 'Secondary delusional parasitosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625581\">",
"    <span class=\"h2\">",
"     Hypochondriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient&rsquo;s thoughts of a parasitic infection prove shakable, and diagnosis of hypochondriasis is made, then the symptoms may respond to a cognitive or behavioral therapy. Several small, randomized trials have shown positive results for cognitive therapy, behavioral therapy, cognitive behavioral therapy (CBT), and behavioral stress management for hypochondriasis compared to psychological control conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=see_link\">",
"     \"Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depressive and anxiety disorders are common comorbidities of hypochondriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/12\">",
"     12",
"    </a>",
"    ] and can respond to treatment with cognitive behavioral therapy or medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625588\">",
"    <span class=\"h2\">",
"     Primary delusional parasitosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625596\">",
"    <span class=\"h3\">",
"     Antipsychotic medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for primary delusional parasitosis is antipsychotic medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625603\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials of antipsychotic medication for delusional parasitosis or delusional disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A review of published case series and observational trials involving approximately 100 patients with primary delusional parasitosis found reported response rates for antipsychotics of 60 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/13\">",
"     13",
"    </a>",
"    ]. These data did not find any one antipsychotic was superior to others, nor did they find a difference in response rates between first and second-generation antipsychotics.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     Pimozide",
"    </a>",
"    , a first-generation antipsychotic, has been widely used in practice and published reports for delusional parasitosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/9,15-18\">",
"     9,15-18",
"    </a>",
"    ], but is no longer considered first-line treatment. In addition to a selective blockade of dopamine type 2 receptors, pimozide has antagonistic effects on opiate receptors, which have been postulated as contributing to a reduction in pruritus and formication [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/13,19\">",
"     13,19",
"    </a>",
"    ]. Response to pimozide has been reported to occur in as many as 90 percent of patients in case series and uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/2/19495?source=see_link\">",
"     trifluoperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    have shown comparably high response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     Pimozide",
"    </a>",
"    , along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    &nbsp;and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , prolong the QT interval, particularly at higher doses. Sudden death in patients on pimozide has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/21\">",
"     21",
"    </a>",
"    ], typically with doses of 10 to 20 mg daily. These medications should be avoided in patients with cardiac disease, a history of syncope, a family history of sudden death, elderly patients, and in conjunction with other medications that prolong the QT interval such as",
"1ff8",
" antiarrhythmics and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . In other patients, serum electrolytes should be measured and an ECG should be performed prior to starting pimozide, and periodically during treatment, although no clear guidelines exist [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/22\">",
"     22",
"    </a>",
"    ]. We perform an ECG every four to six months, when doses are increased rapidly, or when doses approach or exceed 10 mg daily. Increase of the QT interval by 25 percent or more from baseline, or a QT interval &gt;520 milliseconds, warrant temporary cessation of the drug, followed by dose reduction or change in antipsychotic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other first-generation antipsychotics described in published cases as effectively treating delusional parasitosis are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/23\">",
"     23",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/24\">",
"     24",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/25\">",
"     25",
"    </a>",
"    ]. Common adverse effects of these agents include extrapyramidal side effects (tremor, bradykinesia, shuffling gait, akathisia), acute dystonic reactions, tardive dyskinesia, and hyperprolactinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More recently, second-generation antipsychotics have been described in case reports and case series as effectively treating delusional parasitosis, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/26-29\">",
"     26-29",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/30-33\">",
"     30-33",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/28\">",
"     28",
"    </a>",
"    ], sertindole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/34\">",
"     34",
"    </a>",
"    ], sulpiride [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/35\">",
"     35",
"    </a>",
"    ], aripiprazole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/36\">",
"     36",
"    </a>",
"    ], and paliperidone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/34\">",
"     34",
"    </a>",
"    ]. Side effects associated with second-generation antipsychotics include weight gain, diabetes, hyperlipidemia, and tardive dyskinesia. Some of these medications also cause extrapyramidal side effects but generally at rates lower than first-generation agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625610\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with delusional parasitosis often respond to antipsychotic drugs at lower doses than patients with other psychotic disorders. The antipsychotic should be initiated at a low dose and increased gradually (eg, in weekly increments) to minimize side effects and arrive at the lowest effective daily dose. After achieving an adequate clinical response, the antipsychotic should be maintained at a therapeutic dose for at least one month, and preferably several months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. When discontinued, the medication should be tapered gradually over a period of weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. If relapse occurs, it often responds to reinstitution of the drug. Relapses are common though the rate is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/9\">",
"     9",
"    </a>",
"    ]. Some patients require prolonged therapy to avoid relapse.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     Risperidone",
"    </a>",
"    can be started at 0.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (given as one or two daily doses) and advanced weekly to the lowest clinically effective dose. The dose can be increased up to 8",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    though in our experience most patients require between 2 and 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1575/abstract/26,27,29\">",
"     26,27,29",
"    </a>",
"    ]. Alternative second-generation antipsychotics that can be used include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    (starting dose 2.5",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    typical dose 2.5 to 7.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    (starting dose 25 to 50 mg; typical dose 200 mg daily). If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     pimozide",
"    </a>",
"    is used, a daily dose of 1 to 6 mg is typically required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12625617\">",
"    <span class=\"h3\">",
"     Patient acceptance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Convincing patients to take antipsychotic medications is a major challenge in the management of this disorder. Rejection of a psychiatric basis for the dermopathy is a defining characteristic of the illness, thus rejection of psychiatric treatment is to be expected. A number of strategies have been suggested in prescribing antipsychotics for these patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One strategy is to tell the patient that the problem is a \"biochemical imbalance,\" possibly the result of a previous infection that is no longer present. Patients may be more likely to agree to take medication for treatment of a \"chemical imbalance\" than for a psychiatric problem.",
"     </li>",
"     <li>",
"      It should be explained to the patient that although antipsychotic drugs are a commonly used for schizophrenia, it is not being used for schizophrenia and the patient does not have the disorder.",
"     </li>",
"     <li>",
"      It can be further explained to the patient that drugs used for one purpose are often found to have additional unrelated uses. It is important to provide examples, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for pyrexia and stroke prevention, beta blockers for coronary artery disease and prevention of migraine headaches, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      for depression and neuritis.",
"     </li>",
"     <li>",
"      Some patients may be persuaded to try medication when told that other patients with a similar condition have experienced great relief in their symptoms.",
"     </li>",
"     <li>",
"      For patients who ask why they continue to \"see\" parasites when others do not, the concept of the \"phantom limb\" may be presented as a possible explanation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a last resort, a combination of an antipsychotic agent and a short course of a relatively safe antiparasitic drug (such as &lt;",
"1ff8",
"a href=\"./mebendazole-drug-information?source=see_link\" class=\"drug drug_general\"&gt;mebendazole",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    ) can be proposed for a patient who is adamant he or she will not take the antipsychotic agent alone. &nbsp;The risk of side effects or an allergic reaction should be weighed against the patient&rsquo;s impairment stemming from the delusion. An additional concern is that, in the event of a response to the combination, the patient may become convinced that the antiparasitic drug and not the antipsychotic agent caused the improvement, reinforcing the delusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12626396\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delusional parasitosis features a fixed, false belief that an individual is infected with parasites or other living organisms. Classified as a delusional disorder, delusional parasitosis is one of a number of disorders also described as a monosymptomatic hypochondriacal psychosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two forms of delusional parasitosis have been described.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary delusional parasitosis is a psychiatric disorder with the delusion of parasitic infection as its only manifestation. It is a diagnosis of exclusion after ruling out a parasitic infection and other medical and psychiatric illnesses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=see_link&amp;anchor=H15122193#H15122193\">",
"       \"Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis\", section on 'Primary delusional parasitosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary delusional parasitosis is a symptom of another psychiatric or medical illness rather than a disorder. Treatment is generally focused on the primary disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=see_link&amp;anchor=H15122200#H15122200\">",
"       \"Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis\", section on 'Secondary delusional parasitosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with delusional parasitosis typically present in primary care or to a dermatologist. They typically are highly resistant to the idea of assessment by a psychiatrist. Whether in general medical care or psychiatric care, the development of a strong, therapeutic relationship instilling trust is central to clinical management. Means of doing so include: (See",
"      <a class=\"local\" href=\"#H12625559\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A non-judgmental approach",
"     </li>",
"     <li>",
"      Acknowledgment that the patient's symptoms are real",
"     </li>",
"     <li>",
"      Empathetic exploration into the impact of the patient&rsquo;s symptoms on his or her daily life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with delusional parasitosis receive treatment with an antipsychotic medication (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Randomized trials have not been conducted of treatments for delusional parasitosis. Several case series, observational trials, and our clinical experience suggest antipsychotics are an effective treatment for the condition. There is no evidence to suggest that any one antipsychotic is more effective than the others. (See",
"      <a class=\"local\" href=\"#H12625596\">",
"       'Antipsychotic medication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      (0.25 to 8 mg daily) can be administered once or twice daily. Antipsychotics should be started at a low dose and increased slowly. Most patients respond to between 2 and 4",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of risperidone. (See",
"      <a class=\"local\" href=\"#H12625610\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"       Pimozide",
"      </a>",
"      , at a typical dose of 1 to 6 mg daily, has been most frequently studied and widely used for the disorder. However, pimozide (along with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"       thioridazine",
"      </a>",
"      &nbsp;and intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ) prolong the QT interval, particularly at higher doses. It should be avoided in elderly patients, those with cardiac disease, and in conjunction with other drugs that prolong the QT interval. In other patients, pimozide should be accompanied by baseline and subsequent ECG monitoring. (See",
"      <a class=\"local\" href=\"#H12625610\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a therapeutic dose is achieved, we suggest the patient be maintained on the antipsychotic for at least one month, and preferably several months. The medication should be discontinued with slow taper. Relapse, if it occurs, usually responds to reinstitution of therapy. (See",
"      <a class=\"local\" href=\"#H12625610\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/1\">",
"      Lynch PJ. Delusions of parasitosis. Semin Dermatol 1993; 12:39.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision, American Psychiatric Association, Washington, DC 2000. p.323.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/3\">",
"      Musalek M, Bach M, Passweg V, Jaeger S. The position of delusional parasitosis in psychiatric nosology and classification. Psychopathology 1990; 23:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/4\">",
"      Freinhar JP. Delusions of parasitosis. Psychosomatics 1984; 25:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/5\">",
"      Gould WM, Gragg TM. Delusions of parasitosis. An approach to the problem. Arch Dermatol 1976; 112:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/6\">",
"      Wykoff RF. Delusions of parasitosis: a review. Rev Infect Dis 1987; 9:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/7\">",
"      Aw DC, Thong JY, Chan HL. Delusional parasitosis: case series of 8 patients and review of the literature. Ann Acad Med Singapore 2004; 33:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/8\">",
"      Winsten M. Delusional parasitosis: a practical guide for the family practitioner in evaluation and treatment strategies. J Am Osteopath Assoc 1997; 97:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/9\">",
"      Lyell A. The Michelson Lecture. Delusions of parasitosis. Br J Dermatol 1983; 108:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/10\">",
"      Zanol K, Slaughter J, Hall R. An approach to the treatment of psychogenic parasitosis. Int J Dermatol 1998; 37:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/11\">",
"      Thomson AB, Page LA. Psychotherapies for hypochondriasis. Cochrane Database Syst Rev 2007; :CD006520.",
"     </a>",
"    </li>",
"    <li>",
"     <a 1ff8 class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/12\">",
"      Noyes R Jr, Kathol RG, Fisher MM, et al. Psychiatric comorbidity among patients with hypochondriasis. Gen Hosp Psychiatry 1994; 16:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/13\">",
"      Lepping P, Russell I, Freudenmann RW. Antipsychotic treatment of primary delusional parasitosis: systematic review. Br J Psychiatry 2007; 191:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/14\">",
"      Manschreck TC, Khan NL. Recent advances in the treatment of delusional disorder. Can J Psychiatry 2006; 51:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/15\">",
"      Trabert W. 100 years of delusional parasitosis. Meta-analysis of 1,223 case reports. Psychopathology 1995; 28:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/16\">",
"      Bhatia MS, Jagawat T, Choudhary S. Delusional parasitosis: a clinical profile. Int J Psychiatry Med 2000; 30:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/17\">",
"      Reilly TM, Batchelor DH. The presentation and treatment of delusional parasitosis: a dermatological perspective. Int Clin Psychopharmacol 1986; 1:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/18\">",
"      Zomer SF, De Wit RF, Van Bronswijk JE, et al. Delusions of parasitosis. A psychiatric disorder to be treated by dermatologists? An analysis of 33 patients. Br J Dermatol 1998; 138:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/19\">",
"      Ungv&aacute;ri G, Vlad&aacute;r K. Pimozide treatment for delusion of infestation. Act Nerv Super (Praha) 1986; 28:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/20\">",
"      Hamann K, Avnstorp C. Delusions of infestation treated by pimozide: a double-blind crossover clinical study. Acta Derm Venereol 1982; 62:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/21\">",
"      Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000; 20:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/22\">",
"      Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008; 23 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/23\">",
"      May WW, Terpenning MS. Delusional parasitosis in geriatric patients. Psychosomatics 1991; 32:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/24\">",
"      Srinivasan TN, Suresh TR, Jayaram V, Fernandez MP. Nature and treatment of delusional parasitosis: a different experience in India. Int J Dermatol 1994; 33:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/25\">",
"      Freyne A, Wrigley M. Delusional infestation in an elderly population. Ir Med J 1994; 87:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/26\">",
"      De Le&oacute;n OA, Furmaga KM, Canterbury AL, Bailey LG. Risperidone in the treatment of delusions of infestation. Int J Psychiatry Med 1997; 27:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/27\">",
"      Safer DL, Wenegrat B, Roth WT. Risperidone in the treatment of delusional parasitosis: a case report. J Clin Psychopharmacol 1997; 17:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/28\">",
"      Gallucci G, Beard G. Risperidone and the treatment of delusions of parasitosis in an elderly patient. Psychosomatics 1995; 36:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/29\">",
"      Wenning MT, Davy LE, Catalano G, Catalano MC. Atypical antipsychotics in the treatment of delusional parasitosis. Ann Clin Psychiatry 2003; 15:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/30\">",
"      Nakaya M. Olanzapine treatment of monosymptomatic hypochondriacal psychosis. Gen Hosp Psychiatry 2004; 26:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/31\">",
"      Freudenmann RW. [A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy]. Nervenarzt 2003; 74:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/32\">",
"      Meehan WJ, Badreshia S, Mackley CL. Successful treatment of delusions of parasitosis with olanzapine. Arch Dermatol 2006; 142:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/33\">",
"      Freudenmann RW, Sch&ouml;nfeldt-Lecuona C, Lepping P. Primary delusional parasitosis treated with olanzapine. Int Psychogeriatr 2007; 19:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/34\">",
"      Freudenmann RW, K&uuml;hnlein P, Lepping P, Sch&ouml;nfeldt-Lecuona C. Secondary delusional parasitosis treated with paliperidone. Clin Exp Dermatol 2009; 34:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/35\">",
"      Koo J, Gambla C. Delusions of parasitosis and other forms of monosymptomatic hypochondriacal psychosis. General discussion and case illustrations. Dermatol Clin 1996; 14:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/36\">",
"      Rocha FL, Hara C. Aripiprazole in delusional parasitosis: Case report. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1575/abstract/37\">",
"      Driscoll MS, Rothe MJ, Grant-Kels JM, Hale MS. Delusional parasitosis: a dermatologic, psychiatric, and pharmacologic approach. J Am Acad Dermatol 1993; 29:1023.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15747 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1575=[""].join("\n");
var outline_f1_34_1575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12626396\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H521793394\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H521793401\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521793416\">",
"      Primary delusional parasitosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521793423\">",
"      Secondary delusional parasitosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12625559\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12625566\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12625574\">",
"      Secondary delusional parasitosis",
"     </a>",
"    </li>",
"    <li \"bulletitem\" class=\"1422\">",
"     <a class=\"outlineLink\" href=\"#H12625581\">",
"      Hypochondriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12625588\">",
"      Primary delusional parasitosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12625596\">",
"      - Antipsychotic medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12625603\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12625610\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12625617\">",
"      - Patient acceptance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12626396\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=related_link\">",
"      Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=related_link\">",
"      Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_34_1576="The molecular biology of melanoma";
var content_f1_34_1576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The molecular biology of melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1576/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1576/contributors\">",
"     Ryan J Sullivan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1576/contributors\">",
"     David E Fisher, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1576/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1576/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1576/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/34/1576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5643571\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma is currently the fifth and seventh most common cancer in American men and women, respectively, and its incidence has risen dramatically [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H5112797#H5112797\">",
"     \"Risk factors for the development of melanoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with localized disease can be treated successfully with surgical resection in the majority of cases, some individuals present with or subsequently develop disseminated disease. The prognosis for patients with distant metastases from melanoma is poor, and the vast majority of those with stage IV melanoma will die from their disease.",
"   </p>",
"   <p>",
"    An increasing understanding of melanocyte biology and melanoma pathogenesis is leading to the development of targeted therapies and the potential for major improvements in the care of patients with advanced melanoma. The most important breakthroughs have been the discovery that the mitogen activated protein kinase (MAPK) pathway is the key signaling pathway and the elucidation of the critical role of microphthalmia-associated transcription factor (MITF).",
"   </p>",
"   <p>",
"    This topic provides an overview of melanocyte biology and the important molecular alterations of genes and signaling pathways that are critical to the",
"    <em>",
"    </em>",
"    development and pathogenesis of melanoma. The clinical results with targeted agents that are being developed based upon this information are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5643578\">",
"    <span class=\"h1\">",
"     MELANOCYTE BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanocytes are the pigment-containing cells of the skin that produce melanin in response to stimuli such as ultraviolet (UV) radiation. Melanocytes also make the pigment that determines skin and hair color.",
"   </p>",
"   <p>",
"    Melanocytes are derived from pluripotent neural crest stem cells. Melanocyte development is modulated by the KIT and MITF, factors that are mutated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amplified oncogenes in many cases of melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alpha-melanocyte stimulating hormone (MSH) is a pro-pigmentation peptide that stimulates the melanocortin 1 receptor (MC1R) on the surface of melanocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/3\">",
"     3",
"    </a>",
"    ]. The MC1R gene exists in numerous variant (polymorphic) forms; non-signaling variants produce the",
"    <span class=\"nowrap\">",
"     red-hair/fair-skin",
"    </span>",
"    phenotype, which is associated with an increased risk of melanoma and non-melanoma skin cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracellular cAMP induction downstream of MC1R activates the expression of microphthalmia-associated transcription factor (MITF), which stimulates transcription of numerous genes that participate in the conversion of tyrosine into melanin pigments. Stimulation of cutaneous pigmentation following UV exposure (tanning) is thought to occur via keratinocyte DNA damage, p53-mediated induction of",
"    <span class=\"nowrap\">",
"     POMC/MSH",
"    </span>",
"    expression, followed by secretion of MSH and stimulation of MC1R in epidermal melanocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous UV exposure may induce behavioral effects, perhaps related to endorphin components of the",
"    <span class=\"nowrap\">",
"     POMC/MSH",
"    </span>",
"    complex, which may produce an addiction to sun bathing and therefore contribute to the increase in melanoma incidence observed over recent decades [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/6\">",
"     6",
"    </a>",
"    ]. &ldquo;Rescue&rdquo; of this cAMP-MITF-pigment cascade has been achieved via topical drug delivery in mouse models and confers protection against UV-induced carcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5643585\">",
"    <span class=\"h1\">",
"     MAPK PATHWAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MAPK pathway is activated in almost all melanomas (",
"    <a class=\"graphic graphic_figure graphicRef53134 \" href=\"UTD.htm?41/46/42724\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/9\">",
"     9",
"    </a>",
"    ]. In nonmalignant cells, the interaction between a growth factor receptor and its ligand is required to activate this pathway. This leads to a series of events that promote cellular growth and survival. The RAS family members are G-proteins, which serve as critical mediators in the transduction of such signals.",
"   </p>",
"   <p>",
"    NRAS mutations have been identified in 10 to 15 percent of melanomas and are thought to be an important driver of oncogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. A somatic mutation in the NRAS gene can cause constitutive activity of the NRAS protein, which is thus incapable of being &ldquo;turned off&rdquo;. This leads to the serial activation of",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinases, which promotes cell cycle progression, cellular transformation, and increased cell survival. In addition, this cascade of events may be mediated through the overexpression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperactivation of various growth factor receptors, such as c-Met, epidermal growth factor receptor (EGFR), and KIT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important downstream mediators of activated RAS are the",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinases BRAF and CRAF, which are activated following RAS binding (",
"    <a class=\"graphic graphic_figure graphicRef53134 \" href=\"UTD.htm?41/46/42724\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In contrast to BRAF, activation of the pathway by CRAF requires additional steps, whereas activation of BRAF alone is sufficient. This may explain why an activating mutation in the BRAF kinase domain is present in 40 to 50 percent of patients with melanoma, but there are no descriptions of activating mutations of CRAF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following activation, RAF, typically in the form of either a homo- or heterodimer, interacts with the",
"    <span class=\"nowrap\">",
"     MAPK/Extracellular",
"    </span>",
"    signal-regulated kinase (ERK) Kinase MEK thereby initiating MEK phosphorylation, which in turn leads to an activating phosphorylation of ERK, its only known substrate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/17,22,23\">",
"     17,22,23",
"    </a>",
"    ]. The activation of ERK leads to a pro-growth and transforming signal, through its interaction with a number of molecules, which appears to be critical to the pathogenesis of many malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220469\">",
"    <span class=\"h2\">",
"     Molecular characterization of melanocytic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;BRAF mutations appear to be an acquired event that occurs in early invasive melanoma and leads to clonal expansion and tumor progression. The BRAF mutation thus is not a founder event but rather facilitates malignant transformation with the acquisition of subsequent oncogenic stimuli. Evidence supporting this interpretation includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BRAF mutations are common in melanocytic nevi, vertical growth phase melanomas, and metastatic melanoma (70 to 80, 40 to 50, and 40 to 50 percent, respectively). However, BRAF mutations are rarely detected in radial growth phase melanomas or in situ melanoma (10 and 6 percent, respectively), which are thought to be the initial malignant lesions prior to development of frankly invasive lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/21,24-26\">",
"       21,24-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polyclonality (ie, BRAF mutated cells mixed with BRAF wild type cells) has been observed in both atypical nevi and primary melanomas, though such polyclonality has not been seen in individual metastatic tumors nor in tumors from distinct sites in an individual patient [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/9,27,28\">",
"       9,27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings&nbsp;can be viewed as contradicting the popularly held belief that BRAF mutation precedes all other oncogenic events in BRAF mutant melanoma, based primarily on the fact that BRAF mutations are present in 70 to 80 percent of dysplastic nevi [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/24\">",
"     24",
"    </a>",
"    ].&nbsp;However the precise relationship between nevi and melanomagenesis remains incompletely understood. Further elucidation of the mechanisms of transformation in BRAF mutant melanoma is needed.&nbsp;Irrespective of the mechanism, however, when these BRAF mutations occur in invasive melanoma, the resultant constitutive activation of MEK (and subsequently ERK) leads to oncogenesis through the promotion of cellular growth and opposition of apoptosis, as well as to the strict reliance of these cells upon the signaling cascade [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220084\">",
"    <span class=\"h2\">",
"     Genetic abnormalities in melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genomic mutations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aberrations are present in the majority of melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/9,30\">",
"     9,30",
"    </a>",
"    ]. These can lead to activation of the MAPK pathway and create an oncogenic addiction to the mutated or hyperactivated protein. Within this pathway, the patterns of mutation frequencies for each subtype differ significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/30-38\">",
"     30-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219765\">",
"    <span class=\"h3\">",
"     Cutaneous melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cutaneous melanoma, BRAF and NRAS mutations are the most frequently observed (40 to 50 and 15 to 20 percent of cases, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/10-13,21\">",
"     10-13,21",
"    </a>",
"    ]. Both BRAF and NRAS mutations are more common in cutaneous melanomas without chronic sun damage compared with those associated with chronic sun damage (60 versus 6 to 22 percent and 20 to 22 versus 0 to 15 percent, respectively).",
"   </p>",
"   <p>",
"    Inhibitors of both BRAF and MEK are being developed for use in the treatment of cutaneous advanced melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473006#H100473006\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'MEK inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219772\">",
"    <span class=\"h3\">",
"     Uveal melanomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In uveal melanoma, the MAPK pathway is upregulated by an activating mutation in either of the g-proteins GNAQ or GNA11, which together are observed in over 80 percent of cases. Mutations in BRAF, NRAS, and KIT are rarely, if ever, seen in uveal melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220060\">",
"    <span class=\"h4\">",
"     GNAQ and GNA11",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with uveal melanoma, somatic mutations in either of the homologous GNAQ or GNA11 genes can activate the MAP kinase pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/32\">",
"     32",
"    </a>",
"    ]. These mutations are either at the Q209 position of exon 5 or less frequently at the R183 position in exon 4. The oncogenic potential of these mutations and their ability to activate the MAP kinase pathway has been confirmed in murine models.",
"   </p>",
"   <p>",
"    The potential importance of this pathway in patients with uveal melanoma was illustrated by a series of 187 patients with uveal melanocytic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/32\">",
"     32",
"    </a>",
"    ]. Somatic mutations were identified in about 80 percent of cases. In 139 blue nevi, a cutaneous lesion associated with uveal melanoma, mutations were present in over 60 percent of cases. Of potential importance, GNAQ mutations were proportionally more common in blue nevi and primary uveal melanomas while GNA11 mutations predominated in metastatic uveal melanoma deposits.",
"   </p>",
"   <p>",
"    In contrast, these somatic mutations in GNAQ and GNA11 were absent in all nine cases of conjunctival melanoma, and a somatic mutation in these genes was identified in only 1 of 273 cases of extraocular melanoma (0.4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219814\">",
"    <span class=\"h4\">",
"     BRCA1-associated protein 1 (BAP1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monosomy of chromosome 3 has been associated with the development of metastatic disease in patients with uveal melanoma but is rare in patients with cutaneous melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. As an example, genetic analysis of fine needle aspirate found that partial or complete monosomy of chromosome 3 was present in 27 and 25 percent of cases in a series of 500 uveal melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/44\">",
"     44",
"    </a>",
"    ]. The presence of complete monosomy was associated with significantly poorer survival at three years.",
"   </p>",
"   <p>",
"    Somatic mutations in the gene encoding BRCA1-associated protein 1 (BAP1) on chromosome 3 have been identified in 26 of 31 uveal melanomas (84 percent) with a gene expression profile consistent with a high metastatic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, mutations in BAP1 were present in only 1 of 26 patients (4 percent) classified as being at low risk for metastases. Loss of function of this tumor suppressor gene is thought to result from the combination of a somatic mutation in one allele and the loss of one chromosome 3 allele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220235\">",
"    <span class=\"h3\">",
"     Acral and mucosal melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mucosal and acral melanomas, KIT is the most frequently mutated gene (15 to 40 percent of cases). BRAF and NRAS mutations are much less common, occurring in less that 10 percent of cases overall. Inhibitors of kit, a cell surface receptor that can activate ras, are being evaluated in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473006#H100473006\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'MEK inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5643606\">",
"    <span class=\"h2\">",
"     Mutation status and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with advanced melanoma is influenced by the specific mutations present in a specific tumor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melanomas with somatic mutations of either NRAS or BRAF are associated with a poorer prognosis. However, patients whose tumors contain BRAF mutations have improved response rates and survival when treated with BRAF-inhibitors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"       \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with acral or mucosal melanoma that contain KIT mutations have a poorer prognosis compared with similar patients whose tumors do not contain identifiable KIT mutations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473013#H100473013\">",
"       \"Molecularly targeted therapy for metastatic melanoma\", section on 'Kit inhibition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with ocular melanoma, somatic mutations in either GNAQ or GNA11 mutation do not appear to be associated with poor prognosis (at least relative to the small group of patients with tumors lacking either mutation). Mutation in the BAP1 gene, which is thought to regulate cellular growth control via as yet incompletely understood mechanisms, does appear to be associated with increased risk of metastasis and worsened prognosis. (See",
"      <a class=\"local\" href=\"#H219772\">",
"       'Uveal melanomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220317\">",
"    <span class=\"h1\">",
"     ROLE OF MITF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microphthalmia-associated transcription factor (MITF) is crucial to melanin production. (See",
"    <a class=\"local\" href=\"#H5643578\">",
"     'Melanocyte biology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    MITF also has important roles in cell cycling during melanocyte differentiation, melanocyte invasion during physiologic migration, and the promotion of melanocyte survival [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/45\">",
"     45",
"    </a>",
"    ]. While these functions are critical to normal melanocyte biology, MITF dysregulation can contribute to the pathogenesis of melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MITF amplification occurs in approximately 20 percent of melanomas and appears to be associated with poorer survival [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Additionally, a specific germline mutation in MITF has been associated with increased nevus count, non-blue eye color, and elevated melanoma risk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanistic data have revealed an intriguing relationship between MITF and the MAPK pathway, which is relevant to therapies targeting BRAF. MITF serves as a direct substrate for phosphorylation at serine 73 by MAPK [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/50\">",
"     50",
"    </a>",
"    ]. One of the critical sequelae of this phosphorylation is the targeting of MITF for ubiquitin-modification, resulting in rapid degradation of MITF protein [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/51\">",
"     51",
"    </a>",
"    ]. A key consequence of this homeostatic circuitry is that BRAF antagonists block MITF phosphorylation, ubiquitination, and degradation, resulting in its stabilization and profound upregulation of certain (if not all) MITF transcriptional target genes. Some of these target genes are known antigens in immunologic recognition of melanomas, such as Mart1 or gp100. Thus, BRAF antagonism may enhance the antigenicity of melanomas via enhanced MITF stability and subsequent upregulation of melanocytic antigen expression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5643613\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small molecule inhibitors have been developed that effectively target mutated BRAF. The other protein that can be effectively targeted in patients with melanoma is mutant KIT. Inhibitors of the downstream mediators of RAF activation (MEK and ERK) are also being developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5643627\">",
"    <span class=\"h2\">",
"     BRAF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potent, selective inhibitors of BRAF, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    , have induced tumor regression and prolonged overall survival in patients with metastatic melanoma that contains the mutated form of BRAF-V600E. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As would be predicted, treatment with these agents leads to a reduction in levels of pERK in tumors containing the BRAF-V600E mutation, which is associated with clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    However, selective BRAF inhibitors may paradoxically hyperstimulate RAF kinases within cells in which the RAS pathway is activated upstream of a wild type BRAF kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5643641\">",
"    <span class=\"h3\">",
"     Mechanisms of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually every patient treated with an inhibitor of BRAF eventually has disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/58\">",
"     58",
"    </a>",
"    ]. No consistent mechanism of resistance has been identified.",
"   </p>",
"   <p>",
"    Resistance has not been associated with the development of a second mutation that impairs the binding of the treatment drug to BRAF, a resistance mechanism observed in targeted therapy in other malignancies. Several resistance mechanisms have been described that typically involve tumor cell reactivation via the MAPK pathway through a variety of alternative means.",
"   </p>",
"   <p>",
"    Studies using BRAF-V600E mutated cells that were generated to exhibit acquired resistance to BRAF inhibitors provide insights into how BRAF mutated cells survive BRAF inhibition. Several mechanisms of resistance have been identified, each of which has been investigated in at least a small number of tumor cells:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bypass mechanisms within the MAPK pathway can restore ERK activation regardless of ongoing BRAF inhibition. Reestablishment of signaling can be achieved through upregulation of receptor tyrosine kinases (ie, PDGFRB, ERBB2) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/59,60\">",
"       59,60",
"      </a>",
"      ], activation of NRAS via mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/60-62\">",
"       60-62",
"      </a>",
"      ], upregulation of CRAF [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/59,63\">",
"       59,63",
"      </a>",
"      ], activating mutations of MEK [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/62,64,65\">",
"       62,64,65",
"      </a>",
"      ], and activation of the",
"      <span class=\"nowrap\">",
"       serine/threonine",
"      </span>",
"      MAPK kinases (COT) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Shortened forms of the BRAF protein may be produced due to altered RNA processing [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/66\">",
"       66",
"      </a>",
"      ]. These modified forms of the BRAF protein can activate the MAPK pathway even in the presence of a BRAF inhibitor. This abnormality was identified in 6 of 19 patients with acquired resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Signaling through the parallel growth and survival PI3K pathway, which is initiated by insulin growth factor receptor 1 (IGF-1R), is an alternative mechanism of acquired resistance that has been described and fits the definition of an outside of pathway bypass mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary resistance to BRAF inhibition is seen in less than 10 percent of patients with BRAF mutant melanoma treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/68\">",
"     68",
"    </a>",
"    ]. Currently, there are no data that permit identification of those patients who are likely not to benefit from BRAF inhibitors. Preclinical studies suggest that elevated pretreatment levels of CRAF, as well as baseline CCND1 amplification in tumors, leading to downstream overexpression of cyclin D1 and enhanced CDK4 expression, are pretreatment biomarkers worth further investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/63,69\">",
"     63,69",
"    </a>",
"    ]. This is particularly important in light of the clinical development of orally available, selective CDK",
"    <span class=\"nowrap\">",
"     4/6",
"    </span>",
"    inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216837\">",
"    <span class=\"h2\">",
"     KIT inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating mutations of KIT have been demonstrated in only a small percentage of all melanoma cases. Initial clinical trials with KIT inhibitors did not show evidence of significant activity, but subsequent studies in highly selected populations were encouraging. Additional clinical trials are in progress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473013#H100473013\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'Kit inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216686\">",
"    <span class=\"h2\">",
"     MEK inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of MEK have shown promise in preclinical studies; although the MAP kinase pathway is activated in most melanomas, the presence of BRAF-V600E mutation correlates strongly with response to MEK inhibition in murine melanoma xenograft models [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/70\">",
"     70",
"    </a>",
"    ]. Clinically, several agents are being evaluated and have shown some evidence of activity, particularly in patients with characteristic BRAF mutations. Trametinib and MEK162 have recently been shown to be associated with clinical benefit in patients with tumors harboring BRAF-V600 mutations.&nbsp;Additionally, MEK162 is associated with responses in a minority of patients with NRAS mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1576/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473006#H100473006\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'MEK inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5643648\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Research into the molecular pathogenesis of melanoma has identified the MAPK pathway (",
"      <a class=\"graphic graphic_figure graphicRef53134 \" href=\"UTD.htm?41/46/42724\">",
"       figure 1",
"      </a>",
"      ) and microphthalmia-associated transcription factor (MITF) as key factors in the development of melanoma. (See",
"      <a class=\"local\" href=\"#H5643585\">",
"       'MAPK pathway'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H220317\">",
"       'Role of MITF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the MAPK pathway is activated in almost all melanomas, different abnormalities in the pathway are associated with specific subtypes of melanoma. The most common include BRAF and NRAS in cutaneous melanomas, KIT in acral and mucosal melanomas, and GNAQ and GNA11 in ocular melanomas. (See",
"      <a class=\"local\" href=\"#H220469\">",
"       'Molecular characterization of melanocytic lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Understanding of the importance of the MAPK pathway and BRAF mutations has led to the development of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      , which has been shown to significantly prolong survival in patients with melanoma containing a V600 mutation. Additional agents are under development to target this and other components of the MAPK pathway. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"       \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5643613\">",
"       'Clinical implications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/2\">",
"      Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/3\">",
"      Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007; 445:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/4\">",
"      Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003; 37:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/5\">",
"      Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007; 128:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/6\">",
"      Fisher DE, James WD. Indoor tanning--science, behavior, and policy. N Engl J Med 2010; 363:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/7\">",
"      Khaled M, Levy C, Fisher DE. Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev 2010; 24:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/8\">",
"      D'Orazio JA, Nobuhisa T, Cui R, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006; 443:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/9\">",
"      Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/10\">",
"      Albino AP, Le Strange R, Oliff AI, et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 1984; 308:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/11\">",
"      Ball NJ, Yohn JJ, Morelli JG, et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/12\">",
"      Platz A, Ringborg U, Brahme EM, Lagerl&ouml;f B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res 1994; 4:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/13\">",
"      van 't Veer LJ, Burgering BM, Versteeg R, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989; 9:3114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/14\">",
"      Bardeesy N, Kim M, Xu J, et al. Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol 2005; 25:4176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/15\">",
"      Furge KA, Kiewlich D, Le P, et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A 2001; 98:10722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/16\">",
"      Monsel G, Ortonne N, Bagot M, et al. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 2010; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/17\">",
"      Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23:6771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/18\">",
"      Chong H, Guan KL. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J Biol Chem 2003; 278:36269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/19\">",
"      Fischer A, Hekman M, Kuhlmann J, et al. B- and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Ras binding. J Biol Chem 2007; 282:26503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/20\">",
"      Tran NH, Wu X, Frost JA. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem 2005; 280:16244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/21\">",
"      Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/22\">",
"      Garnett MJ, Rana S, Paterson H, et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005; 20:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/23\">",
"      Terai K, Matsuda M. The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. EMBO J 2006; 25:3556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/24\">",
"      Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/25\">",
"      Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003; 63:3883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/26\">",
"      Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/27\">",
"      Lin J, Goto Y, Murata H, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 2011; 104:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/28\">",
"      Lin J, Takata M, Murata H, et al. Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst 2009; 101:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/29\">",
"      Sharma A, Trivedi NR, Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005; 65:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/30\">",
"      Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/31\">",
"      Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/32\">",
"      Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/33\">",
"      Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/34\">",
"      Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011; 17:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/35\">",
"      Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/36\">",
"      Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29:2904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/37\">",
"      Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24:4340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/38\">",
"      Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14:6821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/39\">",
"      Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/40\">",
"      Desjardins L, Levy-Gabriel C, Lumbroso-Lerouic L, et al. [Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research]. J Fr Ophtalmol 2006; 29:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/41\">",
"      Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997; 19:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/42\">",
"      Becher R, Korn WM, Prescher G. Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Cancer Genet Cytogenet 1997; 93:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/43\">",
"      Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res 1999; 59:3032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/44\">",
"      Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011; 118:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/45\">",
"      Haq R, Fisher DE. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 2011; 29:3474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/46\">",
"      Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/47\">",
"      Ugurel S, Houben R, Schrama D, et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res 2007; 13:6344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/48\">",
"      Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011; 480:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/49\">",
"      Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011; 480:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/50\">",
"      Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998; 391:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/51\">",
"      Wu M, Hemesath TJ, Takemoto CM, et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 2000; 14:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/52\">",
"      Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/53\">",
"      Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/54\">",
"      Joseph EW, Pratilas CA, Poulikakos PI, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010; 107:14903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/55\">",
"      Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/56\">",
"      Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/57\">",
"      Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/58\">",
"      Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/59\">",
"      Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/60\">",
"      Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/61\">",
"      Tap WD, Gong KW, Dering J, et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 2010; 12:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/62\">",
"      Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/63\">",
"      Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008; 68:4853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/64\">",
"      Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/65\">",
"      Wang H, Daouti S, Li WH, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res 2011; 71:5535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/66\">",
"      Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/67\">",
"      Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/68\">",
"      Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/69\">",
"      Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008; 7:2876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/70\">",
"      Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1576/abstract/71\">",
"      Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16540 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1576=[""].join("\n");
var outline_f1_34_1576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5643648\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5643571\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5643578\">",
"      MELANOCYTE BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5643585\">",
"      MAPK PATHWAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220469\">",
"      Molecular characterization of melanocytic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220084\">",
"      Genetic abnormalities in melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H219765\">",
"      - Cutaneous melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H219772\">",
"      - Uveal melanomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H220060\">",
"      GNAQ and GNA11",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H219814\">",
"      BRCA1-associated protein 1 (BAP1)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H220235\">",
"      - Acral and mucosal melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5643606\">",
"      Mutation status and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H220317\">",
"      ROLE OF MITF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5643613\">",
"      CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5643627\">",
"      BRAF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5643641\">",
"      - Mechanisms of resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216837\">",
"      KIT inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216686\">",
"      MEK inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5643648\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16540\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16540|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/46/42724\" title=\"figure 1\">",
"      MAP kinase pathway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_34_1577="Management of heart failure in pregnancy";
var content_f1_34_1577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of heart failure in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Jeanne M DeCara, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Roberto M Lang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Michael R Foley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1577/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/34/1577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is associated with substantial hemodynamic changes, including 30 to 50 percent increases in both cardiac output and blood volume. In women with a history of heart failure (HF) or other cardiovascular disorders, these demands can lead to clinical decompensation. In addition, women without a history of cardiovascular disease can develop HF due to diseases acquired during pregnancy, such as peripartum cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=see_link\">",
"     \"Peripartum cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heart failure (HF) is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. It is characterized by specific symptoms, such as dyspnea and fatigue, and signs, such as fluid retention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the concerns related to potential adverse effects on the fetus and the mother, medication use during pregnancy is a challenge. This is an important issue in women with both chronic and acute HF. For example, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), which are part of the standard long-term therapeutic regimen in nonpregnant patients with HF due to systolic dysfunction, are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and management of HF during pregnancy will be reviewed here. The general approach to pregnancy in women with known congenital or acquired heart disease, and overviews of the management of acute and chronic HF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHRONIC VERSUS ACUTE CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are pregnant or considering pregnancy, issues related to HF management can be important in two settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with a history of chronic HF or other cardiovascular disorders can present in a stable condition either prior to or in the early stages of pregnancy. In such patients, management focuses on the adjustment of chronic medical therapies and monitoring for decompensation.",
"      <br/>",
"      <br/>",
"      Conditions that increase the risk of developing HF during pregnancy include cardiomyopathy, mitral stenosis, aortic stenosis, severe mitral or aortic regurgitation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. In addition, the growing population of adult women with congenital heart disease includes some at risk of HF during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. Ischemic heart disease is uncommon in this population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"       \"Acquired heart disease and pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"       \"Pregnancy in women with congenital heart disease: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women can present with decompensated HF during pregnancy or in the peripartum period. Such decompensation can occur in patients with preexisting disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/4\">",
"       4",
"      </a>",
"      ], or it can be the result of disease acquired during pregnancy. Because pregnancy can be proarrhythmic, women with lesions such as mitral stenosis can develop arrhythmias which precipitate HF during pregnancy. Examples of cardiovascular disorders that can develop during pregnancy include peripartum cardiomyopathy, infective endocarditis, sepsis and pericardial disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=see_link\">",
"       \"Peripartum cardiomyopathy\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nature of the initial evaluation of a woman with or at risk for HF varies according to the setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stable patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a history of HF or other cardiovascular disorders often present in a stable, well-compensated condition prior to or in the early stages of pregnancy. The initial approach to such patients involves assessing the cardiovascular risks associated with pregnancy and discussing these risks with the patient. There are increased risks for both the mother and for the",
"    <span class=\"nowrap\">",
"     fetus/neonate",
"    </span>",
"    (low birth",
"    <span class=\"nowrap\">",
"     weight/prematurity).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link&amp;anchor=H8#H8\">",
"     \"Acquired heart disease and pregnancy\", section on 'Assessing risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H4#H4\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Management guidelines'",
"    </a>",
"    .) The late effects of pregnancy on the diseased heart are unknown and women should be aware that there may be late sequelae.",
"   </p>",
"   <p>",
"    A baseline evaluation should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful history and physical examination with consideration of physiologic changes during pregnancy. Findings such as mild pedal edema and presence of a fourth heart sound (S4) may be observed during uncomplicated pregnancy.",
"     </li>",
"     <li>",
"      Assessment of NYHA functional class (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An electrocardiogram",
"     </li>",
"     <li>",
"      Echocardiography if not recently performed (eg, within the past year) or if reassessment may change clinical management",
"     </li>",
"     <li>",
"      In select cases, CMR or other cardiac imaging studies may be required (ie congenital heart disease with RV",
"      <span class=\"nowrap\">",
"       dilation/dysfunction).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, issues to be addressed in this initial evaluation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plans for ongoing surveillance during the antepartum period",
"     </li>",
"     <li>",
"      Plans for monitoring at the time of delivery",
"     </li>",
"     <li>",
"      Medication adjustments (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Medical management'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Re-assessment by echocardiography during each trimester is prudent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decompensated heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with decompensated HF most commonly present with progressive dyspnea or perhaps a persistent cough, which may or may not be associated with chest discomfort. The diagnosis is made using a constellation of clinical signs and symptoms and selected laboratory findings. The general approach to the diagnosis of acute decompensated HF is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of acute decompensated heart failure\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial evaluation usually includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A focused history and physical examination, with particular attention to evidence of preexisting cardiovascular disease.",
"     </li>",
"     <li>",
"      Echocardiography, which may reveal previously undetected structural heart disease (eg, valve abnormalities or congenital heart disease), or worsening LV function.",
"     </li>",
"     <li>",
"      An electrocardiogram, which may reveal left or right ventricular hypertrophy, left atrial abnormalities, myocardial ischemia, or atrial fibrillation.",
"     </li>",
"     <li>",
"      Laboratory tests, including a complete blood count, electrolytes, and renal function tests. In selected patients additional tests can be appropriate, including an arterial blood gas, cardiac enzymes, and serum B-type natriuretic peptide (BNP) or N-terminal pro-BNP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"       \"Natriuretic peptide measurement in heart failure\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Limited data are available on the value of BNP or N-terminal pro-BNP levels in evaluating volume status during pregnancy. In small series, normal BNP or N-terminal pro-BNP levels were observed in pregnant women without cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. Elevated BNP or N-terminal pro-BNP levels have been observed in pregnant women with preeclampsia and other clinical conditions associated with acute volume overload [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chest x-ray &mdash; Chest x-ray is not necessary to make the diagnosis of HF if there is clear clinical evidence of pulmonary edema. The use of x-ray in general is especially discouraged if the woman is still pregnant. If, despite a thorough physical exam, the diagnosis of pulmonary edema is still uncertain, and a CXR is necessary to make that diagnosis, its use should be discussed with the woman, and fetal shielding should be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"       \"Diagnostic imaging procedures during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for HF symptoms during pregnancy or in the peripartum period includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute lung injury due to infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tocolytic therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34681?source=see_link&amp;anchor=H5#H5\">",
"       \"Critical illness during pregnancy and the peripartum period\", section on 'Acute respiratory failure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Amniotic fluid embolism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=see_link\">",
"       \"Amniotic fluid embolism syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary embolism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pneumonia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myocardial infarction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe preeclampsia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a pregnant woman with HF, the goals of medical therapy are similar to those in nonpregnant patients. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Optimizing hemodynamics",
"     </li>",
"     <li>",
"      Relief of symptoms",
"     </li>",
"     <li>",
"      When possible, continuation of chronic therapies that improve long-term outcomes in women with chronic cardiovascular disorders.",
"     </li>",
"     <li>",
"      Treatment of precipitating factors (anemia, arrhythmias, thyroid disorders)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methods for achieving these goals include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of pulmonary congestion with diuretics",
"     </li>",
"     <li>",
"      Afterload reduction",
"     </li>",
"     <li>",
"      Control of hypertension",
"     </li>",
"     <li>",
"      Right heart catheterization if physical signs are discordant or unreliable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"       \"Pulmonary artery catheterization: Indications and complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General discussions of the treatment of acute and chronic HF are presented separately [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the unique issues related to pregnancy, each medication must be carefully considered in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/9\">",
"     9",
"    </a>",
"    ]. Since there are changes in the volume of distribution and GFR during pregnancy, dosing of certain medication may need to be increased during pregnancy.",
"   </p>",
"   <p>",
"    The following discussion addresses the role of medications commonly used for the treatment of HF in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Avoid angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors and ARBs, which are part of the standard long-term therapeutic regimen in nonpregnant patients with HF due to systolic dysfunction, are CONTRAINDICATED in pregnancy. These drugs are associated with a high risk of adverse effects in the fetus. Consequences include fetal renal failure and even neonatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, the risks associated with these drugs were considered highest when taken in the second and third trimesters. However, data also suggest that these drugs are associated with an increased risk of cardiovascular and central nervous system malformations even when taken in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among women with chronic HF who are treated with ACE inhibitors or ARBs, two important questions need to be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When should chronic ACE inhibitor and ARB therapy be discontinued (ie, when planning to conceive or only after pregnancy is confirmed)? Due to the risks of embryopathy associated with ACE inhibitor use in the first trimester, we recommend discontinuation of these medications when a woman with chronic stable HF is attempting conception. Repeat cardiac imaging should be considered following the discontinuation of ACE inhibitors.",
"     </li>",
"     <li>",
"      Should chronic ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      therapy be converted to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      during pregnancy? Hydralazine is the vasodilator of choice when such therapy is necessary in pregnant women. However, hydralazine does not have the same long-term benefits as ACE inhibitors or ARBs, so its use should be governed by clinical need. Therefore, we suggest that hydralazine not be routinely started when ACEI or ARB therapy is discontinued in women who are clinically stable and normotensive. Hydralazine should be used instead of ACE inhibitors or ARBs in pregnant women with HF who are hypertensive or have evidence of congestion and decompensated HF. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      alone or in combination with hydralazine has also been reported as an alternative to ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      therapy for vasodilator therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vasodilators'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , are important components of the treatment regimen for patients with chronic HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Much of what is known about the use of beta blockers in pregnancy is from data on its use to treat hypertension in pregnant patients. These agents are generally safe and effective during pregnancy, although there may be an increased rate of fetal growth restriction when they are administered [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In general, agents that are beta-1 selective are preferable, since these agents are less likely to interfere with beta-2 mediated uterine relaxation and peripheral vasodilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    are excreted in breast milk. However, the American Academy of Pediatrics (AAP) considers these drugs compatible with breast feeding. When a nursing mother is taking one of these medications, the newborn should be observed for evidence of beta blockade and it is prudent to consult the managing pediatrician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stable HF patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuation of chronic beta blocker therapy in stable asymptomatic women is reasonable assuming that there is no discernable adverse effect on the fetus. Fetal growth should be monitored by ultrasound. Beta blockers are not associated with an increased risk of congenital anomalies, although occasional cases of neonatal apnea, hypotension, bradycardia, and hypoglycemia have also been reported, especially after prolonged use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    . Infants born to mothers treated with these medications should be observed for 72 to 96 hours after parturition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Decompensated HF patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are not initiated in the setting of acute decompensated HF. Similarly, patients on chronic beta blocker therapy who develop acute decompensated HF often have the dose reduced or therapy withheld during initial treatment. Once the patient with an episode of acute decompensation has stabilized, chronic beta blocker therapy may be initiated, usually after several days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nonpregnant patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is not considered first-line therapy for acute decompensated HF, since it has not been shown to improve mortality. However, digoxin is appropriate for selected HF patients, usually for one of the two following indications (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The persistence of symptoms (such as fatigue, dyspnea, and exercise intolerance) despite treatment with standard initial therapies including ACE inhibitors, beta-blockers and diuretics.",
"     </li>",
"     <li>",
"      For control of the ventricular rate in HF patients with atrial fibrillation who cannot achieve adequate control on beta blockers alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During pregnancy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    can be particularly useful for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of conventional HF therapies is limited, most notably due to the contraindication of angiotensin blockade with ACE inhibitors or ARBs.",
"     </li>",
"     <li>",
"      The increased physiologic demands of pregnancy can exacerbate HF symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is generally safe in pregnancy, despite anecdotal reports of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Dosing may need to be increased to achieve a therapeutic effect during pregnancy. The decision to do so should be based upon the perceived adequacy of the therapeutic effect rather than purely on serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transplacental passage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    has been documented and this pharmacokinetic property has been used for the in&ndash;utero treatment of fetal tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/21\">",
"     21",
"    </a>",
"    ]. Digoxin is also secreted in breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/19\">",
"     19",
"    </a>",
"    ]. The AAP considers digoxin use compatible with breast feeding. The infant typically ingests a very small percentage of the dose and no adverse effects have been reported in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics are given for symptomatic relief of exertional and paroxysmal nocturnal dyspnea and marked peripheral edema in pregnancy. As in nonpregnant patients, loop diuretics are generally preferred over thiazide diuretics and potassium-sparing diuretics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loop diuretics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ) are used in gravidas with HF when sodium restriction alone has been unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment with loop diuretics (without waiting for response to sodium restriction) is recommended for patients with any degree of pulmonary congestion. Potential maternal complications of loop diuretic use are similar to those of nonpregnant patients and include volume contraction, metabolic alkalosis, decreased carbohydrate tolerance, hypokalemia, hyponatremia, hyperuricemia, and pancreatitis. Potential risks to the fetus are related to the potential for intravascular volume contraction and reduced placental perfusion.",
"   </p>",
"   <p>",
"    A thiazide diuretic may be added if volume cannot be adequately controlled with a loop diuretic alone. In addition to the general risks associated with diuretic use described above, a bleeding diathesis and hyponatremia have been reported in neonates of patients who have taken thiazide diuretics during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasodilator therapy improves cardiac output in moderate to severe HF and slows the rate of myocardial deterioration at all stages by inducing afterload reduction. Because ACE inhibitors and ARBs are contraindicated in pregnancy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    is the drug of choice for antepartum vasodilator therapy. It has been used for many years in the treatment of hypertension during pregnancy and appears to be safe for both the mother and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/4,24,25\">",
"     4,24,25",
"    </a>",
"    ]. Alternatively, if hydralazine is not tolerated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    can be as a substitute for afterload reduction in the peripartum patient with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue is the use of intravenous vasodilators in patients with decompensated HF, particularly if associated with hypertension. In this setting, cautious use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    can be attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/26\">",
"     26",
"    </a>",
"    ]. Experience with these agents in pregnant patients comes largely from treatment of hypertensive emergencies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for pronounced afterload reduction is a reason to consider",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    as opposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    . Examples of such settings include hypertensive emergency, acute aortic regurgitation, acute mitral regurgitation, aortic dissection or acute ventricular septal defect. However, nitroprusside should be used only when all other interventions have failed and when it is essential for maternal well&ndash;being. Even under these conditions, the dose and duration of therapy should be minimized due to the metabolism of this agent to thiocyanate and cyanide, which has resulted in fetal cyanide poisoning in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=see_link&amp;anchor=H3#H3\">",
"     \"Drug treatment of hypertensive emergencies\", section on 'Nitroprusside'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, afterload reduction should be undertaken with great care given the risk of deterioration of the fetal heart rate with rapid and profound drop in maternal blood pressure. Continuous fetal monitoring is recommended if viability has been achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Nesiritide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     Nesiritide",
"    </a>",
"    , recombinant human brain natriuretic peptide, is an intravenous agent with vasodilatory properties. The largest trial of nesiritide in acute heart failure found that it increased rates of hypotension, did not alter rates of death or rehospitalization at 30 days, and showed a borderline significant trend toward reducing dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/31\">",
"     31",
"    </a>",
"    ]. Therefore, nesiritide is not recommended for routine use in acute heart failure, even in nonpregnant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=see_link\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     Nesiritide",
"    </a>",
"    is labeled class C in pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ). Animal reproductive studies have not been performed. It is not clear whether the medication is harmful to the fetus. In addition, it is unknown whether this drug is excreted in breast milk. As with the use of sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , the general approach to the use of nesiritide in the pregnant patient would be to consider this agent as an option to be used only when all other interventions have failed and when it is essential for maternal well&ndash;being. Nesiritide use should be limited to patients without hypotension or cardiogenic shock. Nesiritide has a longer effective half-life than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or nitroprusside, so side effects such as hypotension may persist longer. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     \"Nesiritide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24715673\">",
"    <span class=\"h2\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aldosterone antagonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , which compete with aldosterone for the mineralocorticoid receptor, prolong survival in selected patients with HF. However, in animal studies the antiandrogen effects of spironolactone caused feminization of the male fetus. There is neither data nor clinical experience to support the safety of these agents during pregnancy. Thus, we suggest that these agents",
"    <strong>",
"     not",
"    </strong>",
"    be used during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Inotropes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute decompensated HF and systolic dysfunction who are hypotensive or who remain in pulmonary edema despite oxygen, diuresis, and, if tolerated, vasodilators, may benefit from intravenous inotropic support. As each of these medications has slightly different properties, in a seriously ill pregnant woman the selection of a specific agent should be based upon the clinical scenario. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    is a beta agonist with both inotropic and vasodilator properties. Dopamine has an inotropic effect and variable effects on the peripheral vasculature, depending upon the dose administered. Like dobutamine, the phosphodiesterase inhibitors have vasodilatory properties. Drugs with both inotropic and vasodilatory properties address the two hemodynamic problems that most commonly lead to low cardiac output in severe HF, poor cardiac contractility and peripheral vasoconstriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressors (eg, norepinephrine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    ) are usually avoided in patients with HF, since such patients usually have high systemic vascular resistance at baseline and further peripheral vasoconstriction may impair cardiac output. In pregnant women, vasopressors carry the additional risk of impairing uterine blood flow. In critically ill, hypotensive patients, however, blood pressure may need to be supported. There are few data to guide selection of an appropriate vasopressor in a pregnant woman. Animal studies suggest that dopamine may have less deleterious effects on uterine blood flow than norepinephrine or phenylephrine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34681?source=see_link&amp;anchor=H14#H14\">",
"     \"Critical illness during pregnancy and the peripartum period\", section on 'Vasopressors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both pregnancy and HF are independently associated with an increased risk of thromboembolic phenomena. Venous thromboembolism (VTE) complicates between 1 in 500 and 1 in 2000 pregnancies and is more common postpartum than antepartum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1577/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This tendency probably reflects the hypercoagulable state of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    .) and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Prophylactic anticoagulation is recommended for women who are at an elevated risk of thromboembolism (eg, prosthetic heart valves). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data defining the risk of thromboembolic complications from ventricular thrombi in pregnant women with severe LV dysfunction (eg, LV ejection fraction &le;30 percent). It is our practice, however, to treat these patients with prophylactic anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Choosing a specific anticoagulation regimen for a pregnant woman is challenging due to the potential teratogenic effects and dosing complexities of the various agents. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations refer to the management of heart failure during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Evaluation of HF during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with a history of HF or cardiac disorders that put them at risk for HF should undergo a thorough initial evaluation prior to or in the early stage of pregnancy. Ideally, counseling should occur prior to pregnancy. This initial evaluation should include baseline physical exam, laboratory testing, an assessment of functional status, medication adjustments, and plans for ongoing monitoring during pregnancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Stable patient'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link&amp;anchor=H8#H8\">",
"       \"Acquired heart disease and pregnancy\", section on 'Assessing risk'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H4#H4\">",
"       \"Pregnancy in women with congenital heart disease: General principles\", section on 'Management guidelines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women who develop signs or symptoms of HF during pregnancy should undergo an initial evaluation similar to that recommended for nonpregnant patients with the exception that the use of a chest x-ray should be reserved for cases in which the diagnosis of pulmonary edema is in doubt and cannot be established by other means. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Decompensated heart failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment of HF during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that ACE inhibitors and ARBs NOT be used in women who are pregnant or are planning to become pregnant (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Avoid angiotensin inhibition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that aldosterone antagonists NOT be used in women who are pregnant (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Women with chronic HF due to systolic dysfunction who are taking these medications as part of a chronic regimen should discontinue them during pregnancy. (See",
"      <a class=\"local\" href=\"#H24715673\">",
"       'Aldosterone antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with chronic HF due to systolic dysfunction who are taking a beta blocker as part of a chronic regimen to improve long-term outcomes, we suggest that the beta blocker be continued throughout pregnancy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Beta blockers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women who develop acute decompensated HF during pregnancy, we suggest that beta blocker therapy be approached in the same manner as in nonpregnant patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Beta blockers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"       \"Treatment of acute decompensated heart failure: General considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For pregnant women with moderate peripheral edema due to HF without pulmonary congestion, we suggest sodium restriction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'General principles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For pregnant women with mild or greater pulmonary congestion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe peripheral edema due to HF, and in women with moderate peripheral edema that does not improve with sodium restriction, we suggest the addition of a loop diuretic to the medical regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diuretics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=see_link\">",
"       \"Use of diuretics in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For pregnant women with mild or moderate symptoms of HF we suggest that vasodilator therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      be added to the medical regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vasodilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women with severe decompensated HF and a stable blood pressure, we suggest the addition of intravenous vasodilator therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      to the medical regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In selected cases, the cautious use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      may be an appropriate alternative to nitroglycerin. Hemodynamic and fetal monitoring should be employed, as appropriate (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Vasodilators'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For pregnant women with severe decompensated HF and hypotension, we suggest that intravenous inotropic therapy be used according to the same approach used in nonpregnant patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Inotropes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"       \"Inotropic agents in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For pregnant women with symptoms of HF due to systolic dysfunction that persist despite diuresis and vasodilator therapy, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      to her medical regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Digoxin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"       \"Use of digoxin in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In pregnant women with severe LV dysfunction (eg, LV ejection fraction &le;30 percent), we suggest that prophylactic anticoagulation be included in her medical regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Anticoagulation'",
"      </a>",
"      above.) Choosing a specific anticoagulation regimen for a pregnant woman is challenging due to the potential teratogenic effects and dosing complexities of the various agents. These issues are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"       \"Indications for antithrombotic therapy in heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"       \"Anticoagulation during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/1\">",
"      Siu SC, Colman JM. Heart disease and pregnancy. Heart 2001; 85:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/2\">",
"      Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/3\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     Lang RM, Borow KM. Heart disease. In: Medical Disorders During Pregnancy, 3rd ed, Barron WM, Lindheimer MD (Eds), Mosby Inc, St. Louis 2000. p.180.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/5\">",
"      Kale A, Kale E, Yalinkaya A, et al. The comparison of amino-terminal probrain natriuretic peptide levels in preeclampsia and normotensive pregnancy. J Perinat Med 2005; 33:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/6\">",
"      Resnik JL, Hong C, Resnik R, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005; 193:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/7\">",
"      Folk JJ, Lipari CW, Nosovitch JT, et al. Evaluating ventricular function with B-type natriuretic peptide in obstetric patients. J Reprod Med 2005; 50:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/8\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/9\">",
"      Lee W. Clinical management of gravid women with peripartum cardiomyopathy. Obstet Gynecol Clin North Am 1991; 18:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/10\">",
"      Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005; 73:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/11\">",
"      Lavoratti G, Seracini D, Fiorini P, et al. Neonatal anuria by ACE inhibitors during pregnancy. Nephron 1997; 76:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/12\">",
"      Schubiger G, Flury G, Nussberger J. Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med 1988; 108:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/13\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/14\">",
"      Brown CS, Bertolet BD. Peripartum cardiomyopathy: a comprehensive review. Am J Obstet Gynecol 1998; 178:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/15\">",
"      Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/16\">",
"      Easterling TR, Carr DB, Brateng D, et al. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 2001; 98:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/17\">",
"      Bayliss H, Churchill D, Beevers M, Beevers DG. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for \"pharmacological programming\" in the first trimester? Hypertens Pregnancy 2002; 21:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/18\">",
"      Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf 1999; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/19\">",
"      Widerhorn J, Rubin JN, Frishman WH, Elkayam U. Cardiovascular drugs in pregnancy. Cardiol Clin 1987; 5:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/20\">",
"      Lees KR, Rubin PC. Treatment of cardiovascular diseases. Br Med J (Clin Res Ed) 1987; 294:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/21\">",
"      King CR, Mattioli L, Goertz KK, Snodgrass W. Successful treatment of fetal supraventricular tachycardia with maternal digoxin therapy. Chest 1984; 85:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/22\">",
"      Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/23\">",
"      Lindheimer MD, Katz AI. Sodium and diuretics in pregnancy. N Engl J Med 1973; 288:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/24\">",
"      Vink GJ, Moodley J, Philpott RH. Effect of dihydralazine on the fetus in the treatment of maternal hypertension. Obstet Gynecol 1980; 55:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/25\">",
"      Kuzniar J, Skret A, Piela A, et al. Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension. Obstet Gynecol 1985; 66:453.",
"     </a>",
"    </li>",
"    <li>",
"     Hall JB, Schmidt GA. Critical illness. In: Medical Disorders During Pregnancy, Barron WM, Lindheimer MD (Eds), Mosby Inc, St. Louis 2000. p.240.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/27\">",
"      Rubin PC. Treatment of hypertension in pregnancy. Clin Obstet Gynaecol 1986; 13:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/28\">",
"      Wasserstrum N. Nitroprusside in preeclampsia. Circulatory distress and paradoxical bradycardia. Hypertension 1991; 18:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/29\">",
"      Cotton DB, Jones MM, Longmire S, et al. Role of intravenous nitroglycerin in the treatment of severe pregnancy-induced hypertension complicated by pulmonary edema. Am J Obstet Gynecol 1986; 154:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/30\">",
"      Palmer RF, Lasseter KC. Drug therapy. Sodium nitroprusside. N Engl J Med 1975; 292:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/31\">",
"      O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/32\">",
"      Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1577/abstract/33\">",
"      Refuerzo JS, Hechtman JL, Redman ME, Whitty JE. Venous thromboembolism during pregnancy. Clinical suspicion warrants evaluation. J Reprod Med 2003; 48:767.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3507 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C815FD8784-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1577=[""].join("\n");
var outline_f1_34_1577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHRONIC VERSUS ACUTE CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stable patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Avoid angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stable HF patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Decompensated HF patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Nesiritide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24715673\">",
"      Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Inotropes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Evaluation of HF during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment of HF during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3507\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3507|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34681?source=related_link\">",
"      Critical illness during pregnancy and the peripartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=related_link\">",
"      Nesiritide in the treatment of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=related_link\">",
"      Nesiritide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=related_link\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_34_1578="Sublingual and oral immunotherapy for allergic rhinitis";
var content_f1_34_1578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sublingual and oral immunotherapy for allergic rhinitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1578/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1578/contributors\">",
"     Peter S Creticos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1578/contributors\">",
"     Philip S Norman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/34/1578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/34/1578/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/34/1578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen immunotherapy for the treatment of allergic respiratory diseases has traditionally been administered by subcutaneous injections. Subcutaneous immunotherapy (SCIT) has proven efficacy in allergic rhinitis and asthma, but it requires regular injections at a clinician's office (typically over a period of three to five years) and carries the risk of potentially serious systemic allergic reactions in response to the treatment itself.",
"   </p>",
"   <p>",
"    Oral immunotherapy (OIT) offers several specific advantages over injection immunotherapy. OIT is more easily administered, avoids cumbersome injections regimens, and carries a much lower risk of anaphylaxis compared with SCIT. This article will discuss the mechanisms of action, advantages, and limitations of OIT for allergic rhinitis. The most common methods of administering immunotherapy via an oral route: sublingual aqueous allergen extracts (SLIT-aqueous), sublingual allergen tablets (SLIT-tablet), and enteric or microencapsulated allergen will also be reviewed. SCIT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OIT for the treatment of other allergic diseases is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44057?source=see_link\">",
"     \"Future therapies for food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=see_link&amp;anchor=H9#H9\">",
"     \"Latex allergy: Management\", section on 'Immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral immunotherapy (OIT) was first proposed as a method of treatment for allergic disease in the early 1900s. In the 1980s, properly designed clinical trials first demonstrated a dose-dependent therapeutic response with specific and well-characterized aeroallergens. In 2006, the World Health Organization recognized the cumulative evidence that OIT represented a viable alternative to SCIT and encouraged continued clinical investigation to characterize optimal techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sublingual tablet immunotherapy (SLIT-tablet) has been approved by the European regulatory authorities and is in use throughout the European Union (EU). Some SLIT-tablets are available in Canada. In the United States, OIT has not been approved by the US Food and Drug Administration at the time of this writing. However, there is increasing &ldquo;off-label&rdquo; use of aqueous allergen extracts for sublingual immunotherapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Sublingual aqueous allergen extracts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gut is the largest mucosal organ of the body and is exposed to numerous foreign proteins on a constant basis. The normal response of the gut immune system to nonpathogenic proteins is tolerance, a fact which forms the basis for the concept of oral immunization.",
"   </p>",
"   <p>",
"    The gut immune system is comprised of various physical barriers, secretory IgA, the gut associated lymphoid tissue (GALT), and lymphoid organs (mesenteric lymph nodes, spleen, and liver). Within the GALT, two areas of importance for antigen processing are the tonsils and adjacent ring of lymphoid tissue in the posterior pharynx, and the Peyer's patches of the duodenum, jejunum, and small intestine. The GALT is essential for normal tolerance to most foreign proteins, as well as in the immunologic response to OIT. The role of the GALT in the pathogenesis of food allergy is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=see_link\">",
"     \"Pathogenesis of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allergens used in OIT are usually intended for absorption either in the mouth or within the small intestine, as the conditions of the gastric environment (pH and other factors) destroy many allergenic proteins. Whether the immunologic response to allergens absorbed through the oral mucosa is different from that to allergens absorbed through the intestine is an area of ongoing investigation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen extracts given sublingually are primarily taken up by dendritic cells in the mucosa and presented to T cells in the draining lymph nodes. Likely mechanisms of action include activation of T regulatory cells and downregulation of mucosal mast cells [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/2\">",
"       2",
"      </a>",
"      ]. Within the oral and sublingual mucosa, effector cells, such as mast cells, are less numerous [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/2\">",
"       2",
"      </a>",
"      ]. This characteristic of the oral mucosa is believed to be an important factor in the lower rates of adverse systemic allergic reactions seen with OIT.",
"     </li>",
"     <li>",
"      Allergenic proteins that reach the small intestine are processed through columnar mucosal cells and presented to T lymphocytes within Peyer's patches [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/3\">",
"       3",
"      </a>",
"      ]. Allergen processing within the GALT is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=see_link\">",
"       \"Pathogenesis of food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Under normal conditions, local tolerance is believed to arise through stimulation of antigen-specific T-helper (Th) cells to increase immunoglobulin A (IgA) production with concomitant suppression of IgG and IgM production [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/4\">",
"       4",
"      </a>",
"      ]. Systemic tolerance occurs as a result of a decline in T-helper mechanisms or stimulation of T-suppressor cells involved in IgE production. Mechanisms of oral tolerance are discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=see_link&amp;anchor=H29#H29\">",
"       \"Pathogenesis of food allergy\", section on 'Factors influencing sensitization or tolerance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunologic changes following OIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral immunotherapy (OIT) is less well-studied than subcutaneous immunotherapy (SCIT), although similar immunologic mechanisms appear to be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/5\">",
"     5",
"    </a>",
"    ]. The immunologic changes observed with SCIT are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following changes in the humoral responses to allergens are seen with OIT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases in allergen-specific IgG4 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/6-8,10\">",
"       6-8,10",
"      </a>",
"      ]. Several studies now suggest that IgG4 production is under the control of IL-10.",
"     </li>",
"     <li>",
"      Blunting of seasonal increases in allergen-specific IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OIT also results in changes in the cellular response to allergens, including [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases in CD8+ T cells and decreases in the CD4:CD8 T cell ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increases in interleukin (IL)-10 production and",
"      <span class=\"nowrap\">",
"       IL-12/interferon-gamma",
"      </span>",
"      by peripheral blood monocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. As mentioned previously, IgG4 production may be regulated by IL-10, and SCIT has been shown to induce T regulatory cells to produce IL-10. IL-10 down regulates Th2-dependent inflammation and suppressed B cell isotype switching to IgE. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=see_link\">",
"       \"Pathogenesis of allergic rhinitis (rhinosinusitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreases in IL-13 levels and serum eosinophil cationic protein",
"      <span class=\"nowrap\">",
"       (ECP)/eosinophil",
"      </span>",
"      ratio. Serum eosinophilic cationic protein is an indicator of activated eosinophils, and reductions in the",
"      <span class=\"nowrap\">",
"       ECP/eosinophil",
"      </span>",
"      ratio suggest that a smaller percentage of eosinophils are in an activated state as a result of successful IT. Furthermore, IL-13 changes are associated with airway remodeling and its reduction is also a positive marker of successful IT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral immunotherapy can be administered in several ways. Technical variations include preparation of allergen, the types of allergens used, the doses involved, and schedules of administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Forms of oral allergen immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several allergen preparations have been studied in oral immunotherapy. The following forms are most promising:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sublingual aqueous allergen extracts (SLIT-aqueous)",
"      </strong>",
"      &mdash; An aqueous extract of allergen is generally held under the tongue for a specified period of time and then swallowed. The allergen is taken up through the rich vascular-lymphoid network of the mouth. Oral solutions that are held in the mouth for a period of time, but then spit out rather than swallowed, have also been evaluated in clinical trials.",
"     </li>",
"     <li>",
"      <strong>",
"       Sublingual allergen tablets (SLIT-tablet)",
"      </strong>",
"      &mdash; Allergen is formulated into a rapidly-dissolving tablet that is held under the tongue for one to two minutes and then swallowed.",
"     </li>",
"     <li>",
"      <strong>",
"       Enteric and microencapsulated preparations",
"      </strong>",
"      &mdash; Allergen is contained in an enteric coated bead, or polymer, which passes through the stomach intact and then dissolves in the small intestine. This approach is designed to protect the allergenic proteins from breakdown in the stomach, but allow a pH-dependent release in the small intestine for processing by the gut-associated lymphoid tissue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Types of allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of studies of oral immunotherapy have been performed with pollen allergens in patients with allergic rhinitis. There are a smaller number of studies of dust mite immunotherapy. The use of food allergens or latex allergens in oral immunotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44057?source=see_link\">",
"     \"Future therapies for food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=see_link&amp;anchor=H9#H9\">",
"     \"Latex allergy: Management\", section on 'Immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cumulative amount of allergen administered in the course of a year is generally 20 to 200 times greater with oral forms of immunotherapy compared with SCIT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/19\">",
"     19",
"    </a>",
"    ]. In some studies, the daily dose of allergenic protein in micrograms is equivalent to the dose given every two to four weeks in SCIT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A range of allergen doses were evaluated in a dose-exploratory Phase I safety study of patients with seasonal allergic rhinoconjunctivitis treated with grass pollen sublingual tablets [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/20\">",
"       20",
"      </a>",
"      ]. Eighty-four subjects were randomized to seven different Timothy grass tablet strengths: 25,000; 75,000; 100,000; 300,000; 500,000; 750,000; and 1 million SQ-T units. In this system, 100,000 SQ-T units was equivalent to ~ 20 mcg Phleum p 5, a dose similar to the effective maintenance dose for grass pollen SCIT. No serious or systemic adverse events were observed in the study, providing evidence that daily doses as high as 1 million SQ-T units (~200 mcg Phleum p 5) were well-tolerated.",
"     </li>",
"     <li>",
"      A similar safety study of the 5-grass standardized allergen tablet for sublingual immunotherapy was performed to establish a tolerated dose for subsequent trials [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/21\">",
"       21",
"      </a>",
"      ]. Doses of 100 to 500 IR were evaluated for safety and tolerability in 30 grass-allergic adults over a 10 day treatment period. Through incorporation of a 5-day up-dosing regimen, high-dose treatment with 500 IR (~42 mcg Group 5 major allergens) could be reached without significant untoward adverse events. The majority of adverse events were mild to moderate with the most common being oral pruritus, throat irritation, and tongue swelling. No serious adverse events occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason(s) that higher doses are needed have not been fully defined, although they may include loss of allergen through digestion, as well as the immunologic effects of high versus low levels of allergen exposure in the gut.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Escalating doses are administered once daily, usually beginning a few months before the pollen season. As an example, SLIT-tablet treatment for seasonal allergens is generally started two to three months prior to the start of the relevant pollen season. Continuous year-round SLIT is another option, although in one open-label study of grass pollen SLIT, this did not appear to be superior to preseasonal treatment after the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the best approach is not clear, since the studies that showed persistent benefit two years after completion of a three-year course of therapy used continuous year-round treatment, as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Persistence of therapeutic benefit'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Maintenance doses are reached by 3 to 12 weeks of treatment. During the maintenance phase, SLIT is administered daily to weekly through the pollen season.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523955\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of a course of oral immunotherapy has not been defined. However, one controlled but nonrandomized study of 78 patients undergoing dust mite SLIT for three, four, or five years found that patients experienced persistent reduction in symptoms lasting seven, eight, and eight years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/24\">",
"     24",
"    </a>",
"    ]. Based on this, the authors suggested four years of therapy was a reasonable goal until more data are available. Other studies evaluating the persistence of benefit after stopping therapy are reviewed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Persistence of therapeutic benefit'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFICACY AND SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of SLIT, using products designed for oral use, has been demonstrated in a number of properly designed European trials, for both children and adults with allergic rhinitis. Trials involving each of the main forms of SLIT are reviewed below.",
"   </p>",
"   <p>",
"    In a 2011 systematic review of 60 randomized trials (published through 2009), which included approximately 2300 adults and children receiving active SLIT treatment, treatment resulted in a statistically significant reduction in symptoms [standardized mean difference of -0.42 (95% CI -0.69 to -0.15)] and in medication requirements [standardized mean difference of -0.43 (95% CI -0.63 to -0.23)] [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/25\">",
"     25",
"    </a>",
"    ]. Most studies involved treatment with single pollens (most commonly grass) or house dust mite preparations, at a range of doses. Fifteen studies included only children, with results that were similar to those in adults. There was a trend for greater improvement with treatments lasting longer than one year. Local side effects (oral pruritus and swelling, throat irritation) and nausea were more common with active treatment, although systemic adverse effects (rhinitis or rhinoconjunctivitis) were equal in active treatment and placebo groups. No trial reported anaphylaxis or the need to administer epinephrine. Effects on quality of life could not be assessed because a variety of different measurements were used. Publication bias could not be excluded, as with any systematic review.",
"   </p>",
"   <p>",
"    There have been efforts to standardize the outcome measures in trials of immunotherapy for respiratory allergy, use validated tools that can be compared across studies, and reach consensus about what degree of therapeutic benefit should be considered clinically meaningful [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many study designs have now chosen the clinical outcome of &ldquo;total combined score&rdquo; (TCS) as the accepted evaluation tool to measure primary efficacy. However, no standardized scoring methodology has been adopted across the industry for quantification of symptoms and medication use.",
"     </li>",
"     <li>",
"      In an attempt to define clinically meaningful improvement, the World Allergy Organization (WAO) has proposed that a 20 percent mean reduction in TCS compared with placebo be demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/29\">",
"       29",
"      </a>",
"      ]. The decision as to what represents a sufficient therapeutic effect must be tempered by the risk:benefit ratio of the therapeutic agent. Traditionally, the &ldquo;bar&rdquo; has been set somewhat higher for a",
"      <strong>",
"      </strong>",
"      treatment such as immunotherapy, where the risk:benefit ratio is perceived as being greater. It is not clear that the bar will be lowered for oral immunotherapy, even though the safety data with the SLIT-tablet studies is consistently showing rates of anaphylaxis that are lower than those observed with SCIT. As of this time, the FDA has not yet published final guidelines on what is an acceptable clinical effect with this combined assessment tool. However, as larger numbers of patients undergo treatment with standardized allergens in properly designed clinical trials of sublingual immunotherapy, it is anticipated that new guidelines will be issued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sublingual allergen tablets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the different approaches to oral immunotherapy, studies using sublingual tablets (SLIT-tablet) of grass pollen have yielded some of the best results. The following series of studies illustrates the steps required to define an effective approach for each type of oral immunotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6514669\">",
"    <span class=\"h3\">",
"     Single grass allergen",
"    </span>",
"    &nbsp;&mdash;&nbsp;European studies with Timothy grass SLIT-tablet have demonstrated clinical benefit in grass allergic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/11,30\">",
"     11,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial was conducted in 2002 to 2003 in centers throughout Europe to evaluate three different strengths of a Timothy grass sublingual tablet (Graxaz; ALK), compared with placebo in treating 855 adults with grass pollen-induced rhinoconjunctivitis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/11\">",
"       11",
"      </a>",
"      ]. Subjects were randomized to one of three doses of the major Timothy allergen (Phleum p 5): 2500 SQ-T units (0.5 mcg of major allergen), 25,000 SQ-T units (5 mcg), or 75,000 SQ-T units (15 mcg). Treatment was initiated eight weeks prior to grass pollen season and continued daily throughout the season (mean duration of therapy was 18 weeks).",
"      <br/>",
"      <br/>",
"      Ninety-two percent of participants completed the trial. There was a significant improvement in quality of life (QOL) compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/11\">",
"       11",
"      </a>",
"      ]. Reductions were observed in rhinoconjunctivitis symptom scores (16 percent) and medication usage (28 percent), but these did not reach statistical significance. Benefits were greatest in the highest dose group (15 mcg Phleum p 5). This study defined an effective dose for subsequent clinical trials with Timothy SLIT-tablet.",
"     </li>",
"     <li>",
"      In a subsequent trial by a different group, 634 adult patients with grass-induced seasonal allergic rhinoconjunctivitis were treated with once daily treatment with a Timothy SLIT-tablet (Grazax) containing 15 mcg Phl p 5 or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/30\">",
"       30",
"      </a>",
"      ]. Treatment was initiated 16 weeks preseason and continued during the season, within a study design that incorporated a two year maintenance phase and a two year follow-up on continued therapy.",
"      <br/>",
"      <br/>",
"      There were no serious or life-threatening adverse events, and &lt;4 percent of patients withdrew. A fivefold higher adverse event rate probably- or possibly-related to drug was observed with active drug versus placebo, including oral pruritus (46 versus 4 percent), mouth edema (18 versus 1 percent), ear itch (42 versus 1 percent), and throat irritation (9 versus 1 percent) respectively.",
"      <br/>",
"      <br/>",
"      Mean rhinoconjunctivitis symptom scores and medication scores (30 and 38 percent, respectively) improved significantly compared with placebo (",
"      <a class=\"graphic graphic_figure graphicRef56433 \" href=\"UTD.htm?36/54/37743\">",
"       figure 1",
"      </a>",
"      ). Additionally, there were significant increases in the number of well days (53 versus 44 percent) and improvements in quality of life in the treatment group.",
"     </li>",
"     <li>",
"      When protocols similar to those used in these high quality European studies were attempted in the US, initial results were disappointing. This created some controversy about the use of existing forms of OIT within the US patient population.",
"      <br/>",
"      <br/>",
"      The first American study of SLIT-tablet (Graxaz;",
"      <span class=\"nowrap\">",
"       ALK/Schering-Plough),",
"      </span>",
"      conducted in 2007, failed to demonstrate comparable clinical benefit in contrast to the European studies reviewed above [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/31\">",
"       31",
"      </a>",
"      ]. A measurable clinical effect could not be observed, probably because the majority of patients in both the active and placebo arms failed to demonstrate an increase in rhinoconjunctivitis symptoms during the grass pollen season. Proposed explanations for this included low pollen counts during the years studied, and the influence of confounding allergens (eg, Johnson, Sweet Vernal,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Bermuda grass). In addition, overlapping pollen seasons may have been an important confounder in some US centers, as tree season in late April to early May can overlap with grass season in certain years, so that patients were significantly symptomatic at the start of the study from tree pollen and did not show meaningful changes resulting from treatment of grass pollen allergy. In Europe, allergenic tree species tend to be more limited in number.",
"     </li>",
"     <li>",
"      A subsequent pair of US studies addressed these problems in study design and patient selection and was able to circumvent the geographic and weather-related vagaries of pollen seasons, as well as the negative influences of confounding allergens.",
"      <br/>",
"      <br/>",
"      The first US randomized trials to demonstrate positive clinical outcomes with grass pollen SLIT-tablet were completed in 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The protocol was similar to the European studies and used a dose of 15 &micro;g Phl p 5 in both adults and children. Both trials were large (300 to 400 patients each), and 85 to 90 percent of patients were sensitized to multiple allergens in addition to grass pollen. The primary endpoint, the combined daily symptom plus medication score, improved 26 and 20 percent compared to placebo-treated groups, in",
"      <span class=\"nowrap\">",
"       children/adolescents",
"      </span>",
"      and adults, respectively. Neither serious treatment-related adverse events nor anaphylaxis was reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Multiple grass allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a small number of high-quality studies in which multiple allergens were given simultaneously in SLIT-tablet form.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A standardized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/40/18053?source=see_link\">",
"       five-grass pollen sublingual tablet",
"      </a>",
"      has been produced (Oralair, Stallergenes) that contains allergens from five grass species that are prevalent in Europe: Timothy (Phleum), Rye (Lolium), June (Poa), Orchard (Dactylis), and Sweet Vernal (Anthoxanthum). A study to establish dosing of the 5-grass product randomized 628 grass-allergic adults with rhinoconjunctivitis to three different doses: 100 Index of Reactivity units (IR) (~8.3 mcg group five major grass allergen), 300 IR (~25 mcg), or 500 IR (~42 mcg) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/34\">",
"       34",
"      </a>",
"      ]. Treatment was initiated 16 weeks prior to the grass season, with an incremental step-up dosing of 100 IR over the first five days until the final dose was achieved, and continued through the grass season. Therapy was well-tolerated. Adverse effects included mild to moderate oral pruritus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      throat irritation.",
"      <br/>",
"      <br/>",
"      A statistically significant benefit was seen in the primary efficacy variable (rhinoconjunctivitis total symptom score) for both the 300 IR and the 500 IR treatment arms versus placebo (37 percent and 35 percent respectively), but not in the lower 100 IR dose arm [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/34\">",
"       34",
"      </a>",
"      ]. Reliance on &ldquo;rescue&rdquo; medication was also significantly less in the active treatment groups. Improvements were observed for rhinoconjunctivitis quality of life and individual rhinitis symptom scores.",
"     </li>",
"     <li>",
"      Another similar study of 278 children and adolescents with",
"      <sup>",
"      </sup>",
"      rhinoconjunctivitis found that the 300 IR dose was well-tolerated and effective in this younger age group [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/35\">",
"       35",
"      </a>",
"      ]. Dosing two and four months preseason, in addition to during the grass season, were similarly effective in a randomized trial of 633 adults, treated for three consecutive seasons [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/36\">",
"       36",
"      </a>",
"      ]. The mean average adjusted symptom score was 36 and 35 percent lower during the third season, for the two and four month groups, respectively, compared with placebo.",
"     </li>",
"     <li>",
"      Another randomized, placebo-controlled trial administered the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/40/18053?source=see_link\">",
"       five-grass pollen sublingual tablet",
"      </a>",
"      , at the 300 IR dose (~25",
"      <span class=\"nowrap\">",
"       &mu;g/mL",
"      </span>",
"      group five major allergens) to an American study population (n = 473 adults), and reproduced the findings from the European study cited above [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/37\">",
"       37",
"      </a>",
"      ]. Compared to those receiving placebo, active-treatment patients showed a 28 percent improvement in the primary efficacy measure of Total Combined Symptom + Medication Score. Similar improvements were observed in the secondary outcome measurements, including daily rhinitis total symptom score (23 percent), daily rhinitis rescue medication score (46 percent), overall rhinoconjunctivitis quality of life questionnaire score, and respective individual symptom scores (except nasal itch). Despite the fact that many patients in this study were highly grass-allergic, the most frequent AEs in this trial were again oral pruritus, throat itch, and nasopharyngitis; there were no anaphylactic events and no patients required epinephrine.",
"      <br/>",
"      <br/>",
"      In this study, an interesting observation was made about the choice of patients for oral immunotherapy. Inclusion was based upon clinical history and a positive skin test reactivity reaction to Timothy pollen (prick skin test wheal &gt;5 mm versus control), although Timothy-specific serum IgE levels were also measured. Eleven percent of skin test-positive study subjects had undetectable Timothy grass-specific serum IgE (&lt;0.1",
"      <span class=\"nowrap\">",
"       kU/L).",
"      </span>",
"      This subgroup of patients was essentially asymptomatic during the grass pollen season, and thus did not benefit from therapy, suggesting that the combination of skin test sensitivity and serum-specific IgE can identify a more appropriate population of study patients for inclusion in clinical trials of immunotherapy and for treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Persistence of therapeutic benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some preliminary data are available about the persistence of benefit with several years of therapy, as well as after treatment is stopped. SLIT appears to be similar to subcutaneous immunotherapy in these respects, as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/30,36,38,39\">",
"     30,36,38,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    The Timothy grass SLIT-tablet trial discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/30\">",
"     30",
"    </a>",
"    ] was extended in its double-blind, randomized, placebo-controlled fashion for an additional two years with a subsequent two-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/38\">",
"     38",
"    </a>",
"    ]. Three-hundred-fifty-five (355) of the original 634 participants volunteered to participate in the double-blind, placebo-controlled extension arm of this long-term treatment phase of the study. Clinically, the significant improvements in mean rhinoconjunctivitis symptom scores and QOL persisted in the extension phase. In addition, there was a continued increase in IgG4 levels through the course of the two years of treatment in the grass allergen tablet-treated group, while the antibody levels did not change in the placebo-treated group.",
"   </p>",
"   <p>",
"    The grass SLIT-tablet was well-tolerated and &lt;1 percent of participants dropped out due to a serious adverse event. In contrast to the first year of study, during which 46 percent of grass-treated subjects (versus 4 percent of placebo) reported oral pruritus, only four events of oral pruritus were reported. Thus, the therapy was better tolerated over time.",
"   </p>",
"   <p>",
"    Subsequent reports provided information about the same group of patients, who had received three years of active therapy (or placebo), and were reevaluated one and two years after discontinuing treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/23,40\">",
"     23,40",
"    </a>",
"    ]. The grass allergen-treated group demonstrated sustained reductions in rhinoconjunctivitis symptom scores and medication scores and improvements in quality of life at the end of the second year following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/23,41\">",
"     23,41",
"    </a>",
"    ]. Other studies have demonstrated similar persistence of effect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/39\">",
"     39",
"    </a>",
"    ]. These studies demonstrate that oral immunotherapy, like subcutaneous injection immunotherapy, can provide benefit that persists after treatment is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sublingual aqueous allergen extracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to the delivery of SLIT involves glycerinated aqueous allergen extracts that are initially held under the tongue for two to three minutes and then swallowed (ie, SLIT-aqueous). This construct has gained acceptance in Europe and is being studied in US clinical trials. In the United States, phase I studies on safety and tolerability have been carried out with ragweed, grass, house dust mite, and cat glycerinated extracts [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The studies examining clinical endpoints are reviewed below [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/43-48\">",
"     43-48",
"    </a>",
"    ]. These studies used the commercially available standardized glycerinated extracts currently licensed for subcutaneous immunotherapy. However, at the time of this review, the data do not support consistent and clinically meaningful benefit. It is clear that further work is required with standardized allergens, as well as with mixes of multiple allergens to determine effective dose, tolerability, and clinical evidence of effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ragweed",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most advanced clinical trials have been performed with ragweed in a series of studies conducted by Greer Laboratories Inc (Lenoir, NC) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. These clinical studies used the commercially available standardized glycerinated ragweed extract currently licensed for SCIT.",
"   </p>",
"   <p>",
"    A randomized dose-response clinical trial was conducted in 115 adult patients with a history of ragweed-induced seasonal allergic rhinoconjunctivitis with or without asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/43\">",
"     43",
"    </a>",
"    ]. In this study, a modest improvement in the primary endpoint &ndash; the total rhinoconjunctivitis symptom score for the",
"    <em>",
"     entire",
"    </em>",
"    pollen season &ndash; was observed with both active treatment arms (~15 percent); however, this was not statistically significant. The secondary endpoint of rescue medication usage did reach significance in the high-dose group during the",
"    <em>",
"     peak season",
"    </em>",
"    . A short ragweed pollen extract was used, which was standardized based on the major ragweed allergenic protein, Amb a 1 (where 1 unit = 1 mcg Amb a 1). Treatment was initiated 8 to 10 weeks prior to the ragweed season and continued through the ragweed season. An initial \"rush-dose\" escalation was conducted, during which subjects were up-dosed to receive either a medium dose of antigen (4.8 units Amb a 1), a high dose of antigen (48 units Amb a 1), or placebo administered once daily as a maintenance regimen through the course of the ragweed season. No serious adverse events were attributable to SLIT, although mucosal adverse events were reported at higher frequency rates in the two active treatment arms as opposed to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     House dust mite",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLIT-aqueous with house dust mite allergen can induce the immunologic changes associated with clinical improvement. However, significant reductions in clinical symptom scores and medication use have not been clearly demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 31 patients with dust mite induced allergic rhinitis, with or without mild intermittent asthma, randomized patients to one year of treatment with high dose SLIT (4200",
"      <span class=\"nowrap\">",
"       AU/d",
"      </span>",
"      or 70mcg Der f1 per day), low dose SLIT or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/45\">",
"       45",
"      </a>",
"      ]. A commercial preparation in 50 percent glycerinated saline (10,000",
"      <span class=\"nowrap\">",
"       AU/mL)",
"      </span>",
"      was self-administered daily in a dose-escalation protocol. After one year of therapy, high dose SLIT increased the bronchial threshold to allergen challenge and increased allergen-specific IgG4. However, there were no significant reductions in symptoms scores or medication use in either treatment group compared to placebo.",
"     </li>",
"     <li>",
"      A combination allergen SLIT-aqueous study investigated the immunologic biomarkers associated with treatment of grass and dust mite allergic patients with both sublingual preparations [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/46\">",
"       46",
"      </a>",
"      ]. The study demonstrated that treatment resulted in an increase in markers of tolerance (IL-10 and TGF-beta) with corresponding decreases in Th-2 inflammatory cytokines",
"      <span class=\"nowrap\">",
"       (IL-4/IL-13).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Microencapsulated OIT with ragweed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microencapsulated preparations of allergens have also been studied, although results have been mixed. This form of oral immunotherapy requires further study before it can be applied clinically.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a unpublished precursor trial, microencapsulated (ragweed) pollen extract (MRPE, standardized for units of Amb a 1) was studied in 607 ragweed-allergic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/49\">",
"       49",
"      </a>",
"      ]. Patients received 40 units Amb a 1 per day, 40 units Amb a 1 per week, or placebo. Treatment started 8 to 12 weeks prior to ragweed season and continued up to 24 weeks. Subjects receiving the once-daily regimen for 10 weeks experienced a 36 percent improvement in the primary endpoint. The therapy was generally safe and well-tolerated, though the number and severity of gastrointestinal side effects was higher with the once-daily regimen.",
"     </li>",
"     <li>",
"      A 2007 clinical trial was designed to establish an effective and safe dose for oral microencapsulated immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Active treatment (40 mcg Amb a 1 per day; started 10 to 24 weeks pre-ragweed season) resulted in a significant increase in ragweed-specific antibody, but no clinical improvement in allergy symptoms compared with placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26665626\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published data addressing the safety of OIT or SLIT in pregnancy is lacking. However, reports of adverse outcomes or fetal harm have not emerged despite decades of use in various countries. European manufacturers suggest an approach similar to the one used for injection immunotherapy, ie, that treatment not be initiated in a pregnant patient, but if a woman becomes pregnant during treatment, therapy could be continued provided the patient has not had significant allergic reactions to therapy in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PATIENTS WITH CONCOMITANT ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of trials have examined the safety and efficacy of OIT in patients with rhinoconjunctivitis and concomitant asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. These studies suggest that OIT can be safely administered to most patients with asthma, although it may not significantly improve asthma control. However, most studies have included patients with mild or intermittent asthma in conjunction with allergic rhinitis. Information about patients with persistent asthma or those requiring daily inhaled glucocorticoids is relatively limited. In addition, more information is required about the safety of SLIT in the home setting in patients with persistent asthma who are, by definition, at greater risk of adverse systemic reactions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylaxis.",
"   </p>",
"   <p>",
"    Representative randomized trials of SLIT in patients with asthma are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial of 114 adult subjects (aged 18 to 65) with mild to moderate grass pollen-induced asthma and rhinoconjunctivitis, assigned subjects to treatment with 75,000 SQ-T (15 mcg Phleum p 5), Timothy grass allergen sublingual tablet (Grazax), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/53\">",
"     53",
"    </a>",
"    ]. The primary endpoints were average asthma symptom and medication scores during the grass pollen season.",
"   </p>",
"   <p>",
"    During the grass season, asthma symptom and medication scores rose slightly in both active and placebo groups, but no discernible differences were observed between groups. Consistent with other trials with the SLIT-tablet construct, significant improvement in mean rhinoconjunctivitis symptom scores, medication scores, and well days (37, 41, and 54 percent respectively) was observed in the group receiving active SLIT-tablet. No serious adverse events were reported in the study and the number of adverse events linked to asthma was reported as similar between groups.",
"   </p>",
"   <p>",
"    This clinical trial provided data on the safety of self-administration of the grass allergen tablet in asthmatic subjects and showed that allergen treatment did not impair asthma control, although there was no significant improvement in asthma symptoms either.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial of 253 children (5 to 16 years of age) with seasonal allergic rhinoconjunctivitis with or without asthma, demonstrated that the same Timothy grass sublingual tablet formulation (75,000 SQ-T units (15 mcg Phl p 5)) was safe and effective, and did appear to have a positive impact on asthma symptoms and medication use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment was initiated 8 to 23 weeks prior to the grass season and continued through the season. Ninety-two percent of children completed the trial. No serious adverse events were assessed as being treatment-related [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the grass tablet-treated group, the primary endpoints of median improvement of rhinoconjunctivitis symptom scores and medication scores were met [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/54\">",
"     54",
"    </a>",
"    ]. The active treatment also showed a significantly greater number of \"well days\" versus placebo treatment. During the study, 105 children (42 percent) reported asthma (5 percent severe, 48 percent moderate). Although only 23 percent used any asthma medications, a relative difference in median asthma symptom score was observed in the active treatment group versus placebo-treated children and use of asthma \"relief\" medication was nominally lower in the active treatment group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPARISON OF OIT AND SCIT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Advantages and disadvantages of OIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several potential advantages of OIT, compared with SCIT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SLIT is safer, with fewer local and systemic allergic reactions than SCIT. Serious systemic adverse events are uncommon to rare with SLIT, although a small number have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]. The European literature has provided extensive data on the safety of oral immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. Well-designed clinical trials in Europe and North America are providing important safety information on research subjects receiving the newer sublingual pollen tablet constructs [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/60\">",
"       60",
"      </a>",
"      ]. SLIT is more comfortable for patients, since allergens are ingested rather than injected.",
"     </li>",
"     <li>",
"      SLIT is more convenient for patients and clinicians, because therapy is self-administered by the patient at home.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The disadvantages of SLIT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benefit is reliant upon consistent patient self-administration. Patients who regularly miss doses may not have satisfactory results. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Practical considerations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      SLIT agents will probably be approved in the US for",
"      <span class=\"nowrap\">",
"       self/home",
"      </span>",
"      administration, and patient education will be required to ensure that it is carried out safely and effectively. As an example, patients will require education about how to resume therapy after missed doses. Post-marketing surveillance studies should be performed to identify the frequency and severity of untoward",
"      <span class=\"nowrap\">",
"       reactions/adverse",
"      </span>",
"      events that may be observed at an increased rate in the \"real-world\" use of these products.",
"     </li>",
"     <li>",
"      At present, there are no commercially available allergen preparations sold in the United States that have been FDA-approved for oral use. Thus, use of the extracts intended for SCIT constitutes an \"off label\" application of the product, which is not generally reimbursed by third-party payers. This has lead to hesitancy on the part of the US medical community to embrace this therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14339799\">",
"    <span class=\"h2\">",
"     Comparative efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One group compared various meta-analyses of SLIT (via sublingual extracts or tablets) and SCIT studies that measured changes in symptom scores and medication use in patients with allergic rhinitis due to grass pollen treated with grass pollen immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/61\">",
"     61",
"    </a>",
"    ]. The analysis included 36 randomized controlled trials of over 3000 treated patients and a similar number of placebo-treated controls. To account for the methodologic variation among the studies, results were converted to standardized mean differences. Although indirect and limited by a very high degree of heterogeneity, this analysis showed greater overall benefit with SCIT compared with SLIT.",
"   </p>",
"   <p>",
"    Another review identified eight head-to-head comparative studies, although the five additional studies included were open label [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small number of trials have directly compared SLIT and SCIT. Three randomized trials involved head-to-head, double dummy protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/19,63,64\">",
"     19,63,64",
"    </a>",
"    ]. Although each study had methodologic issues and small numbers of patients, two of three found SCIT to be at least somewhat more effective than SLIT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The earliest study included 20 adults monosensitized to grass (and without asthma) treated with SLIT-aqueous or SCIT, which found that both therapies resulted in reductions in symptoms and medication scores of at least 50 percent after one year of therapy; however, there was no placebo arm [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/63\">",
"       63",
"      </a>",
"      ]. In contrast, immunologic measures of efficacy, such as allergen-specific IgG4, changed only in the group receiving SCIT.",
"     </li>",
"     <li>",
"      A subsequent trial involved 58 birch-allergic adults (one-third with asthma) treated with either SLIT-aqueous or SCIT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/19\">",
"       19",
"      </a>",
"      ]. Some were also sensitized to other allergens. Rhinitis disease severity was significantly reduced in both treatment arms compared with placebo, although the two therapies were not statistically different from each other.",
"     </li>",
"     <li>",
"      In a third trial, 30 children, all with both rhinitis and asthma and monosensitized to house dust mite, were randomized to SLIT-aqueous, SCIT, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/64\">",
"       64",
"      </a>",
"      ]. SCIT significantly reduced rhinitis and asthma symptoms and medication use. SLIT modestly reduced symptoms for both rhinitis and asthma, and medication use for rhinitis, but the changes with SLIT were not statistically significant compared with placebo. The doses given were also not quantified in terms of micrograms of allergen, so it was difficult to assess whether SLIT dosing was adequate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Issues requiring further study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further research is needed in several areas, in addition to optimizing dosing and delivery systems. Incompletely answered questions include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/26,60\">",
"     26,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Can oral forms of immunotherapy be used to alter disease progression or prevent the onset of other allergic diseases? No studies have yet addressed this question.",
"     </li>",
"     <li>",
"      Which patients are the best candidates for oral immunotherapy? Because SLIT is safe and convenient, proponents have hoped this therapy could be administered by primary care providers. However, the first published trial of grass pollen SLIT administered to children and adolescents in the primary care setting failed to show efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/65\">",
"       65",
"      </a>",
"      ]. Thus, patient selection may be critical to outcome.",
"     </li>",
"     <li>",
"      Studies are needed to define optimal doses and dosing schedules. Both SLIT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/30,32-35,54,60\">",
"       30,32-35,54,60",
"      </a>",
"      ] and SCIT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/66-68\">",
"       66-68",
"      </a>",
"      ] can produce clinical benefit within three to four months, although the optimal duration of SLIT has yet to be defined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Practical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal way to incorporate OIT into clinical practice remains to be determined. The following types of patients raise specific questions about the best use of OIT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       The polysensitized allergic patient",
"      </strong>",
"      &mdash; The most compelling data for use of OIT is in the monosensitized pediatric or adult patient with seasonal allergic rhinoconjunctivitis with or without mild asthma. Nearly all the high-quality studies available have shown benefit in this context. However, the typical patient in North America is sensitized to multiple aeroallergens, both seasonally and perennially. At present, the few multiple allergen studies performed in the US have not shown clinical benefit. In one study, 54 grass-allergic patients were randomized to placebo, monotherapy with Timothy extract (19 mcg Phleum p 5 daily), or Timothy extract plus nine additional unstandardized pollen extracts [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/47\">",
"       47",
"      </a>",
"      ]. A modest positive trend was observed in clinical parameters in the multiple pollens group, which did not reach clinical significance.",
"      <br/>",
"      <br/>",
"      However, a post-hoc analysis of data from six randomized trials of grass pollen tablet immunotherapy, including 1871 adults and children, found no significant difference in the benefit reported by patients who were monosensitized to grass and those who were polysensitized to grass and other allergens during the grass pollen season [",
"      <a class=\"abstract\" href=\"UTD.htm?1/34/1578/abstract/69\">",
"       69",
"      </a>",
"      ]. This analysis does not address the question of whether SLIT with one allergen has any effect on patients&rsquo; symptoms from exposure to other allergens, a controversy that also applies to subcutaneous immunotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40327?source=see_link&amp;anchor=H15449436#H15449436\">",
"       \"SCIT: Preparation of allergen extracts for therapeutic use\", section on 'Multiple-allergen immunotherapy extracts'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition, until a full range of oral products has been produced, tested, and made commercially available, it is not clear that it would be practical or cost effective to combine OIT (eg, grass SLIT-tablet) with SCIT in a patient with multiple allergen sensitivities, as opposed to simply continuing SCIT to cover all the allergens relevant to that patient.",
"     </li>",
"     <li>",
"      <strong>",
"       The pediatric patient",
"      </strong>",
"      &mdash; SLIT might be a valuable initial therapy for young allergic children, as it should be better tolerated than injections. However, it is not known if SLIT will prove to have the same potential to prevent the development of asthma that has been shown with SCIT. Until well-controlled clinical trials determine this, clinicians and parents may be unwilling to substitute SLIT for SCIT.",
"     </li>",
"     <li>",
"      <strong>",
"       The noncompliant patient",
"      </strong>",
"      &mdash; OIT requires a commitment by the patient to long-term daily maintenance therapy, and compliance may be lower than that obtained in supervised clinical trials. Adherence data from studies with \"controller\" therapies for asthma have shown that, by six months from the time of prescription, up to 40 percent of patients are no longer compliant with their treatment.",
"      <br/>",
"      <br/>",
"      Compliance may be important for safety, as well as efficacy. Long-term surveillance reporting will be needed to ascertain the risks associated with noncompliance as related to stopping-restarting therapy, the tendency for patients to overdose in an attempt to \"catch up\" if they have missed doses, or",
"      <strong>",
"      </strong>",
"      when patients have gaps",
"      <strong>",
"      </strong>",
"      in their treatment schedule and attempt to restart it, possibly at times when symptoms are most severe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     SUMMARY AND RECOMMENDATIONS",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral immunotherapy (OIT) involves the application of allergen to the oral mucosa or sublingual tissues for a few minutes, after which the preparation is swallowed. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The immunologic changes that result from oral allergen immunotherapy with inhalant allergens appear to be similar to those induced by injection immunotherapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral immunotherapy is in use in many areas of Europe for the treatment of allergic rhinoconjunctivitis. In the United States, oral immunotherapy products are not yet approved by the US Food and Drug Administration and are not available outside of clinical trials. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Availability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three forms of oral immunotherapy with inhalant allergens are in development for use in the United States: sublingual aqueous allergen extracts (SLIT-aqueous), dissolvable sublingual tablets (SLIT-tablet), and enteric and microencapsulated preparations. The best results have been obtained with SLIT-tablet formulations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy and safety of SLIT, using products designed for oral use, has been demonstrated in a number of properly designed European trials, for both children and adults with allergic rhinitis. However, in the United States, clinical trials have not reproduced these findings. Despite this, extracts are being used &ldquo;off-label&rdquo; in the US for SLIT, although the effectiveness of this practice is unknown. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Efficacy and safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The small number of studies that have included patients with both allergic rhinitis and allergic asthma found that OIT was generally well-tolerated, although efficacy in reducing the symptoms of allergic asthma has not been conclusively demonstrated. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Patients with concomitant asthma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/1\">",
"      Bousquet J. Sublingual immunotherapy: validated. Allergy 2006; 61(supplement 81):5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/2\">",
"      Frati F, Moingeon P, Marcucci F, et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 2007; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     Hemmings WA. Antigen absorption by the gut, MTP Press, Lancaster, England 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/4\">",
"      Elson CO, Heck JA, Strober W. T-cell regulation of murine IgA synthesis. J Exp Med 1979; 149:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/5\">",
"      Frew AJ. How does sublingual immunotherapy work? J Allergy Clin Immunol 2007; 120:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/6\">",
"      La Rosa M, Ranno C, Andr&eacute; C, et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/7\">",
"      Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/8\">",
"      Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990; 18:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/9\">",
"      Bufe A, Ziegler-Kirbach E, Stoeckmann E, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/10\">",
"      Smith H, White P, Annila I, et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004; 114:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/11\">",
"      Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/12\">",
"      Bah&ccedil;eciler NN, I��ik U, Barlan IB, Ba��aran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/13\">",
"      Calder&oacute;n M, Essendrop M. Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 2006; 16:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/14\">",
"      Ciprandi G, Cirillo I, Fenoglio D, et al. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol 2006; 6:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/15\">",
"      Arikan C, Bahceciler NN, Deniz G, et al. Bacillus Calmette-Gu&eacute;rin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004; 34:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/16\">",
"      Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/17\">",
"      Passalacqua G, Canonica GW. Sublingual or injection immunotherapy: the final answer? Allergy 2004; 59:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/18\">",
"      Bahceciler NN, Ozdemir C, Barlan IB. Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma. Curr Med Chem 2007; 14:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/19\">",
"      Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/20\">",
"      Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/21\">",
"      Larsen TH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy--a phase-1 study. Allergy 2006; 61:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/22\">",
"      Pajno GB, Caminiti L, Crisafulli G, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 2011; 22:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/23\">",
"      Durham SR, GT-08 investigators. Sustained effects of grass pollen AIT. Allergy 2011; 66 Suppl 95:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/24\">",
"      Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010; 126:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/25\">",
"      Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/26\">",
"      Casale TB, Canonica GW, Bousquet J, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009; 124:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/27\">",
"      Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64 Suppl 91:1.",
"     </a>",
"    </li>",
"    <li>",
"     Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. European Medicines Agency; London, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/29\">",
"      Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/30\">",
"      Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434.",
"     </a>",
"    </li>",
"    <li>",
"     Press release may be accessed at www.forbes.com/feeds/afx/2007/11/16/afx4348325.html (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/32\">",
"      Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011; 127:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/33\">",
"      Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011; 127:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/34\">",
"      Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/35\">",
"      Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/36\">",
"      Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/37\">",
"      Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012; 130:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/38\">",
"      Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/39\">",
"      Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/40\">",
"      Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/41\">",
"      Fr&oslash;lund L, Durham SR, Calderon M, et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2010; 65:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/42\">",
"      Esch RE, Bush RK, Peden D, Lockey RF. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol 2008; 100:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/43\">",
"      Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol 2010; 125:660.",
"     </a>",
"    </li>",
"    <li>",
"     Press release. www.greerlabs.com/research_dev/rdev.slit.updates.php (Accessed on January 09, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/45\">",
"      Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011; 127:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/46\">",
"      Reshamwala SJ, Song GP, Yu R, et al. Study of sublingual immunotherapy in subjects with dermatophagoides farinae and Timothy grass allergy. J Allergy Clin Immunol 2009; 123:S126 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/47\">",
"      Amar SM, Harbeck RJ, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009; 124:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/48\">",
"      Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004; 93:425.",
"     </a>",
"    </li>",
"    <li>",
"     Creticos PS, Balcer-Whaley SL, Moldt P, Pedersen O. Safety and efficacy of oral immunotherapy with a microencapsulated ragweed pollen extract (MRPE) in patients with ragweed-induced seasonal allergic rhinitis. Presented at the 27th Symposium of Collegium Internationale Allergologicum in Curacao, May 2008. (Abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/50\">",
"      Creticos PS, Balcer-Whaley SL, Moldt P, Pedersen O. Comparison of compositional differences and relative potency between different manufacturers of ragweed pollen extracts. J Allergy Clin Immunol 2007; 119:S57 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/51\">",
"      Calamita Z, Saconato H, Pel&aacute; AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/52\">",
"      Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/53\">",
"      Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/54\">",
"      Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/55\">",
"      Passalacqua G, Guerra L, Compalati E, Canonica GW. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf 2007; 2:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/56\">",
"      Rodr&iacute;guez-P&eacute;rez N, Ambriz-Moreno Mde J, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008; 101:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/57\">",
"      de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009; 64:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/58\">",
"      Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; :CD002893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/59\">",
"      Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/60\">",
"      Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/61\">",
"      Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol 2012; 130:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/62\">",
"      Bahceciler NN, Galip N. Comparing subcutaneous and sublingual ��mmunotherapy: what do we know? Curr Opin Allergy Clin Immunol 2012; 12:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/63\">",
"      Quirino T, Iemoli E, Siciliani E, et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996; 26:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/64\">",
"      Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012; 157:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/65\">",
"      R&ouml;der E, Berger MY, Hop WC, et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007; 119:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/66\">",
"      Taylor WW, Ohman JL Jr, Lowell FC. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol 1978; 61:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/67\">",
"      Norman PS, Winkenwerder WL, Lichtenstein LM. Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos. J Allergy 1968; 42:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/68\">",
"      Creticos PS. Legends in allergy: Philip S. Norman and Lawrence M. Lichtenstein--the Hopkins experience. J Allergy Clin Immunol 2007; 119:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/34/1578/abstract/69\">",
"      Nelson H, Blaiss M, Nolte H, et al. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 2013; 68:252.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7538 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1578=[""].join("\n");
var outline_f1_34_1578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunologic changes following OIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Forms of oral allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Types of allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523955\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFICACY AND SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sublingual allergen tablets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6514669\">",
"      - Single grass allergen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Multiple grass allergens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Persistence of therapeutic benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sublingual aqueous allergen extracts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ragweed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - House dust mite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Microencapsulated OIT with ragweed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26665626\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PATIENTS WITH CONCOMITANT ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPARISON OF OIT AND SCIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Advantages and disadvantages of OIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14339799\">",
"      Comparative efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Issues requiring further study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Practical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/7538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7538|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/54/37743\" title=\"figure 1\">",
"      Grass STIT trial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44057?source=related_link\">",
"      Future therapies for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=related_link\">",
"      Pathogenesis of allergic rhinitis (rhinosinusitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40327?source=related_link\">",
"      SCIT: Preparation of allergen extracts for therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_34_1579="Initial prenatal labs";
var content_f1_34_1579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial prenatal laboratory examination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Blood type and antibody screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhesus type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematocrit or hemoglobin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAP smear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubella status (immune or nonimmune)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary infection screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B surface antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV counseling and testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1579=[""].join("\n");
var outline_f1_34_1579=null;
var title_f1_34_1580="Volume of fetal blood samples and collection tubes for lab tests";
var content_f1_34_1580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Volume of fetal blood samples and collection tubes for laboratory studies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tube content",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample volume, mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete blood count",
"       </td>",
"       <td>",
"        EDTA",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reticulocyte count",
"       </td>",
"       <td>",
"        EDTA",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kleihauer-Betke",
"       </td>",
"       <td>",
"        EDTA",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulation studies",
"       </td>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood group typing",
"       </td>",
"       <td>",
"        Dry",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direct/indirect Coombs",
"       </td>",
"       <td>",
"        Dry",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total and specific IgM",
"       </td>",
"       <td>",
"        Dry",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum chemistry",
"       </td>",
"       <td>",
"        Dry",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molecular biology analysis",
"       </td>",
"       <td>",
"        Sodium heparin",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymerase chain reaction",
"       </td>",
"       <td>",
"        EDTA",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood gas analysis",
"       </td>",
"       <td>",
"        Heparinized syringe",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Karyotype or fluorescence in situ hybridization",
"       </td>",
"       <td>",
"        Sodium heparin",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1580=[""].join("\n");
var outline_f1_34_1580=null;
var title_f1_34_1581="Efficacy antifungal agents";
var content_f1_34_1581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effectiveness of antifungal agents against common yeast, fungi and bacteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Common",
"yeast and fungi",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Common",
"bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        A. niger",
"       </td>",
"       <td class=\"subtitle2\">",
"        C. albi- cans",
"       </td>",
"       <td class=\"subtitle2\">",
"        C. para- psilosis",
"       </td>",
"       <td class=\"subtitle2\">",
"        Peni- cillium",
"       </td>",
"       <td class=\"subtitle2\">",
"        S. aureus",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pseudo- monas",
"       </td>",
"       <td class=\"subtitle2\">",
"        S. Epider- midis",
"       </td>",
"       <td class=\"subtitle2\">",
"        P. mira- bilis",
"       </td>",
"       <td class=\"subtitle2\">",
"        Entero- cocci",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphotericin B",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clotrimazole",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        NT",
"       </td>",
"       <td>",
"        NT",
"       </td>",
"       <td>",
"        NT",
"       </td>",
"       <td>",
"        NT",
"       </td>",
"       <td>",
"        NT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miconazole",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natamycin",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nystatin",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolnaftate",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ++: Very effective (&gt;25 mm); +: Effective (15-25 mm); 0: Ineffective (&lt;15 mm); NT: not tested.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with data from Stern, JC, Shah, MK, Lucente, FE, Laryngoscope 1988; 98:1173.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1581=[""].join("\n");
var outline_f1_34_1581=null;
var title_f1_34_1582="ICD vs no ICD MUSTT";
var content_f1_34_1582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    ICD reduces sudden death in MUSTT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 302px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MUSTT trial enrolled 704 patients with coronary artery disease, nonsustained ventricular tachycardia (VT) and a left ventricular ejection fraction &le;40 percent who had sustained VT induced during electrophysiologic (EP) study. Kaplan-Meier estimates show that the incidence of cardiac arrest or death from arrhythmia is significantly lower in those receiving an implantable cardioverter-defibrillator (ICD) compared to those receiving no therapy or those with EP-guided (EPG) antiarrhythmic drug (AAD) therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Buxton AE, Lee KL, Fisher JD, et al. N Engl J Med 1999; 341:1882.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1582=[""].join("\n");
var outline_f1_34_1582=null;
var title_f1_34_1583="Osteonecrosis of hip";
var content_f1_34_1583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteonecrosis of the femoral head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the pelvis and hips of a 41-year-old man who has received a cardiac transplant and who is on corticosteroids. There is stage III (moderately late) avascular necrosis of both femoral heads manifested by increased density within each femoral head but no collapse (arrows). The increased density reflects marrow infarcts with calcification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Robbins, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_34_1583=[""].join("\n");
var outline_f1_34_1583=null;
